,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"Science.
","('Product_Design_And_Lifecycle_Management', 0.09684973210096359)","('Supply_Chain_Management', 0.06944214552640915)","('Access_And_Affordability', 0.066627137362957)","('NON-ESG', 0.09684973210096359)","('NON-ESG', 0.06944214552640915)","('NON-ESG', 0.066627137362957)"
Line 2,"Humanity.
","('Human_Rights_And_Community_Relations', 0.19511690735816956)","('Competitive_Behavior', 0.08816685527563095)","('Ecological_Impacts', 0.07323853671550751)","('NON-ESG', 0.19511690735816956)","('NON-ESG', 0.08816685527563095)","('NON-ESG', 0.07323853671550751)"
Line 3,"Purpose.
","('Director_Removal', 0.1130162701010704)","('Human_Rights_And_Community_Relations', 0.08996808528900146)","('Business_Ethics', 0.08701804280281067)","('NON-ESG', 0.1130162701010704)","('NON-ESG', 0.08996808528900146)","('NON-ESG', 0.08701804280281067)"
Line 4,"2020 PERFORMANCE REPORT	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Boston Scientific is   dedicated to transforming  lives through innovative  medical solutions that   improve the health of   patients around the world.
","('Access_And_Affordability', 0.5339739322662354)","('Customer_Welfare', 0.06579560041427612)","('Employee_Health_And_Safety', 0.0581400990486145)","(['Health Outcome Contribution'], 0.5339739322662354)","('NON-ESG', 0.06579560041427612)","('NON-ESG', 0.0581400990486145)"
Line 5,"When science, humanity   and purpose connect,   lives can be transformed.
","('Human_Rights_And_Community_Relations', 0.4382680058479309)","('Employee_Engagement_Inclusion_And_Diversity', 0.11768747121095657)","('Business_Model_Resilience', 0.056842878460884094)","('NON-ESG', 0.4382680058479309)","('NON-ESG', 0.11768747121095657)","('NON-ESG', 0.056842878460884094)"
Line 6,"Advancing science   for lifePURPOSE A deep caring for   human lifeHUMANITY Pushing the boundaries  of what’s possibleSCIENCE	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly At Boston Scientific, our 2020 story unfolded through   the experiences of health care professionals, patients, our  employees and communities during a global pandemic.
","('Access_And_Affordability', 0.3868548274040222)","('Employee_Engagement_Inclusion_And_Diversity', 0.08522643148899078)","('Customer_Welfare', 0.065501369535923)","('NON-ESG', 0.3868548274040222)","('NON-ESG', 0.08522643148899078)","('NON-ESG', 0.065501369535923)"
Line 7,"Advancing science   for lifePURPOSE A deep caring for   human lifeHUMANITY Pushing the boundaries  of what’s possibleSCIENCE	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly At Boston Scientific, our 2020 story unfolded through   the experiences of health care professionals, patients, our  employees and communities during a global pandemic.
","('Human_Rights_And_Community_Relations', 0.6798533797264099)","('Access_And_Affordability', 0.06246716156601906)","('Critical_Incident_Risk_Management', 0.05708293244242668)","(['Community Relations'], 0.6798533797264099)","('NON-ESG', 0.06246716156601906)","('NON-ESG', 0.05708293244242668)"
Line 8,"As we saw humanity tested, our people stepped up in   unforeseen ways to work safely as they served customers   and navigated the complexities of delivering critical   solutions to patients everywhere.
","('Access_And_Affordability', 0.3189327120780945)","('Product_Design_And_Lifecycle_Management', 0.09203960001468658)","('Critical_Incident_Risk_Management', 0.06380987912416458)","('NON-ESG', 0.3189327120780945)","('NON-ESG', 0.09203960001468658)","('NON-ESG', 0.06380987912416458)"
Line 9,"In a year of reckoning,   we were compelled to act — inside and outside the   company — as we came face to face with deep social  unrest, inequities and health disparities.
","('Systemic_Risk_Management', 0.9013338685035706)","('Physical_Impacts_Of_Climate_Change', 0.015424283221364021)","('Business_Model_Resilience', 0.013300666585564613)","(['Risk & Crisis Management'], 0.9013338685035706)","('NON-ESG', 0.015424283221364021)","('NON-ESG', 0.013300666585564613)"
Line 10,"Our people   cared for one another and our communities in ways never   imagined as they stayed true to our values and focused   on addressing the needs of patients.
","('Human_Rights_And_Community_Relations', 0.8711287975311279)","('Access_And_Affordability', 0.04922586306929588)","('Employee_Engagement_Inclusion_And_Diversity', 0.009143674746155739)","(['Community Relations'], 0.8711287975311279)","('NON-ESG', 0.04922586306929588)","('NON-ESG', 0.009143674746155739)"
Line 11,"Pamela Chang is one of those patients.
","('Employee_Health_And_Safety', 0.16117575764656067)","('Access_And_Affordability', 0.13696107268333435)","('Employee_Engagement_Inclusion_And_Diversity', 0.12222199887037277)","('NON-ESG', 0.16117575764656067)","('NON-ESG', 0.13696107268333435)","('NON-ESG', 0.12222199887037277)"
Line 12,"Her experience  exemplifies why we are dedicated to advancing science   for life and why — when science, humanity and purpose  come together — we can change and save lives.
","('Ecological_Impacts', 0.1333683580160141)","('Human_Rights_And_Community_Relations', 0.1290614902973175)","('Access_And_Affordability', 0.12378507107496262)","('NON-ESG', 0.1333683580160141)","('NON-ESG', 0.1290614902973175)","('NON-ESG', 0.12378507107496262)"
Line 13,"“ We’re focused on delivering meaningful innovations and making   sure everyone who needs quality care gets it.
","('Access_And_Affordability', 0.5921723246574402)","('Product_Design_And_Lifecycle_Management', 0.06428058445453644)","('Employee_Health_And_Safety', 0.05273769050836563)","(['Health Outcome Contribution'], 0.5921723246574402)","('NON-ESG', 0.06428058445453644)","('NON-ESG', 0.05273769050836563)"
Line 14,"That objective became  very real for my family in 2020.
","('Human_Rights_And_Community_Relations', 0.37142908573150635)","('Access_And_Affordability', 0.09536606073379517)","('Management_Of_Legal_And_Regulatory_Framework', 0.07277202606201172)","('NON-ESG', 0.37142908573150635)","('NON-ESG', 0.09536606073379517)","('NON-ESG', 0.07277202606201172)"
Line 15,"The hard work of people across   Boston Scientific saved my mom’s life.”   Camille Chang Gilmore , global chief diversity, equity and inclusion officer, Boston Scientific,  and Pamela’s daughter  ” I feel much better.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9593948721885681)","('Human_Rights_And_Community_Relations', 0.004907355643808842)","('Employee_Health_And_Safety', 0.0041516367346048355)","(['Human Capital Development'], 0.9593948721885681)","('NON-ESG', 0.004907355643808842)","('NON-ESG', 0.0041516367346048355)"
Line 16,"I don’t know if I could  run a marathon, but I could try!”       Pamela Chang , Boston Scientific patient, and   Camille’s momPamela Chang is a survivor.
","('Employee_Health_And_Safety', 0.2363569289445877)","('Employee_Engagement_Inclusion_And_Diversity', 0.21448038518428802)","('Access_And_Affordability', 0.16349968314170837)","('NON-ESG', 0.2363569289445877)","('NON-ESG', 0.21448038518428802)","('NON-ESG', 0.16349968314170837)"
Line 17,"The 73-year-old has a long, complex history of heart disease,   but to her family, she is a pillar of strength.
","('Employee_Health_And_Safety', 0.3495437800884247)","('Access_And_Affordability', 0.08349478989839554)","('Employee_Engagement_Inclusion_And_Diversity', 0.0771559402346611)","('NON-ESG', 0.3495437800884247)","('NON-ESG', 0.08349478989839554)","('NON-ESG', 0.0771559402346611)"
Line 18,"After immigrating to the United States from   Jamaica, she worked as a nurse for 40 years and took on multiple shifts to ensure her children,   including our Chief Diversity, Equity and Inclusion Officer Camille Chang Gilmore, could   go to college.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9675683975219727)","('Human_Rights_And_Community_Relations', 0.0027438418474048376)","('Access_And_Affordability', 0.0025106591638177633)","(['Human Capital Development'], 0.9675683975219727)","('NON-ESG', 0.0027438418474048376)","('NON-ESG', 0.0025106591638177633)"
Line 19,"Over the years, Pamela has been treated with several coronary therapies from  Boston Scientific.
","('Access_And_Affordability', 0.5694389343261719)","('Employee_Health_And_Safety', 0.07098143547773361)","('Product_Quality_And_Safety', 0.05564720556139946)","(['Health Outcome Contribution'], 0.5694389343261719)","('NON-ESG', 0.07098143547773361)","('NON-ESG', 0.05564720556139946)"
Line 20,"But recently, after experiencing painful swelling in her right leg, physicians   discovered blockages there.
","('Employee_Health_And_Safety', 0.8955003023147583)","('Employee_Engagement_Inclusion_And_Diversity', 0.01569659635424614)","('Waste_And_Hazardous_Materials_Management', 0.008987260982394218)","(['Operational Eco-Efficiency'], 0.8955003023147583)","('NON-ESG', 0.01569659635424614)","('NON-ESG', 0.008987260982394218)"
Line 21,"Pamela underwent a peripheral vascular procedure, in which  doctors used Boston Scientific technology to open the blood vessels in her lower leg and foot.
","('Employee_Health_And_Safety', 0.6688697338104248)","('Employee_Engagement_Inclusion_And_Diversity', 0.03775849938392639)","('Access_And_Affordability', 0.03126612678170204)","(['Operational Eco-Efficiency'], 0.6688697338104248)","('NON-ESG', 0.03775849938392639)","('NON-ESG', 0.03126612678170204)"
Line 22,"Now, once again, Pamela is back enjoying a full life with her family.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2695940434932709)","('Employee_Health_And_Safety', 0.09802769124507904)","('Access_And_Affordability', 0.08356029540300369)","('NON-ESG', 0.2695940434932709)","('NON-ESG', 0.09802769124507904)","('NON-ESG', 0.08356029540300369)"
Line 23,"Watch Pamela’s story    	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Table of Contents This report has been prepared in accordance with   the Global Reporting Initiative guidelines.
","('Access_And_Affordability', 0.29380661249160767)","('Management_Of_Legal_And_Regulatory_Framework', 0.1952233910560608)","('Business_Model_Resilience', 0.09037121385335922)","('NON-ESG', 0.29380661249160767)","('NON-ESG', 0.1952233910560608)","('NON-ESG', 0.09037121385335922)"
Line 24,"Unless   otherwise indicated, data in the 2020 Performance   Report Addendum are as of December 31, 2020, or   for the one-year period ending in December 31, 2020,   as applicable.1 OUR MISSION 2 PATIENT SPOTLIGHT: PAMELA CHANG 4 A MESSAGE FROM OUR CHAIRMAN, PRESIDENT AND CEO  7 COMPANY PROFILE  7 Boston Scientific at a Glance  8 Meaningful Innovation  9 Boston Scientific by the Numbers  10 Corporate Social Responsibility at Boston Scientific 11 TRANSFORMING CARE  12 Our Approach to Innovative and Quality Products  17 Building Digital Capability  19 Collaborating with Customers 23 INVESTING IN OUR PEOPLE    24 Talent and Company Culture  27 Fostering a Diverse, Equitable and Inclusive Culture  32 Benefits to Fit People’s Lives  34 Prioritizing Employee Health and Safety35 ADVANCING POSSIBILITIES  36 Confronting Health Inequities  38  Playing Our Part: Combating Racism  39 Supporting Our Communities 46 PROTECTING THE ENVIRONMENT  47 Responding to Climate Change  50 Our Environmental Impact 55 CREATING VALUE RESPONSIBLY  56 Compliance, Ethics and Integrity  58 Risk Management and Global Security  60 Governance  62 Sustainable Supply Chain	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Mike Mahoney,   Chairman, President    and CEO 2020 has been a year unlike any we could have imagined.
","('Human_Rights_And_Community_Relations', 0.25733286142349243)","('Business_Model_Resilience', 0.2070479840040207)","('Access_And_Affordability', 0.078571617603302)","('NON-ESG', 0.25733286142349243)","('NON-ESG', 0.2070479840040207)","('NON-ESG', 0.078571617603302)"
Line 25,"Unless   otherwise indicated, data in the 2020 Performance   Report Addendum are as of December 31, 2020, or   for the one-year period ending in December 31, 2020,   as applicable.1 OUR MISSION 2 PATIENT SPOTLIGHT: PAMELA CHANG 4 A MESSAGE FROM OUR CHAIRMAN, PRESIDENT AND CEO  7 COMPANY PROFILE  7 Boston Scientific at a Glance  8 Meaningful Innovation  9 Boston Scientific by the Numbers  10 Corporate Social Responsibility at Boston Scientific 11 TRANSFORMING CARE  12 Our Approach to Innovative and Quality Products  17 Building Digital Capability  19 Collaborating with Customers 23 INVESTING IN OUR PEOPLE    24 Talent and Company Culture  27 Fostering a Diverse, Equitable and Inclusive Culture  32 Benefits to Fit People’s Lives  34 Prioritizing Employee Health and Safety35 ADVANCING POSSIBILITIES  36 Confronting Health Inequities  38  Playing Our Part: Combating Racism  39 Supporting Our Communities 46 PROTECTING THE ENVIRONMENT  47 Responding to Climate Change  50 Our Environmental Impact 55 CREATING VALUE RESPONSIBLY  56 Compliance, Ethics and Integrity  58 Risk Management and Global Security  60 Governance  62 Sustainable Supply Chain	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Mike Mahoney,   Chairman, President    and CEO 2020 has been a year unlike any we could have imagined.
","('Human_Rights_And_Community_Relations', 0.504944384098053)","('Employee_Engagement_Inclusion_And_Diversity', 0.222340390086174)","('Employee_Health_And_Safety', 0.09357838332653046)","(['Community Relations'], 0.504944384098053)","('NON-ESG', 0.222340390086174)","('NON-ESG', 0.09357838332653046)"
Line 26,"Unless   otherwise indicated, data in the 2020 Performance   Report Addendum are as of December 31, 2020, or   for the one-year period ending in December 31, 2020,   as applicable.1 OUR MISSION 2 PATIENT SPOTLIGHT: PAMELA CHANG 4 A MESSAGE FROM OUR CHAIRMAN, PRESIDENT AND CEO  7 COMPANY PROFILE  7 Boston Scientific at a Glance  8 Meaningful Innovation  9 Boston Scientific by the Numbers  10 Corporate Social Responsibility at Boston Scientific 11 TRANSFORMING CARE  12 Our Approach to Innovative and Quality Products  17 Building Digital Capability  19 Collaborating with Customers 23 INVESTING IN OUR PEOPLE    24 Talent and Company Culture  27 Fostering a Diverse, Equitable and Inclusive Culture  32 Benefits to Fit People’s Lives  34 Prioritizing Employee Health and Safety35 ADVANCING POSSIBILITIES  36 Confronting Health Inequities  38  Playing Our Part: Combating Racism  39 Supporting Our Communities 46 PROTECTING THE ENVIRONMENT  47 Responding to Climate Change  50 Our Environmental Impact 55 CREATING VALUE RESPONSIBLY  56 Compliance, Ethics and Integrity  58 Risk Management and Global Security  60 Governance  62 Sustainable Supply Chain	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Mike Mahoney,   Chairman, President    and CEO 2020 has been a year unlike any we could have imagined.
","('Business_Ethics', 0.9605218172073364)","('Management_Of_Legal_And_Regulatory_Framework', 0.003887231694534421)","('Product_Quality_And_Safety', 0.0035538969095796347)","(['Business Ethics'], 0.9605218172073364)","('NON-ESG', 0.003887231694534421)","('NON-ESG', 0.0035538969095796347)"
Line 27,"As a society, we confronted  COVID-19 and its economic fallout.
","('Systemic_Risk_Management', 0.609085202217102)","('Competitive_Behavior', 0.18445944786071777)","('Business_Model_Resilience', 0.041379768401384354)","(['Risk & Crisis Management'], 0.609085202217102)","('NON-ESG', 0.18445944786071777)","('NON-ESG', 0.041379768401384354)"
Line 28,"We watched the pandemic take a disproportionate   toll on communities of color, and we saw long-standing inequities and systemic racism   painfully exposed.
","('Business_Ethics', 0.6612472534179688)","('Employee_Engagement_Inclusion_And_Diversity', 0.123324453830719)","('Systemic_Risk_Management', 0.027637707069516182)","(['Business Ethics'], 0.6612472534179688)","('NON-ESG', 0.123324453830719)","('NON-ESG', 0.027637707069516182)"
Line 29,"We experienced political unrest as well as the continued devastating   effects of climate change.
","('Physical_Impacts_Of_Climate_Change', 0.9563284516334534)","('Business_Model_Resilience', 0.005429071374237537)","('Critical_Incident_Risk_Management', 0.0042288945987820625)","(['Climate Change'], 0.9563284516334534)","('NON-ESG', 0.005429071374237537)","('NON-ESG', 0.0042288945987820625)"
Line 30,"Amid this disruption, Boston Scientific was guided and united   by our mission to transform lives through medical solutions that improve the health   of patients around the world.
","('Access_And_Affordability', 0.47032925486564636)","('Employee_Health_And_Safety', 0.16081584990024567)","('Critical_Incident_Risk_Management', 0.05268898606300354)","('NON-ESG', 0.47032925486564636)","('NON-ESG', 0.16081584990024567)","('NON-ESG', 0.05268898606300354)"
Line 31,"Our 38,000 employees were led by our values, and we   fulfilled our mission — as a global business and as a global corporate citizen.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3041810095310211)","('Business_Model_Resilience', 0.19264112412929535)","('Human_Rights_And_Community_Relations', 0.09747350960969925)","('NON-ESG', 0.3041810095310211)","('NON-ESG', 0.19264112412929535)","('NON-ESG', 0.09747350960969925)"
Line 32,"A Message from Our  Chairman, President  and CEO 2020 taught us that when science, humanity and purpose  connect, we can make a meaningful difference in the  world.
","('Human_Rights_And_Community_Relations', 0.48388299345970154)","('Employee_Engagement_Inclusion_And_Diversity', 0.07762154191732407)","('Business_Model_Resilience', 0.06923527270555496)","('NON-ESG', 0.48388299345970154)","('NON-ESG', 0.07762154191732407)","('NON-ESG', 0.06923527270555496)"
Line 33,"We measure our progress by the ways in which we  transform care, invest in our people, advance possibilities,  protect the environment and create value responsibly.
","('Human_Rights_And_Community_Relations', 0.7146477103233337)","('Access_And_Affordability', 0.04568342864513397)","('Ecological_Impacts', 0.04360998421907425)","(['Community Relations'], 0.7146477103233337)","('NON-ESG', 0.04568342864513397)","('NON-ESG', 0.04360998421907425)"
Line 34,"In a year without precedent our teams were resilient and  agile, and as a result of their hard work our business remains  strong.
","('Business_Model_Resilience', 0.9026791453361511)","('Physical_Impacts_Of_Climate_Change', 0.012717620469629765)","('Systemic_Risk_Management', 0.009294387884438038)","(['Codes of Business Conduct'], 0.9026791453361511)","('NON-ESG', 0.012717620469629765)","('NON-ESG', 0.009294387884438038)"
Line 35,"We invested more than $1 billion in research and  development and brought to market 69 new products to  advance patient care.
","('Product_Design_And_Lifecycle_Management', 0.887920618057251)","('Customer_Welfare', 0.027503781020641327)","('Product_Quality_And_Safety', 0.017834926024079323)","(['Product Stewardship'], 0.887920618057251)","('NON-ESG', 0.027503781020641327)","('NON-ESG', 0.017834926024079323)"
Line 36,"Our teams conducted 119 clinical  studies and pursued opportunities to expand access to  health care in emerging markets.
","('Access_And_Affordability', 0.8921459317207336)","('Customer_Welfare', 0.010453823022544384)","('Product_Quality_And_Safety', 0.009186174720525742)","(['Health Outcome Contribution'], 0.8921459317207336)","('NON-ESG', 0.010453823022544384)","('NON-ESG', 0.009186174720525742)"
Line 37,"We increased our digital  investments in customer and patient engagement, medical  education, and remote support for clinical trials.
","('Access_And_Affordability', 0.6221287846565247)","('Employee_Engagement_Inclusion_And_Diversity', 0.061279553920030594)","('Customer_Welfare', 0.051144033670425415)","(['Health Outcome Contribution'], 0.6221287846565247)","('NON-ESG', 0.061279553920030594)","('NON-ESG', 0.051144033670425415)"
Line 38,"Most   important, we touched the lives of nearly 30 million   patients, took care of one another and supported   communities in need.
","('Access_And_Affordability', 0.8163560032844543)","('Human_Rights_And_Community_Relations', 0.037860698997974396)","('Employee_Health_And_Safety', 0.027137959375977516)","(['Health Outcome Contribution'], 0.8163560032844543)","('NON-ESG', 0.037860698997974396)","('NON-ESG', 0.027137959375977516)"
Line 39,"Responding to COVID-Boston Scientific mobilized quickly to protect  our employees and support global COVID-19   relief efforts.
","('Critical_Incident_Risk_Management', 0.6118726134300232)","('Employee_Health_And_Safety', 0.2918208837509155)","('Human_Rights_And_Community_Relations', 0.015524554997682571)","(['Risk & Crisis Management'], 0.6118726134300232)","('NON-ESG', 0.2918208837509155)","('NON-ESG', 0.015524554997682571)"
Line 40,"We helped communities by   contributing more than $18 million in aid through monetary and supply donations and by   volunteering and providing expertise and resources   in engineering and manufacturing.
","('Human_Rights_And_Community_Relations', 0.5758218169212341)","('Access_And_Affordability', 0.15398019552230835)","('Management_Of_Legal_And_Regulatory_Framework', 0.06698295474052429)","(['Community Relations'], 0.5758218169212341)","('NON-ESG', 0.15398019552230835)","('NON-ESG', 0.06698295474052429)"
Line 41,"Here are some   noteworthy examples of what we accomplished:     Assembled more than one million face shields   and donated them to health care providers.
","('Access_And_Affordability', 0.22904404997825623)","('Customer_Welfare', 0.1362253725528717)","('Management_Of_Legal_And_Regulatory_Framework', 0.07392474263906479)","('NON-ESG', 0.22904404997825623)","('NON-ESG', 0.1362253725528717)","('NON-ESG', 0.07392474263906479)"
Line 42,"Worked with the University of Minnesota Bakken   Medical Devices Center and others in the industry   to create the Coventor , an emergency resuscitator   that can be used when traditional ventilators are   not available.
","('Critical_Incident_Risk_Management', 0.9653193950653076)","('Employee_Health_And_Safety', 0.008397651836276054)","('Air_Quality', 0.0036374148912727833)","(['Risk & Crisis Management'], 0.9653193950653076)","('NON-ESG', 0.008397651836276054)","('NON-ESG', 0.0036374148912727833)"
Line 43,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   Collaborated with an international coalition of medical  experts, clinicians and industry leaders to design and  develop the Pneumask ™ Face Shield, a reusable   full-face mask that was authorized by the Food   and Drug Administration (FDA) for use as personal   protective equipment in clinical settings.
","('Employee_Health_And_Safety', 0.41186535358428955)","('Employee_Engagement_Inclusion_And_Diversity', 0.11473994702100754)","('Product_Design_And_Lifecycle_Management', 0.06960699707269669)","('NON-ESG', 0.41186535358428955)","('NON-ESG', 0.11473994702100754)","('NON-ESG', 0.06960699707269669)"
Line 44,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   Collaborated with an international coalition of medical  experts, clinicians and industry leaders to design and  develop the Pneumask ™ Face Shield, a reusable   full-face mask that was authorized by the Food   and Drug Administration (FDA) for use as personal   protective equipment in clinical settings.
","('Employee_Health_And_Safety', 0.8425152897834778)","('Critical_Incident_Risk_Management', 0.07874394953250885)","('Product_Design_And_Lifecycle_Management', 0.00961222406476736)","(['Operational Eco-Efficiency'], 0.8425152897834778)","('NON-ESG', 0.07874394953250885)","('NON-ESG', 0.00961222406476736)"
Line 45,"Tapped our supply chain capabilities to help source   and produce parts for commercial ventilators and to  enable increased global production of transportable  ventilators.
","('Supply_Chain_Management', 0.5680220723152161)","('Product_Design_And_Lifecycle_Management', 0.16853861510753632)","('Energy_Management', 0.05672059953212738)","(['Supply Chain Management'], 0.5680220723152161)","('NON-ESG', 0.16853861510753632)","('NON-ESG', 0.05672059953212738)"
Line 46,"We did all this while making significant changes to   our global workforce operations to keep employees,   customers and patients safe.
","('Employee_Health_And_Safety', 0.7597856521606445)","('Critical_Incident_Risk_Management', 0.06726958602666855)","('Access_And_Affordability', 0.04668872803449631)","(['Operational Eco-Efficiency'], 0.7597856521606445)","('NON-ESG', 0.06726958602666855)","('NON-ESG', 0.04668872803449631)"
Line 47,"Our employees rose to   every challenge, and we added resources  to support   their physical, mental and financial health during this  uncertain time.Building a More Diverse, Equitable   and Inclusive Workplace and Society The challenges of COVID-19 and the racial   injustice and social unrest we experienced   in 2020 underscore how important it is that   we address the root causes of racism and  build a more equitable, inclusive society — within Boston  Scientific and our communities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8285586833953857)","('Human_Rights_And_Community_Relations', 0.07716691493988037)","('Employee_Health_And_Safety', 0.011505953967571259)","(['Human Capital Development'], 0.8285586833953857)","('NON-ESG', 0.07716691493988037)","('NON-ESG', 0.011505953967571259)"
Line 48,"In 2020, we made   progress against our goals and took the following   actions to support diversity, equity and inclusion:     Expanded on our 2017 diversity and inclusion goals   with 3Up by 2023 , an initiative to increase representation  of multicultural talent and women at the supervisory   and managerial levels to 23 percent and 43 percent,  respectively.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9757558107376099)","('Employee_Health_And_Safety', 0.0019953949376940727)","('Human_Rights_And_Community_Relations', 0.00148360978346318)","(['Human Capital Development'], 0.9757558107376099)","('NON-ESG', 0.0019953949376940727)","('NON-ESG', 0.00148360978346318)"
Line 49,"Achieved 99+ percent pay equity for gender globally   and 99+ percent pay equity for multicultural talent in   the United States, including Puerto Rico.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9710772633552551)","('Access_And_Affordability', 0.002645739121362567)","('Human_Rights_And_Community_Relations', 0.0019356805132701993)","(['Human Capital Development'], 0.9710772633552551)","('NON-ESG', 0.002645739121362567)","('NON-ESG', 0.0019356805132701993)"
Line 50,"Announced a $3.5 million multiyear investment to   combat racism in the United States, with a focus on   advocacy in five areas: community, economic   empowerment, education, health care disparities   and government policy.
","('Human_Rights_And_Community_Relations', 0.8349059224128723)","('Access_And_Affordability', 0.05402136966586113)","('Management_Of_Legal_And_Regulatory_Framework', 0.02649625763297081)","(['Community Relations'], 0.8349059224128723)","('NON-ESG', 0.05402136966586113)","('NON-ESG', 0.02649625763297081)"
Line 51,"Through Close the Gap , launched a public service   advertising campaign to increase awareness of health  disparities and promote resources to help health care  providers address them.
","('Access_And_Affordability', 0.6098918914794922)","('Employee_Health_And_Safety', 0.10234972834587097)","('Employee_Engagement_Inclusion_And_Diversity', 0.04304932802915573)","(['Health Outcome Contribution'], 0.6098918914794922)","('NON-ESG', 0.10234972834587097)","('NON-ESG', 0.04304932802915573)"
Line 52,"Supported diverse representation among health care   professionals through scholarships for Black graduate-   level healthcare students.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9561803936958313)","('Access_And_Affordability', 0.005199217237532139)","('Labor_Practices', 0.003174776677042246)","(['Human Capital Development'], 0.9561803936958313)","('NON-ESG', 0.005199217237532139)","('NON-ESG', 0.003174776677042246)"
Line 53,"Funded primary and secondary school grants to   encourage the next generation to achieve in science,  technology, engineering and math (STEM).
","('Access_And_Affordability', 0.8367788195610046)","('Management_Of_Legal_And_Regulatory_Framework', 0.024760058149695396)","('Product_Quality_And_Safety', 0.015233374200761318)","(['Health Outcome Contribution'], 0.8367788195610046)","('NON-ESG', 0.024760058149695396)","('NON-ESG', 0.015233374200761318)"
Line 54,"Our work is guided by core values; they define the culture at Boston Scientific and empower our employees CARING  We act with integrity  and compassion to   support patients,   customers, our   communities and   each other.
","('Human_Rights_And_Community_Relations', 0.6618765592575073)","('Employee_Engagement_Inclusion_And_Diversity', 0.05242069810628891)","('Business_Ethics', 0.043557990342378616)","(['Community Relations'], 0.6618765592575073)","('NON-ESG', 0.05242069810628891)","('NON-ESG', 0.043557990342378616)"
Line 55,"GLOBAL   COLLABORATION We work collaboratively  to pursue global   opportunities that  extend the reach of   our medical solutions.MEANINGFUL   INNOVATION  We foster the creativity  to transform new ideas  into breakthrough   services and solutions  that create value for   patients, customers   and employees.DIVERSITY  We embrace   diversity and value  unique talents, ideas  and experiences of   our employees.HIGH   PERFORMANCE  We strive for high   performance to benefit  our patients, clinicians  and shareholders.WINNING   SPIRIT We adapt to   change and act with  speed, agility and   accountability to   further improve   patient care.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9683618545532227)","('Employee_Health_And_Safety', 0.0034161298535764217)","('Access_And_Affordability', 0.002278589643537998)","(['Human Capital Development'], 0.9683618545532227)","('NON-ESG', 0.0034161298535764217)","('NON-ESG', 0.002278589643537998)"
Line 56,"GLOBAL   COLLABORATION We work collaboratively  to pursue global   opportunities that  extend the reach of   our medical solutions.MEANINGFUL   INNOVATION  We foster the creativity  to transform new ideas  into breakthrough   services and solutions  that create value for   patients, customers   and employees.DIVERSITY  We embrace   diversity and value  unique talents, ideas  and experiences of   our employees.HIGH   PERFORMANCE  We strive for high   performance to benefit  our patients, clinicians  and shareholders.WINNING   SPIRIT We adapt to   change and act with  speed, agility and   accountability to   further improve   patient care.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3043958246707916)","('Access_And_Affordability', 0.1214577928185463)","('Human_Rights_And_Community_Relations', 0.10945221036672592)","('NON-ESG', 0.3043958246707916)","('NON-ESG', 0.1214577928185463)","('NON-ESG', 0.10945221036672592)"
Line 57,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyWorking Together to Create a Better,   More Equitable Future I am grateful for the passion and commitment  of our global team and proud of the progress  we have made.
","('Access_And_Affordability', 0.2464568018913269)","('Human_Rights_And_Community_Relations', 0.18917527794837952)","('Employee_Engagement_Inclusion_And_Diversity', 0.12871116399765015)","('NON-ESG', 0.2464568018913269)","('NON-ESG', 0.18917527794837952)","('NON-ESG', 0.12871116399765015)"
Line 58,"There is much work to be done,  but I continue to be optimistic about the future of our world and the future of Boston Scientific.
","('Business_Model_Resilience', 0.3726896643638611)","('Ecological_Impacts', 0.0841534435749054)","('Management_Of_Legal_And_Regulatory_Framework', 0.07109053432941437)","('NON-ESG', 0.3726896643638611)","('NON-ESG', 0.0841534435749054)","('NON-ESG', 0.07109053432941437)"
Line 59,"We have   a strong pipeline and an extraordinarily talented and   caring team that is committed to achieving our mission   by sustaining ethical and inclusive business practices.
","('Human_Rights_And_Community_Relations', 0.21090982854366302)","('Business_Ethics', 0.20362021028995514)","('Employee_Engagement_Inclusion_And_Diversity', 0.17469371855258942)","('NON-ESG', 0.21090982854366302)","('NON-ESG', 0.20362021028995514)","('NON-ESG', 0.17469371855258942)"
Line 60,"I look forward to continuing our work together to meet   the challenges ahead and to build a better and more   equitable future for all.
","('Human_Rights_And_Community_Relations', 0.4908505380153656)","('Employee_Engagement_Inclusion_And_Diversity', 0.16026371717453003)","('Business_Model_Resilience', 0.06070621311664581)","('NON-ESG', 0.4908505380153656)","('NON-ESG', 0.16026371717453003)","('NON-ESG', 0.06070621311664581)"
Line 61,"Sincerely, Mike Mahoney   Chairman, President and CEO April 15, 2021Adopting Environmentally Sustainable   Business Practices Fulfilling our mission comes with a   responsibility to protect our planet.
","('Product_Design_And_Lifecycle_Management', 0.3104294240474701)","('Ecological_Impacts', 0.27644336223602295)","('Business_Model_Resilience', 0.08317256718873978)","('NON-ESG', 0.3104294240474701)","('NON-ESG', 0.27644336223602295)","('NON-ESG', 0.08317256718873978)"
Line 62,"That’s   why we have set aggressive environmental  goals and consistently achieve reductions  in energy use, greenhouse gas emissions, waste and   water use.
","('GHG_Emissions', 0.9642622470855713)","('Ecological_Impacts', 0.004522826988250017)","('Management_Of_Legal_And_Regulatory_Framework', 0.003993880935013294)","(['Climate Change'], 0.9642622470855713)","('NON-ESG', 0.004522826988250017)","('NON-ESG', 0.003993880935013294)"
Line 63,"In 2017, we committed to achieving carbon neutrality —   net zero carbon emissions — across our manufacturing   and key distribution sites by 2030.
","('GHG_Emissions', 0.7625391483306885)","('Energy_Management', 0.05686691775918007)","('Air_Quality', 0.046415142714977264)","(['Climate Change'], 0.7625391483306885)","('NON-ESG', 0.05686691775918007)","('NON-ESG', 0.046415142714977264)"
Line 64,"To date, we’ve reduced  our carbon footprint by 50 percent.
","('GHG_Emissions', 0.6142070889472961)","('Physical_Impacts_Of_Climate_Change', 0.11621593683958054)","('Ecological_Impacts', 0.07100620120763779)","(['Climate Change'], 0.6142070889472961)","('NON-ESG', 0.11621593683958054)","('NON-ESG', 0.07100620120763779)"
Line 65,"Our manufacturing   sites in Heredia and Coyol, Costa Rica use hydroelectric,  wind and solar power and have been carbon-neutral since  2016.
","('Energy_Management', 0.8242834210395813)","('Product_Design_And_Lifecycle_Management', 0.05133742466568947)","('Supply_Chain_Management', 0.02094980701804161)","(['Operational Eco-Efficiency'], 0.8242834210395813)","('NON-ESG', 0.05133742466568947)","('NON-ESG', 0.02094980701804161)"
Line 66,"Our facilities in Clonmel, Cork and Galway, Ireland, as  well as Kerkrade, the Netherlands source only 100 percent  renewable energy.
","('Energy_Management', 0.9743004441261292)","('Management_Of_Legal_And_Regulatory_Framework', 0.003866736777126789)","('Air_Quality', 0.002102629980072379)","(['Operational Eco-Efficiency'], 0.9743004441261292)","('NON-ESG', 0.003866736777126789)","('NON-ESG', 0.002102629980072379)"
Line 67,"By 2024, we expect to source or   generate 100 percent of our electricity from renewable  energy sources.
","('Energy_Management', 0.9798290133476257)","('Management_Of_Legal_And_Regulatory_Framework', 0.002524102572351694)","('Product_Design_And_Lifecycle_Management', 0.0015418122056871653)","(['Operational Eco-Efficiency'], 0.9798290133476257)","('NON-ESG', 0.002524102572351694)","('NON-ESG', 0.0015418122056871653)"
Line 68,"Although Boston Scientific is already a   low-intensity water user, we’ve reduced water usage by   23 percent over the last decade.
","('Water_And_Wastewater_Management', 0.9770004749298096)","('GHG_Emissions', 0.0023162998259067535)","('Energy_Management', 0.002028629183769226)","(['Operational Eco-Efficiency'], 0.9770004749298096)","('NON-ESG', 0.0023162998259067535)","('NON-ESG', 0.002028629183769226)"
Line 69,"And in 2020 we diverted  94 percent of landfill solid waste through recycling,   plastic segregation, redesigning packaging and other   environmentally responsible measures.
","('Waste_And_Hazardous_Materials_Management', 0.9825721979141235)","('Water_And_Wastewater_Management', 0.0016714617377147079)","('Product_Design_And_Lifecycle_Management', 0.0016332647064700723)","(['Operational Eco-Efficiency'], 0.9825721979141235)","('NON-ESG', 0.0016714617377147079)","('NON-ESG', 0.0016332647064700723)"
Line 70,"“ 2020 taught us that when science,   humanity and purpose connect, we can  make a meaningful difference in the   world.
","('Human_Rights_And_Community_Relations', 0.4104034900665283)","('Employee_Engagement_Inclusion_And_Diversity', 0.11369168758392334)","('Business_Model_Resilience', 0.06810007989406586)","('NON-ESG', 0.4104034900665283)","('NON-ESG', 0.11369168758392334)","('NON-ESG', 0.06810007989406586)"
Line 71,"We measure our progress by the   ways in which we transform care, invest   in our people, advance possibilities,   protect the environment and create   value responsibly.” transform invest protectcreateadvance	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyPERIPHERAL   INTERVENTIONS $1,577 million Devices for   diagnosis and   minimally invasive  treatments of   peripheral   vascular disease   and cancerELECTROPHYSIOLOGY $287 million A broad range   of mapping   and treatment   technologies for   diagnosing and   treating heart   rhythm disordersENDOSCOPY   $1,780 million Minimally   invasive devices   for diagnosing   and treating   gastrointestinal   and pulmonary   conditionsCARDIAC RHYTHM   MANAGEMENT  $1,704 million Technologies   that treat irregular  heart rhythms and  heart failure and   help protect   against sudden   cardiac death  INTERVENTIONAL   CARDIOLOGY  $2,299 million Minimally invasive   innovations that   help improve the   lives of patients   living with heart   and vascular   conditionsNEUROMODULATION $761 million Electronic   implantable   technologies that   help patients manage  debilitating chronic  pain and neurological   conditionsCARDIOVASCULAR RHYTHM   +   NEURO UROLOGY   +   PELVIC HEALTH $1,286 million Solutions for   urological diseases   including stone   disease, men’s   health and   women’s healthMEDSURG Boston Scientific transforms lives through innovative medical solutions that improve the health   of patients around the world.
","('Human_Rights_And_Community_Relations', 0.5610796809196472)","('Access_And_Affordability', 0.12018177658319473)","('Business_Model_Resilience', 0.044552356004714966)","(['Community Relations'], 0.5610796809196472)","('NON-ESG', 0.12018177658319473)","('NON-ESG', 0.044552356004714966)"
Line 72,"We measure our progress by the   ways in which we transform care, invest   in our people, advance possibilities,   protect the environment and create   value responsibly.” transform invest protectcreateadvance	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyPERIPHERAL   INTERVENTIONS $1,577 million Devices for   diagnosis and   minimally invasive  treatments of   peripheral   vascular disease   and cancerELECTROPHYSIOLOGY $287 million A broad range   of mapping   and treatment   technologies for   diagnosing and   treating heart   rhythm disordersENDOSCOPY   $1,780 million Minimally   invasive devices   for diagnosing   and treating   gastrointestinal   and pulmonary   conditionsCARDIAC RHYTHM   MANAGEMENT  $1,704 million Technologies   that treat irregular  heart rhythms and  heart failure and   help protect   against sudden   cardiac death  INTERVENTIONAL   CARDIOLOGY  $2,299 million Minimally invasive   innovations that   help improve the   lives of patients   living with heart   and vascular   conditionsNEUROMODULATION $761 million Electronic   implantable   technologies that   help patients manage  debilitating chronic  pain and neurological   conditionsCARDIOVASCULAR RHYTHM   +   NEURO UROLOGY   +   PELVIC HEALTH $1,286 million Solutions for   urological diseases   including stone   disease, men’s   health and   women’s healthMEDSURG Boston Scientific transforms lives through innovative medical solutions that improve the health   of patients around the world.
","('Employee_Health_And_Safety', 0.37327781319618225)","('Access_And_Affordability', 0.13404260575771332)","('Critical_Incident_Risk_Management', 0.08096485584974289)","('NON-ESG', 0.37327781319618225)","('NON-ESG', 0.13404260575771332)","('NON-ESG', 0.08096485584974289)"
Line 73,"We measure our progress by the   ways in which we transform care, invest   in our people, advance possibilities,   protect the environment and create   value responsibly.” transform invest protectcreateadvance	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyPERIPHERAL   INTERVENTIONS $1,577 million Devices for   diagnosis and   minimally invasive  treatments of   peripheral   vascular disease   and cancerELECTROPHYSIOLOGY $287 million A broad range   of mapping   and treatment   technologies for   diagnosing and   treating heart   rhythm disordersENDOSCOPY   $1,780 million Minimally   invasive devices   for diagnosing   and treating   gastrointestinal   and pulmonary   conditionsCARDIAC RHYTHM   MANAGEMENT  $1,704 million Technologies   that treat irregular  heart rhythms and  heart failure and   help protect   against sudden   cardiac death  INTERVENTIONAL   CARDIOLOGY  $2,299 million Minimally invasive   innovations that   help improve the   lives of patients   living with heart   and vascular   conditionsNEUROMODULATION $761 million Electronic   implantable   technologies that   help patients manage  debilitating chronic  pain and neurological   conditionsCARDIOVASCULAR RHYTHM   +   NEURO UROLOGY   +   PELVIC HEALTH $1,286 million Solutions for   urological diseases   including stone   disease, men’s   health and   women’s healthMEDSURG Boston Scientific transforms lives through innovative medical solutions that improve the health   of patients around the world.
","('Employee_Health_And_Safety', 0.8764110803604126)","('Critical_Incident_Risk_Management', 0.015965769067406654)","('Access_And_Affordability', 0.015279436483979225)","(['Operational Eco-Efficiency'], 0.8764110803604126)","('NON-ESG', 0.015965769067406654)","('NON-ESG', 0.015279436483979225)"
Line 74,"We measure our progress by the   ways in which we transform care, invest   in our people, advance possibilities,   protect the environment and create   value responsibly.” transform invest protectcreateadvance	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyPERIPHERAL   INTERVENTIONS $1,577 million Devices for   diagnosis and   minimally invasive  treatments of   peripheral   vascular disease   and cancerELECTROPHYSIOLOGY $287 million A broad range   of mapping   and treatment   technologies for   diagnosing and   treating heart   rhythm disordersENDOSCOPY   $1,780 million Minimally   invasive devices   for diagnosing   and treating   gastrointestinal   and pulmonary   conditionsCARDIAC RHYTHM   MANAGEMENT  $1,704 million Technologies   that treat irregular  heart rhythms and  heart failure and   help protect   against sudden   cardiac death  INTERVENTIONAL   CARDIOLOGY  $2,299 million Minimally invasive   innovations that   help improve the   lives of patients   living with heart   and vascular   conditionsNEUROMODULATION $761 million Electronic   implantable   technologies that   help patients manage  debilitating chronic  pain and neurological   conditionsCARDIOVASCULAR RHYTHM   +   NEURO UROLOGY   +   PELVIC HEALTH $1,286 million Solutions for   urological diseases   including stone   disease, men’s   health and   women’s healthMEDSURG Boston Scientific transforms lives through innovative medical solutions that improve the health   of patients around the world.
","('Access_And_Affordability', 0.5013803839683533)","('Employee_Health_And_Safety', 0.11803732812404633)","('Critical_Incident_Risk_Management', 0.048779550939798355)","(['Health Outcome Contribution'], 0.5013803839683533)","('NON-ESG', 0.11803732812404633)","('NON-ESG', 0.048779550939798355)"
Line 75,"As a global medical technology leader for more than 40 years, we   advance science for life by providing a broad range of high-performance solutions that address   unmet patient needs and reduce the cost of health care.
","('Energy_Management', 0.2465939074754715)","('Access_And_Affordability', 0.2022417038679123)","('Product_Design_And_Lifecycle_Management', 0.11001111567020416)","('NON-ESG', 0.2465939074754715)","('NON-ESG', 0.2022417038679123)","('NON-ESG', 0.11001111567020416)"
Line 76,"Boston Scientific   at a Glance NET SALES BY PRODUCT CATEGOR Y2 (dollars in millions) NET SALES BY REGION (dollars in millions) $9,913 1	We	have	three	reportable	segments	comprised	of	Medical	Surgical	(MedSurg), 	Rhythm	and	Neuro, 	and	Cardiovascular, 	which	represent	an	 aggregation	of	our	operating	segments	that	generate	revenues	from	the	sale	of	medical	devices	(Medical	Devices).
","('Product_Design_And_Lifecycle_Management', 0.7513071298599243)","('Customer_Welfare', 0.08278847485780716)","('Selling_Practices_And_Product_Labeling', 0.037532106041908264)","(['Product Stewardship'], 0.7513071298599243)","('NON-ESG', 0.08278847485780716)","('NON-ESG', 0.037532106041908264)"
Line 77,"We	have	included	the	results	 of	BTG’s	Interventional	Medicine	business	in	our	Peripheral	Interventions	operating	segment	since	the	date	of	acquisition.
","('Access_And_Affordability', 0.516565203666687)","('Customer_Welfare', 0.07533854246139526)","('Systemic_Risk_Management', 0.03557313606142998)","(['Health Outcome Contribution'], 0.516565203666687)","('NON-ESG', 0.07533854246139526)","('NON-ESG', 0.03557313606142998)"
Line 78,"2 As	part	of	our	 acquisition	of	BTG, 	we	acquired	a	specialty	pharmaceuticals	business	(Specialty	Pharmaceuticals), 	a	stand-alone	operating	segment	presented	 alongside	our	Medical	Device	reportable	segments.
","('Customer_Welfare', 0.23084720969200134)","('Competitive_Behavior', 0.22406964004039764)","('Business_Model_Resilience', 0.08969634026288986)","('NON-ESG', 0.23084720969200134)","('NON-ESG', 0.22406964004039764)","('NON-ESG', 0.08969634026288986)"
Line 79,"On	March	1, 	2021,	we	completed	the	sale	of	the	Specialty	Pharmaceuticals	business	to	Stark	 International	Lux	S.A.R.L. 	and	SERB	SAS, 	affiliates	of	SERB, 	for	a	purchase	price	of	$800	million.
","('Customer_Welfare', 0.21408353745937347)","('Competitive_Behavior', 0.15162605047225952)","('Selling_Practices_And_Product_Labeling', 0.11007653176784515)","('NON-ESG', 0.21408353745937347)","('NON-ESG', 0.15162605047225952)","('NON-ESG', 0.11007653176784515)"
Line 80,"U.S.   $5,508    EMEA (Europe, Middle East and Africa)  2,097     APAC (Asia-Pacific)  1,781     LACA (Latin America and Canada)  307   Medical Devices1  9,694  Specialty Pharmaceuticals2 219  Net Sales   $9,913	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Meaningful   InnovationBoston Scientific collaborates with health care professionals to develop meaningful   innovations that help more people live longer, healthier lives.
","('Business_Model_Resilience', 0.27979743480682373)","('Product_Design_And_Lifecycle_Management', 0.14586569368839264)","('Customer_Welfare', 0.14220984280109406)","('NON-ESG', 0.27979743480682373)","('NON-ESG', 0.14586569368839264)","('NON-ESG', 0.14220984280109406)"
Line 81,"U.S.   $5,508    EMEA (Europe, Middle East and Africa)  2,097     APAC (Asia-Pacific)  1,781     LACA (Latin America and Canada)  307   Medical Devices1  9,694  Specialty Pharmaceuticals2 219  Net Sales   $9,913	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Meaningful   InnovationBoston Scientific collaborates with health care professionals to develop meaningful   innovations that help more people live longer, healthier lives.
","('Access_And_Affordability', 0.47099587321281433)","('Employee_Health_And_Safety', 0.2597910761833191)","('Product_Quality_And_Safety', 0.02972337417304516)","('NON-ESG', 0.47099587321281433)","('NON-ESG', 0.2597910761833191)","('NON-ESG', 0.02972337417304516)"
Line 82,"We invest in bringing new  products to large, high-growth markets while building our unique pipeline of technologies  to expand our category leadership and address unmet patient needs.
","('Product_Design_And_Lifecycle_Management', 0.9515947103500366)","('Customer_Welfare', 0.0069383191876113415)","('Product_Quality_And_Safety', 0.00433534337207675)","(['Product Stewardship'], 0.9515947103500366)","('NON-ESG', 0.0069383191876113415)","('NON-ESG', 0.00433534337207675)"
Line 83,"Our innovative   culture has enabled us to serve approximately 30 million patients annually.
","('Access_And_Affordability', 0.3923634886741638)","('Employee_Engagement_Inclusion_And_Diversity', 0.17461787164211273)","('Customer_Welfare', 0.0688377320766449)","('NON-ESG', 0.3923634886741638)","('NON-ESG', 0.17461787164211273)","('NON-ESG', 0.0688377320766449)"
Line 84,"KEY PRODUCTS  WATCHMAN FLX™ Left Atrial Appendage Closure Device  ACURATE neo2 ™ Aortic Valve System   ROTAPRO™ Rotational Atherectomy System   ELUVIA ™ Drug-Eluting Vascular Stent System and   Ranger™ Drug Coated Balloon  TheraSphere ™ Y-90 Glass Microspheres  AngioJet™ Peripheral Thrombectomy System  EkoSonic™ Endovascular System  HeartLogic™ Heart Failure Diagnostic   LUX-Dx™ Insertable Cardiac Monitor System  POLARx™ Cryoablation System     WaveWriter Alpha™ Spinal Cord Stimulation System   Vertiflex™ Procedure, Superion™ Indirect   Decompression System  Vercise Genus ™ Deep Brain Stimulation System   EXALT™ Model D Single-use Duodenoscope,    SpyGlass™ Discover Digital Catheter   A X I O S ™ Stent and Electrocautery-Enhanced Delivery System   O R I S E ™ Gel Submucosal Lifting Agent and ORISE ™   ProKnife Electrosurgical Knife   LithoVue™ Single-Use Digital Flexible Ureteroscope  SpaceOAR ™ Hydrogel Prostate Spacer    SpaceOAR Vue ™ Hydrogel Radiopaque Perirectal Spacer  Rezūm ™ Water Vapor Therapy BUSINESS SEGMENTS BUSINESS UNITS Cardiovascular Interventional Cardiology         Peripheral Interventions         Rhythm and Neuro Rhythm Management    (CRM and EP)      Neuromodulation       MedSurg Endoscopy           Urology and Pelvic HealthHEART SOUNDS THORACIC IMPEDANCE RESPIRATION HEART RATE ACTIVITY COMPOSITE INDEX % LV PACED AT/AF BURDEN WEIGHT SLEEP INCLINE V THERAPYBLOOD PRESSUREHEART RATE VARIABILITY  (SDANN)RV RATE  DURING AT/AF	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 100%   renewable electricity   by Carbon   neutrality   in manufacturing   and key distribution  sites by ADVANCING POSSIBILITIES +$70 million   medical research,   fellowships, educational  and charitable giving +$18 million   COVID-19 relief 15 years   closing the health   disparity gap United by our core values, we are dedicated to transforming lives through innovative  medical solutions, while also making measurable contributions to the world we share.
","('Employee_Health_And_Safety', 0.241425022482872)","('Access_And_Affordability', 0.2095513939857483)","('Customer_Welfare', 0.07126244902610779)","('NON-ESG', 0.241425022482872)","('NON-ESG', 0.2095513939857483)","('NON-ESG', 0.07126244902610779)"
Line 85,"KEY PRODUCTS  WATCHMAN FLX™ Left Atrial Appendage Closure Device  ACURATE neo2 ™ Aortic Valve System   ROTAPRO™ Rotational Atherectomy System   ELUVIA ™ Drug-Eluting Vascular Stent System and   Ranger™ Drug Coated Balloon  TheraSphere ™ Y-90 Glass Microspheres  AngioJet™ Peripheral Thrombectomy System  EkoSonic™ Endovascular System  HeartLogic™ Heart Failure Diagnostic   LUX-Dx™ Insertable Cardiac Monitor System  POLARx™ Cryoablation System     WaveWriter Alpha™ Spinal Cord Stimulation System   Vertiflex™ Procedure, Superion™ Indirect   Decompression System  Vercise Genus ™ Deep Brain Stimulation System   EXALT™ Model D Single-use Duodenoscope,    SpyGlass™ Discover Digital Catheter   A X I O S ™ Stent and Electrocautery-Enhanced Delivery System   O R I S E ™ Gel Submucosal Lifting Agent and ORISE ™   ProKnife Electrosurgical Knife   LithoVue™ Single-Use Digital Flexible Ureteroscope  SpaceOAR ™ Hydrogel Prostate Spacer    SpaceOAR Vue ™ Hydrogel Radiopaque Perirectal Spacer  Rezūm ™ Water Vapor Therapy BUSINESS SEGMENTS BUSINESS UNITS Cardiovascular Interventional Cardiology         Peripheral Interventions         Rhythm and Neuro Rhythm Management    (CRM and EP)      Neuromodulation       MedSurg Endoscopy           Urology and Pelvic HealthHEART SOUNDS THORACIC IMPEDANCE RESPIRATION HEART RATE ACTIVITY COMPOSITE INDEX % LV PACED AT/AF BURDEN WEIGHT SLEEP INCLINE V THERAPYBLOOD PRESSUREHEART RATE VARIABILITY  (SDANN)RV RATE  DURING AT/AF	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 100%   renewable electricity   by Carbon   neutrality   in manufacturing   and key distribution  sites by ADVANCING POSSIBILITIES +$70 million   medical research,   fellowships, educational  and charitable giving +$18 million   COVID-19 relief 15 years   closing the health   disparity gap United by our core values, we are dedicated to transforming lives through innovative  medical solutions, while also making measurable contributions to the world we share.
","('Access_And_Affordability', 0.20652596652507782)","('Employee_Health_And_Safety', 0.19422516226768494)","('Customer_Welfare', 0.09823048114776611)","('NON-ESG', 0.20652596652507782)","('NON-ESG', 0.19422516226768494)","('NON-ESG', 0.09823048114776611)"
Line 86,"KEY PRODUCTS  WATCHMAN FLX™ Left Atrial Appendage Closure Device  ACURATE neo2 ™ Aortic Valve System   ROTAPRO™ Rotational Atherectomy System   ELUVIA ™ Drug-Eluting Vascular Stent System and   Ranger™ Drug Coated Balloon  TheraSphere ™ Y-90 Glass Microspheres  AngioJet™ Peripheral Thrombectomy System  EkoSonic™ Endovascular System  HeartLogic™ Heart Failure Diagnostic   LUX-Dx™ Insertable Cardiac Monitor System  POLARx™ Cryoablation System     WaveWriter Alpha™ Spinal Cord Stimulation System   Vertiflex™ Procedure, Superion™ Indirect   Decompression System  Vercise Genus ™ Deep Brain Stimulation System   EXALT™ Model D Single-use Duodenoscope,    SpyGlass™ Discover Digital Catheter   A X I O S ™ Stent and Electrocautery-Enhanced Delivery System   O R I S E ™ Gel Submucosal Lifting Agent and ORISE ™   ProKnife Electrosurgical Knife   LithoVue™ Single-Use Digital Flexible Ureteroscope  SpaceOAR ™ Hydrogel Prostate Spacer    SpaceOAR Vue ™ Hydrogel Radiopaque Perirectal Spacer  Rezūm ™ Water Vapor Therapy BUSINESS SEGMENTS BUSINESS UNITS Cardiovascular Interventional Cardiology         Peripheral Interventions         Rhythm and Neuro Rhythm Management    (CRM and EP)      Neuromodulation       MedSurg Endoscopy           Urology and Pelvic HealthHEART SOUNDS THORACIC IMPEDANCE RESPIRATION HEART RATE ACTIVITY COMPOSITE INDEX % LV PACED AT/AF BURDEN WEIGHT SLEEP INCLINE V THERAPYBLOOD PRESSUREHEART RATE VARIABILITY  (SDANN)RV RATE  DURING AT/AF	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 100%   renewable electricity   by Carbon   neutrality   in manufacturing   and key distribution  sites by ADVANCING POSSIBILITIES +$70 million   medical research,   fellowships, educational  and charitable giving +$18 million   COVID-19 relief 15 years   closing the health   disparity gap United by our core values, we are dedicated to transforming lives through innovative  medical solutions, while also making measurable contributions to the world we share.
","('Employee_Health_And_Safety', 0.3779958486557007)","('Access_And_Affordability', 0.1606522500514984)","('Customer_Welfare', 0.07418400794267654)","('NON-ESG', 0.3779958486557007)","('NON-ESG', 0.1606522500514984)","('NON-ESG', 0.07418400794267654)"
Line 87,"KEY PRODUCTS  WATCHMAN FLX™ Left Atrial Appendage Closure Device  ACURATE neo2 ™ Aortic Valve System   ROTAPRO™ Rotational Atherectomy System   ELUVIA ™ Drug-Eluting Vascular Stent System and   Ranger™ Drug Coated Balloon  TheraSphere ™ Y-90 Glass Microspheres  AngioJet™ Peripheral Thrombectomy System  EkoSonic™ Endovascular System  HeartLogic™ Heart Failure Diagnostic   LUX-Dx™ Insertable Cardiac Monitor System  POLARx™ Cryoablation System     WaveWriter Alpha™ Spinal Cord Stimulation System   Vertiflex™ Procedure, Superion™ Indirect   Decompression System  Vercise Genus ™ Deep Brain Stimulation System   EXALT™ Model D Single-use Duodenoscope,    SpyGlass™ Discover Digital Catheter   A X I O S ™ Stent and Electrocautery-Enhanced Delivery System   O R I S E ™ Gel Submucosal Lifting Agent and ORISE ™   ProKnife Electrosurgical Knife   LithoVue™ Single-Use Digital Flexible Ureteroscope  SpaceOAR ™ Hydrogel Prostate Spacer    SpaceOAR Vue ™ Hydrogel Radiopaque Perirectal Spacer  Rezūm ™ Water Vapor Therapy BUSINESS SEGMENTS BUSINESS UNITS Cardiovascular Interventional Cardiology         Peripheral Interventions         Rhythm and Neuro Rhythm Management    (CRM and EP)      Neuromodulation       MedSurg Endoscopy           Urology and Pelvic HealthHEART SOUNDS THORACIC IMPEDANCE RESPIRATION HEART RATE ACTIVITY COMPOSITE INDEX % LV PACED AT/AF BURDEN WEIGHT SLEEP INCLINE V THERAPYBLOOD PRESSUREHEART RATE VARIABILITY  (SDANN)RV RATE  DURING AT/AF	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 100%   renewable electricity   by Carbon   neutrality   in manufacturing   and key distribution  sites by ADVANCING POSSIBILITIES +$70 million   medical research,   fellowships, educational  and charitable giving +$18 million   COVID-19 relief 15 years   closing the health   disparity gap United by our core values, we are dedicated to transforming lives through innovative  medical solutions, while also making measurable contributions to the world we share.
","('Access_And_Affordability', 0.533330500125885)","('Management_Of_Legal_And_Regulatory_Framework', 0.09537166357040405)","('Human_Rights_And_Community_Relations', 0.079465351998806)","(['Health Outcome Contribution'], 0.533330500125885)","('NON-ESG', 0.09537166357040405)","('NON-ESG', 0.079465351998806)"
Line 88,"KEY PRODUCTS  WATCHMAN FLX™ Left Atrial Appendage Closure Device  ACURATE neo2 ™ Aortic Valve System   ROTAPRO™ Rotational Atherectomy System   ELUVIA ™ Drug-Eluting Vascular Stent System and   Ranger™ Drug Coated Balloon  TheraSphere ™ Y-90 Glass Microspheres  AngioJet™ Peripheral Thrombectomy System  EkoSonic™ Endovascular System  HeartLogic™ Heart Failure Diagnostic   LUX-Dx™ Insertable Cardiac Monitor System  POLARx™ Cryoablation System     WaveWriter Alpha™ Spinal Cord Stimulation System   Vertiflex™ Procedure, Superion™ Indirect   Decompression System  Vercise Genus ™ Deep Brain Stimulation System   EXALT™ Model D Single-use Duodenoscope,    SpyGlass™ Discover Digital Catheter   A X I O S ™ Stent and Electrocautery-Enhanced Delivery System   O R I S E ™ Gel Submucosal Lifting Agent and ORISE ™   ProKnife Electrosurgical Knife   LithoVue™ Single-Use Digital Flexible Ureteroscope  SpaceOAR ™ Hydrogel Prostate Spacer    SpaceOAR Vue ™ Hydrogel Radiopaque Perirectal Spacer  Rezūm ™ Water Vapor Therapy BUSINESS SEGMENTS BUSINESS UNITS Cardiovascular Interventional Cardiology         Peripheral Interventions         Rhythm and Neuro Rhythm Management    (CRM and EP)      Neuromodulation       MedSurg Endoscopy           Urology and Pelvic HealthHEART SOUNDS THORACIC IMPEDANCE RESPIRATION HEART RATE ACTIVITY COMPOSITE INDEX % LV PACED AT/AF BURDEN WEIGHT SLEEP INCLINE V THERAPYBLOOD PRESSUREHEART RATE VARIABILITY  (SDANN)RV RATE  DURING AT/AF	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 100%   renewable electricity   by Carbon   neutrality   in manufacturing   and key distribution  sites by ADVANCING POSSIBILITIES +$70 million   medical research,   fellowships, educational  and charitable giving +$18 million   COVID-19 relief 15 years   closing the health   disparity gap United by our core values, we are dedicated to transforming lives through innovative  medical solutions, while also making measurable contributions to the world we share.
","('Access_And_Affordability', 0.30147331953048706)","('Product_Design_And_Lifecycle_Management', 0.2276875227689743)","('Customer_Welfare', 0.08468514680862427)","('NON-ESG', 0.30147331953048706)","('NON-ESG', 0.2276875227689743)","('NON-ESG', 0.08468514680862427)"
Line 89,"Here are some highlights.
","('Systemic_Risk_Management', 0.16914144158363342)","('Management_Of_Legal_And_Regulatory_Framework', 0.10659289360046387)","('Business_Model_Resilience', 0.0906069204211235)","('NON-ESG', 0.16914144158363342)","('NON-ESG', 0.10659289360046387)","('NON-ESG', 0.0906069204211235)"
Line 90,"Boston Scientific   by the Numbers  +$1 billion   invested in R&D ~30 million   patients servedNewsweek   America’s Most   Responsible   Companies Member of   Dow Jones   Sustainability Indices   Powered by the S&P Global CSA  Forbes   America’s Most   JUST  Companies Culture   Champion 2020   MIT Sloan Management  Review/Glassdoor TRANSFORMING CARE PROTECTING THE ENVIRONMENT CREATING VALUE RESPONSIBLY +99%   pay equity Top 10%   globally recognized   leader for workplace  inclusionINVESTING IN OUR PEOPLE 	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly SUSTAINABLE DEVELOPMENT GOALS AND MATERIAL TOPICS At Boston Scientific, corporate social responsibility (CSR)  underpins all our business practices, and our approach is  aligned with the United Nations Sustainable Development  Goals (SDGs).
","('Employee_Engagement_Inclusion_And_Diversity', 0.36491918563842773)","('Human_Rights_And_Community_Relations', 0.26283252239227295)","('Access_And_Affordability', 0.08491837978363037)","('NON-ESG', 0.36491918563842773)","('NON-ESG', 0.26283252239227295)","('NON-ESG', 0.08491837978363037)"
Line 91,"Boston Scientific   by the Numbers  +$1 billion   invested in R&D ~30 million   patients servedNewsweek   America’s Most   Responsible   Companies Member of   Dow Jones   Sustainability Indices   Powered by the S&P Global CSA  Forbes   America’s Most   JUST  Companies Culture   Champion 2020   MIT Sloan Management  Review/Glassdoor TRANSFORMING CARE PROTECTING THE ENVIRONMENT CREATING VALUE RESPONSIBLY +99%   pay equity Top 10%   globally recognized   leader for workplace  inclusionINVESTING IN OUR PEOPLE 	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly SUSTAINABLE DEVELOPMENT GOALS AND MATERIAL TOPICS At Boston Scientific, corporate social responsibility (CSR)  underpins all our business practices, and our approach is  aligned with the United Nations Sustainable Development  Goals (SDGs).
","('Human_Rights_And_Community_Relations', 0.8745654821395874)","('Business_Model_Resilience', 0.02122136950492859)","('Ecological_Impacts', 0.010359843261539936)","(['Community Relations'], 0.8745654821395874)","('NON-ESG', 0.02122136950492859)","('NON-ESG', 0.010359843261539936)"
Line 92,"CSR Strategy and Practices Our CSR strategy, material topics and practices are   informed by conversations with diverse stakeholders   inside and outside the company — locally, nationally   and globally.
","('Human_Rights_And_Community_Relations', 0.35232964158058167)","('Management_Of_Legal_And_Regulatory_Framework', 0.22971737384796143)","('Business_Model_Resilience', 0.0735776349902153)","('NON-ESG', 0.35232964158058167)","('NON-ESG', 0.22971737384796143)","('NON-ESG', 0.0735776349902153)"
Line 93,"In our collaborations and other business   relationships, we work with organizations that share   our commitment to better understand and improve   environmental, social and economic progress.
","('Human_Rights_And_Community_Relations', 0.9381877779960632)","('Management_Of_Legal_And_Regulatory_Framework', 0.0068100024946033955)","('Ecological_Impacts', 0.006005723960697651)","(['Community Relations'], 0.9381877779960632)","('NON-ESG', 0.0068100024946033955)","('NON-ESG', 0.006005723960697651)"
Line 94,"In more than 100 countries, our people work with an  awareness of the world’s most pressing challenges,   including inequity, economic disparity, climate change and  environmental protection.
","('Physical_Impacts_Of_Climate_Change', 0.9467137455940247)","('Business_Model_Resilience', 0.012629007920622826)","('GHG_Emissions', 0.004602854140102863)","(['Climate Change'], 0.9467137455940247)","('NON-ESG', 0.012629007920622826)","('NON-ESG', 0.004602854140102863)"
Line 95,"Their efforts are supported by:    Our cross-functional CSR Council.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4683608412742615)","('Human_Rights_And_Community_Relations', 0.1620955616235733)","('Competitive_Behavior', 0.06306219846010208)","('NON-ESG', 0.4683608412742615)","('NON-ESG', 0.1620955616235733)","('NON-ESG', 0.06306219846010208)"
Line 96,"Environmental Health and Safety (EH&S) policies.
","('Employee_Health_And_Safety', 0.7493963837623596)","('Critical_Incident_Risk_Management', 0.08102354407310486)","('Product_Quality_And_Safety', 0.03548818081617355)","(['Operational Eco-Efficiency'], 0.7493963837623596)","('NON-ESG', 0.08102354407310486)","('NON-ESG', 0.03548818081617355)"
Line 97,"Global Council for Inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7602628469467163)","('Human_Rights_And_Community_Relations', 0.11970312893390656)","('Access_And_Affordability', 0.012525437399744987)","(['Human Capital Development'], 0.7602628469467163)","('NON-ESG', 0.11970312893390656)","('NON-ESG', 0.012525437399744987)"
Line 98,"Local, regional and national employee and community  programs.
","('Human_Rights_And_Community_Relations', 0.8168846964836121)","('Employee_Engagement_Inclusion_And_Diversity', 0.07150755077600479)","('Employee_Health_And_Safety', 0.019010324031114578)","(['Community Relations'], 0.8168846964836121)","('NON-ESG', 0.07150755077600479)","('NON-ESG', 0.019010324031114578)"
Line 99,"Corporate Social   Responsibility   at Boston Scientific The CSR Council includes subject matter experts from  throughout the company who help define our CSR strategy  and ensure accountability.
","('Human_Rights_And_Community_Relations', 0.8574752807617188)","('Management_Of_Legal_And_Regulatory_Framework', 0.031153682619333267)","('Access_And_Affordability', 0.011758793145418167)","(['Community Relations'], 0.8574752807617188)","('NON-ESG', 0.031153682619333267)","('NON-ESG', 0.011758793145418167)"
Line 100,"An executive steering committee  oversees the Council and champions sustainable practices  across the business.
","('Product_Design_And_Lifecycle_Management', 0.5123047828674316)","('Business_Model_Resilience', 0.08243805170059204)","('Management_Of_Legal_And_Regulatory_Framework', 0.058520492166280746)","(['Product Stewardship'], 0.5123047828674316)","('NON-ESG', 0.08243805170059204)","('NON-ESG', 0.058520492166280746)"
Line 101,"Within this framework, everyone in the   company contributes to our social responsibility.
","('Human_Rights_And_Community_Relations', 0.9633352756500244)","('Access_And_Affordability', 0.0034772746730595827)","('Ecological_Impacts', 0.0024159811437129974)","(['Community Relations'], 0.9633352756500244)","('NON-ESG', 0.0034772746730595827)","('NON-ESG', 0.0024159811437129974)"
Line 102,"Each year, we participate in several widely recognized   environmental-, social- and governance-rating surveys.
","('Human_Rights_And_Community_Relations', 0.6979909539222717)","('Management_Of_Legal_And_Regulatory_Framework', 0.07084676623344421)","('Business_Model_Resilience', 0.03030351549386978)","(['Community Relations'], 0.6979909539222717)","('NON-ESG', 0.07084676623344421)","('NON-ESG', 0.03030351549386978)"
Line 103,"In  2020, we initiated a climate risk scenario analysis based  on the Task Force on Climate-related Financial Disclosures  framework.
","('Physical_Impacts_Of_Climate_Change', 0.9347817301750183)","('GHG_Emissions', 0.012881805188953876)","('Business_Model_Resilience', 0.012462192215025425)","(['Climate Change'], 0.9347817301750183)","('NON-ESG', 0.012881805188953876)","('NON-ESG', 0.012462192215025425)"
Line 104,"TRANSFORMING CARE Material topics:  Innovative products INVESTING IN OUR PEOPLE Material topics:  Career, culture and talent    Diversity, equity and inclusion    Worker health and safety ADVANCING POSSIBILITIES Material topics:  Community engagement PROTECTING THE ENVIRONMENT Material topics:  Environmental impact    Climate change   CREATING VALUE RESPONSIBLY Material topics:  Governance  Compliance and ethics  Sustainable supply chain	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Transforming   carePURPOSE Advancing standards   of careHUMANITY Pursuing breakthrough  ideasSCIENCE Transforming   Care Our commitment to improving the   lives of patients requires high levels  of research, quality and innovation in  every aspect of our operations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8239836096763611)","('Employee_Health_And_Safety', 0.025302430614829063)","('Access_And_Affordability', 0.023128140717744827)","(['Human Capital Development'], 0.8239836096763611)","('NON-ESG', 0.025302430614829063)","('NON-ESG', 0.023128140717744827)"
Line 105,"TRANSFORMING CARE Material topics:  Innovative products INVESTING IN OUR PEOPLE Material topics:  Career, culture and talent    Diversity, equity and inclusion    Worker health and safety ADVANCING POSSIBILITIES Material topics:  Community engagement PROTECTING THE ENVIRONMENT Material topics:  Environmental impact    Climate change   CREATING VALUE RESPONSIBLY Material topics:  Governance  Compliance and ethics  Sustainable supply chain	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Transforming   carePURPOSE Advancing standards   of careHUMANITY Pursuing breakthrough  ideasSCIENCE Transforming   Care Our commitment to improving the   lives of patients requires high levels  of research, quality and innovation in  every aspect of our operations.
","('Access_And_Affordability', 0.32384127378463745)","('Customer_Welfare', 0.08868289738893509)","('Business_Model_Resilience', 0.08054528385400772)","('NON-ESG', 0.32384127378463745)","('NON-ESG', 0.08868289738893509)","('NON-ESG', 0.08054528385400772)"
Line 106,"Boston Scientific teams collaborate across the   company and with health care providers and other  trusted external experts to design and make solutions  for the health care challenges that matter the most.
","('Access_And_Affordability', 0.360672265291214)","('Supply_Chain_Management', 0.07708672434091568)","('Customer_Welfare', 0.0765145942568779)","('NON-ESG', 0.360672265291214)","('NON-ESG', 0.07708672434091568)","('NON-ESG', 0.0765145942568779)"
Line 107,"We are inspired by the people who have been   helped by our products, and we are driven to serve  those who need breakthroughs that have not yet  been invented.
","('Product_Design_And_Lifecycle_Management', 0.9313885569572449)","('Customer_Welfare', 0.009136028587818146)","('Product_Quality_And_Safety', 0.007687001023441553)","(['Product Stewardship'], 0.9313885569572449)","('NON-ESG', 0.009136028587818146)","('NON-ESG', 0.007687001023441553)"
Line 108,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Our Approach to   Innovative and Quality  Products  Boston Scientific product development teams follow   a uniform, global approach that combines business,   technical and quality processes.
","('Product_Design_And_Lifecycle_Management', 0.9358605742454529)","('Product_Quality_And_Safety', 0.014616511762142181)","('Selling_Practices_And_Product_Labeling', 0.008428642526268959)","(['Product Stewardship'], 0.9358605742454529)","('NON-ESG', 0.014616511762142181)","('NON-ESG', 0.008428642526268959)"
Line 109,"This allows us to   monitor products over their life cycles, from concept   and commercialization through next-generation designs.
","('Product_Design_And_Lifecycle_Management', 0.9675558805465698)","('Business_Model_Resilience', 0.0029055725317448378)","('Customer_Welfare', 0.0028437450528144836)","(['Product Stewardship'], 0.9675558805465698)","('NON-ESG', 0.0029055725317448378)","('NON-ESG', 0.0028437450528144836)"
Line 110,"The data we gather and analyze helps us pursue new   solutions that advance standards of care and address   unmet customer and patient needs.
","('Access_And_Affordability', 0.46779897809028625)","('Customer_Welfare', 0.06565377861261368)","('Energy_Management', 0.039826154708862305)","('NON-ESG', 0.46779897809028625)","('NON-ESG', 0.06565377861261368)","('NON-ESG', 0.039826154708862305)"
Line 111,"We have research and development sites in the   United States, the European Union, Costa Rica, India   and China.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2393709123134613)","('GHG_Emissions', 0.11475569009780884)","('Access_And_Affordability', 0.10694098472595215)","('NON-ESG', 0.2393709123134613)","('NON-ESG', 0.11475569009780884)","('NON-ESG', 0.10694098472595215)"
Line 112,"Some of the sites also serve as R&D Centers   of Excellence where we identify successful practices   and share them across the company to strengthen   our overall R&D capability.SUSTAINABLE DEVELOPMENT GOALS: Katie Crawford helps lead global processes that ensure  quality and safety are incorporated into everything we do.
","('Employee_Health_And_Safety', 0.6699030995368958)","('Product_Quality_And_Safety', 0.19502060115337372)","('Product_Design_And_Lifecycle_Management', 0.020277947187423706)","(['Operational Eco-Efficiency'], 0.6699030995368958)","('NON-ESG', 0.19502060115337372)","('NON-ESG', 0.020277947187423706)"
Line 113,"“ The global reach of our quality system is  critical.
","('Systemic_Risk_Management', 0.3943289816379547)","('Supply_Chain_Management', 0.20806004106998444)","('Business_Ethics', 0.0677274763584137)","('NON-ESG', 0.3943289816379547)","('NON-ESG', 0.20806004106998444)","('NON-ESG', 0.0677274763584137)"
Line 114,"Boston Scientific employees   everywhere know they share responsibility  for the quality and safety of our products.
","('Product_Quality_And_Safety', 0.8257081508636475)","('Product_Design_And_Lifecycle_Management', 0.04745171219110489)","('Employee_Health_And_Safety', 0.0212799534201622)","(['Product Quality & Recall Management'], 0.8257081508636475)","('NON-ESG', 0.04745171219110489)","('NON-ESG', 0.0212799534201622)"
Line 115,"Each site has a comprehensive system for  maintaining quality, which gives us agility  in meeting new requirements such as the  European Union Medical Device Regulation.”            Katie Crawford,  manager, Quality SystemsQuality and Safety Our commitment to meaningful innovation is   matched by a customer- and patient-centric focus   on quality and safety.
","('Product_Quality_And_Safety', 0.8668898344039917)","('Employee_Health_And_Safety', 0.03587350621819496)","('Business_Ethics', 0.010566415265202522)","(['Product Quality & Recall Management'], 0.8668898344039917)","('NON-ESG', 0.03587350621819496)","('NON-ESG', 0.010566415265202522)"
Line 116,"The work and expertise of   Boston Scientific global quality and safety teams   is supported by:   Quality system training  for all employees.
","('Employee_Health_And_Safety', 0.9712097644805908)","('Employee_Engagement_Inclusion_And_Diversity', 0.004834750667214394)","('Product_Quality_And_Safety', 0.0037232881877571344)","(['Operational Eco-Efficiency'], 0.9712097644805908)","('NON-ESG', 0.004834750667214394)","('NON-ESG', 0.0037232881877571344)"
Line 117,"A companywide plan  that prioritizes quality   improvement projects and leads to higher   quality products and better patient outcomes.
","('Product_Quality_And_Safety', 0.29229772090911865)","('Access_And_Affordability', 0.19327659904956818)","('Product_Design_And_Lifecycle_Management', 0.16342398524284363)","('NON-ESG', 0.29229772090911865)","('NON-ESG', 0.19327659904956818)","('NON-ESG', 0.16342398524284363)"
Line 118,"A global quality system  that integrates customer   feedback and regulatory requirements into our   processes.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9234771728515625)","('Competitive_Behavior', 0.01806376688182354)","('Business_Ethics', 0.010220897383987904)","(['Corporate Governance'], 0.9234771728515625)","('NON-ESG', 0.01806376688182354)","('NON-ESG', 0.010220897383987904)"
Line 119,"The Boston Scientific Best4 quality strategy  for   delivering industry-leading culture, compliance,   performance and agility.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3489665985107422)","('Business_Ethics', 0.1722356528043747)","('Systemic_Risk_Management', 0.12245409190654755)","('NON-ESG', 0.3489665985107422)","('NON-ESG', 0.1722356528043747)","('NON-ESG', 0.12245409190654755)"
Line 120,"Innovation Leadership Our success in pursuing and developing  life-changing innovations is recognized by  leading institutions, as summarized on our  website awards page .
","('Product_Design_And_Lifecycle_Management', 0.5630425214767456)","('Business_Model_Resilience', 0.1348533183336258)","('Supply_Chain_Management', 0.03527101129293442)","(['Product Stewardship'], 0.5630425214767456)","('NON-ESG', 0.1348533183336258)","('NON-ESG', 0.03527101129293442)"
Line 121,"GLOBAL QUALITY SYSTEM:           DEVELOPING INNOVATIVE AND SAFE PRODUCTS 	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly  4Best culture: Together we sustain a culture that makes  the quality policy real for every employee.
","('Product_Design_And_Lifecycle_Management', 0.7823417782783508)","('Product_Quality_And_Safety', 0.10756919533014297)","('Customer_Welfare', 0.017760563641786575)","(['Product Stewardship'], 0.7823417782783508)","('NON-ESG', 0.10756919533014297)","('NON-ESG', 0.017760563641786575)"
Line 122,"Our diverse  quality team reinforces the importance of each role in  improving patient lives.
","('Access_And_Affordability', 0.5084830522537231)","('Employee_Engagement_Inclusion_And_Diversity', 0.13000933825969696)","('Employee_Health_And_Safety', 0.07996810972690582)","(['Health Outcome Contribution'], 0.5084830522537231)","('NON-ESG', 0.13000933825969696)","('NON-ESG', 0.07996810972690582)"
Line 123,"Best agility: We add value by reducing complexity,  removing obstacles and adapting to changing business  needs.
","('Business_Model_Resilience', 0.5021935701370239)","('Product_Design_And_Lifecycle_Management', 0.13654375076293945)","('Systemic_Risk_Management', 0.08353371918201447)","(['Codes of Business Conduct'], 0.5021935701370239)","('NON-ESG', 0.13654375076293945)","('NON-ESG', 0.08353371918201447)"
Line 124,"This means having intentional simplicity in   our systems as well as lean practices and the right   technology for process efficiency.
","('Energy_Management', 0.4871920943260193)","('Product_Design_And_Lifecycle_Management', 0.3943340480327606)","('Product_Quality_And_Safety', 0.010332940146327019)","('NON-ESG', 0.4871920943260193)","('NON-ESG', 0.3943340480327606)","('NON-ESG', 0.010332940146327019)"
Line 125,"Best performance: We provide the best products,   services and solutions for patients and customers,   using a quality by design approach that emphasizes  continuous improvement.
","('Product_Design_And_Lifecycle_Management', 0.9598899483680725)","('Product_Quality_And_Safety', 0.0055809239856898785)","('Customer_Welfare', 0.004014389123767614)","(['Product Stewardship'], 0.9598899483680725)","('NON-ESG', 0.0055809239856898785)","('NON-ESG', 0.004014389123767614)"
Line 126,"Best compliance: We comply with global laws and  regulations using one global quality system.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8890429139137268)","('Business_Ethics', 0.045535460114479065)","('Product_Quality_And_Safety', 0.006350737530738115)","(['Corporate Governance'], 0.8890429139137268)","('NON-ESG', 0.045535460114479065)","('NON-ESG', 0.006350737530738115)"
Line 127,"This work  includes ongoing risk mitigation and an effective   transition to the European Union Medical Device   Regulation (EU MDR).BEST4 STRATEGY To ensure the safety and efficacy of our new technologies  and tools, we follow a global design controls process that  incorporates risk management and usability engineering.
","('Product_Quality_And_Safety', 0.781234860420227)","('Employee_Health_And_Safety', 0.11541328579187393)","('Product_Design_And_Lifecycle_Management', 0.01590244472026825)","(['Product Quality & Recall Management'], 0.781234860420227)","('NON-ESG', 0.11541328579187393)","('NON-ESG', 0.01590244472026825)"
Line 128,"At every stage of development, our teams focus on the  patients who will benefit from their efforts.
","('Access_And_Affordability', 0.8008827567100525)","('Human_Rights_And_Community_Relations', 0.027107276022434235)","('Employee_Health_And_Safety', 0.019985081627964973)","(['Health Outcome Contribution'], 0.8008827567100525)","('NON-ESG', 0.027107276022434235)","('NON-ESG', 0.019985081627964973)"
Line 129,"This includes  assessing component and device materials for quality   and durability, availability, safety and efficacy.
","('Product_Design_And_Lifecycle_Management', 0.4337245225906372)","('Product_Quality_And_Safety', 0.4161750376224518)","('Waste_And_Hazardous_Materials_Management', 0.015885593369603157)","('NON-ESG', 0.4337245225906372)","('NON-ESG', 0.4161750376224518)","('NON-ESG', 0.015885593369603157)"
Line 130,"Our teams  also take into consideration medical and environmental  requirements and other regulations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8208469152450562)","('Product_Quality_And_Safety', 0.020459456369280815)","('Employee_Health_And_Safety', 0.015433463267982006)","(['Corporate Governance'], 0.8208469152450562)","('NON-ESG', 0.020459456369280815)","('NON-ESG', 0.015433463267982006)"
Line 131,"Strategic Quality Process (SQP)  Boston Scientific manufacturing processes reinforce   our quality policy and our overarching SQP, which is   updated yearly and encompasses:   Operations strategy: How we establish our strategic   goals and plans.
","('Business_Model_Resilience', 0.28224483132362366)","('Management_Of_Legal_And_Regulatory_Framework', 0.08211491256952286)","('Product_Quality_And_Safety', 0.0765969455242157)","('NON-ESG', 0.28224483132362366)","('NON-ESG', 0.08211491256952286)","('NON-ESG', 0.0765969455242157)"
Line 132,"Management systems: How we prioritize and execute   our work.
","('Business_Model_Resilience', 0.5081561207771301)","('Supply_Chain_Management', 0.06276959180831909)","('Product_Design_And_Lifecycle_Management', 0.06184577941894531)","(['Codes of Business Conduct'], 0.5081561207771301)","('NON-ESG', 0.06276959180831909)","('NON-ESG', 0.06184577941894531)"
Line 133,"Continuous improvement: How we improve our work.
","('Access_And_Affordability', 0.14640367031097412)","('Human_Rights_And_Community_Relations', 0.12492410838603973)","('Employee_Engagement_Inclusion_And_Diversity', 0.10285644233226776)","('NON-ESG', 0.14640367031097412)","('NON-ESG', 0.12492410838603973)","('NON-ESG', 0.10285644233226776)"
Line 134,"Cascading metrics: How we measure and connect   performance.
","('Systemic_Risk_Management', 0.318328320980072)","('Business_Model_Resilience', 0.19843675196170807)","('Competitive_Behavior', 0.08139721304178238)","('NON-ESG', 0.318328320980072)","('NON-ESG', 0.19843675196170807)","('NON-ESG', 0.08139721304178238)"
Line 135,"Recognition and engagement: How we recognize   teams and individuals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.54752516746521)","('Human_Rights_And_Community_Relations', 0.08740558475255966)","('Employee_Health_And_Safety', 0.056611474603414536)","(['Human Capital Development'], 0.54752516746521)","('NON-ESG', 0.08740558475255966)","('NON-ESG', 0.056611474603414536)"
Line 136,"To ensure cohesive quality throughout the enterprise,   every one of our manufacturing sites uses the overarching  SQP to develop its own SQP to support the facility’s focus  and performance objectives.
","('Business_Model_Resilience', 0.4682723879814148)","('Supply_Chain_Management', 0.11121354252099991)","('Product_Design_And_Lifecycle_Management', 0.10849277675151825)","('NON-ESG', 0.4682723879814148)","('NON-ESG', 0.11121354252099991)","('NON-ESG', 0.10849277675151825)"
Line 137,"A SHARED RESPONSIBILITY FOR QUALITY AND SAFETY  All Boston Scientific employees share   responsibility for quality and safety in   their work every day.
","('Employee_Health_And_Safety', 0.9735743999481201)","('Employee_Engagement_Inclusion_And_Diversity', 0.003069397760555148)","('Product_Quality_And_Safety', 0.002989619504660368)","(['Operational Eco-Efficiency'], 0.9735743999481201)","('NON-ESG', 0.003069397760555148)","('NON-ESG', 0.002989619504660368)"
Line 138,"This commitment   is reinforced by:    Completing a mandatory quality systems training  course when hired.
","('Access_And_Affordability', 0.5297378897666931)","('Product_Quality_And_Safety', 0.08621453493833542)","('Employee_Engagement_Inclusion_And_Diversity', 0.08308963477611542)","(['Health Outcome Contribution'], 0.5297378897666931)","('NON-ESG', 0.08621453493833542)","('NON-ESG', 0.08308963477611542)"
Line 139,"Completing an annual refresher training course.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5717970132827759)","('Access_And_Affordability', 0.07851126790046692)","('Employee_Health_And_Safety', 0.03350644186139107)","(['Human Capital Development'], 0.5717970132827759)","('NON-ESG', 0.07851126790046692)","('NON-ESG', 0.03350644186139107)"
Line 140,"Signing and wearing a badge imprinted with the   quality policy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6713058352470398)","('Business_Ethics', 0.1089935153722763)","('Director_Removal', 0.025122398510575294)","(['Corporate Governance'], 0.6713058352470398)","('NON-ESG', 0.1089935153722763)","('NON-ESG', 0.025122398510575294)"
Line 141,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Our Quality Policy is printed on   employee badges and is highly  visible in our facilities: “ I improve the quality of  patient care and all things  Boston Scientific.” Our Quality Policy is complemented  by our Quality Mission: “ We exceed expectations  with customer-centric  quality solutions that  transform patient lives.”OUR QUALITY POLICY AND QUALITY MISSION 1 Quality system management 2 Documents, records and data control 3 Design controls 4  Product approvals 5 Material controls 6 Production and process controls 7 Post-market support 8 Corrective action, preventive actionGLOBAL QUALITY PROCESS: 8 PILLARS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyMeasuring and Monitoring Quality   and Compliance Effectiveness  We conduct regular audits to verify that our global   quality system meets internal and external requirements  and that it is implemented and maintained effectively.
","('Access_And_Affordability', 0.407304584980011)","('Product_Quality_And_Safety', 0.16115131974220276)","('Employee_Engagement_Inclusion_And_Diversity', 0.04981489107012749)","('NON-ESG', 0.407304584980011)","('NON-ESG', 0.16115131974220276)","('NON-ESG', 0.04981489107012749)"
Line 142,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Our Quality Policy is printed on   employee badges and is highly  visible in our facilities: “ I improve the quality of  patient care and all things  Boston Scientific.” Our Quality Policy is complemented  by our Quality Mission: “ We exceed expectations  with customer-centric  quality solutions that  transform patient lives.”OUR QUALITY POLICY AND QUALITY MISSION 1 Quality system management 2 Documents, records and data control 3 Design controls 4  Product approvals 5 Material controls 6 Production and process controls 7 Post-market support 8 Corrective action, preventive actionGLOBAL QUALITY PROCESS: 8 PILLARS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyMeasuring and Monitoring Quality   and Compliance Effectiveness  We conduct regular audits to verify that our global   quality system meets internal and external requirements  and that it is implemented and maintained effectively.
","('Product_Design_And_Lifecycle_Management', 0.6744035482406616)","('Product_Quality_And_Safety', 0.15613657236099243)","('Customer_Welfare', 0.035432931035757065)","(['Product Stewardship'], 0.6744035482406616)","('NON-ESG', 0.15613657236099243)","('NON-ESG', 0.035432931035757065)"
Line 143,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Our Quality Policy is printed on   employee badges and is highly  visible in our facilities: “ I improve the quality of  patient care and all things  Boston Scientific.” Our Quality Policy is complemented  by our Quality Mission: “ We exceed expectations  with customer-centric  quality solutions that  transform patient lives.”OUR QUALITY POLICY AND QUALITY MISSION 1 Quality system management 2 Documents, records and data control 3 Design controls 4  Product approvals 5 Material controls 6 Production and process controls 7 Post-market support 8 Corrective action, preventive actionGLOBAL QUALITY PROCESS: 8 PILLARS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyMeasuring and Monitoring Quality   and Compliance Effectiveness  We conduct regular audits to verify that our global   quality system meets internal and external requirements  and that it is implemented and maintained effectively.
","('Management_Of_Legal_And_Regulatory_Framework', 0.40907084941864014)","('Business_Ethics', 0.37589025497436523)","('Product_Quality_And_Safety', 0.054510995745658875)","('NON-ESG', 0.40907084941864014)","('NON-ESG', 0.37589025497436523)","('NON-ESG', 0.054510995745658875)"
Line 144,"We follow up with activities that include re-auditing   prior observations and confirming that the requisite   actions were taken.
","('Management_Of_Legal_And_Regulatory_Framework', 0.875124454498291)","('Business_Ethics', 0.04446626827120781)","('Competitive_Behavior', 0.008458994328975677)","(['Corporate Governance'], 0.875124454498291)","('NON-ESG', 0.04446626827120781)","('NON-ESG', 0.008458994328975677)"
Line 145,"Regulatory agencies also review   our performance to ensure quality and compliance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.959138035774231)","('Business_Ethics', 0.007604686543345451)","('Ecological_Impacts', 0.0025367492344230413)","(['Corporate Governance'], 0.959138035774231)","('NON-ESG', 0.007604686543345451)","('NON-ESG', 0.0025367492344230413)"
Line 146,"In 2020, to adapt amid the pandemic, our global   quality team acted quickly to shift from in-person to   virtual audit processes.
","('Business_Ethics', 0.5020986199378967)","('Systemic_Risk_Management', 0.24393866956233978)","('Management_Of_Legal_And_Regulatory_Framework', 0.0452486015856266)","(['Business Ethics'], 0.5020986199378967)","('NON-ESG', 0.24393866956233978)","('NON-ESG', 0.0452486015856266)"
Line 147,"We partnered with vendors   to pilot new technologies for remote auditing and   obtained legal and privacy approvals for camera and   recording activity.
","('Data_Security', 0.6681252717971802)","('Management_Of_Legal_And_Regulatory_Framework', 0.07137105613946915)","('Customer_Privacy', 0.06197384372353554)","(['Information Security/Cybersecurity & System Availability'], 0.6681252717971802)","('NON-ESG', 0.07137105613946915)","('NON-ESG', 0.06197384372353554)"
Line 148,"This approach meant we were able   to secure key regulatory approvals safely and on time.Product Performance Boston Scientific teams review customer and patient   feedback and monitor experiences with our devices.
","('Product_Design_And_Lifecycle_Management', 0.4848393499851227)","('Product_Quality_And_Safety', 0.1650327444076538)","('Selling_Practices_And_Product_Labeling', 0.0809171199798584)","('NON-ESG', 0.4848393499851227)","('NON-ESG', 0.1650327444076538)","('NON-ESG', 0.0809171199798584)"
Line 149,"This information is valuable for our quality system and   for future product iterations and innovations.
","('Product_Design_And_Lifecycle_Management', 0.9539559483528137)","('Product_Quality_And_Safety', 0.0066032009199261665)","('Selling_Practices_And_Product_Labeling', 0.004750868771225214)","(['Product Stewardship'], 0.9539559483528137)","('NON-ESG', 0.0066032009199261665)","('NON-ESG', 0.004750868771225214)"
Line 150,"We follow   a preventive action process to identify root causes for   potential compliance and quality issues, and to develop  preventive solutions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5802630186080933)","('Business_Ethics', 0.0705001950263977)","('Systemic_Risk_Management', 0.05554273724555969)","(['Corporate Governance'], 0.5802630186080933)","('NON-ESG', 0.0705001950263977)","('NON-ESG', 0.05554273724555969)"
Line 151,"We initiate field actions as needed  to ensure that any regulatory or field safety issues are  resolved quickly and effectively.
","('Employee_Health_And_Safety', 0.8333776593208313)","('Product_Quality_And_Safety', 0.07110653072595596)","('Critical_Incident_Risk_Management', 0.018793819472193718)","(['Operational Eco-Efficiency'], 0.8333776593208313)","('NON-ESG', 0.07110653072595596)","('NON-ESG', 0.018793819472193718)"
Line 152,"“ Customer insights are a key resource as   we work to improve our products and   introduce new devices.
","('Product_Design_And_Lifecycle_Management', 0.9545580148696899)","('Customer_Welfare', 0.005070484708994627)","('Product_Quality_And_Safety', 0.004384628962725401)","(['Product Stewardship'], 0.9545580148696899)","('NON-ESG', 0.005070484708994627)","('NON-ESG', 0.004384628962725401)"
Line 153,"That’s how new  generations of products are born.”            Alejandra Hernandez , senior engineer, Quality Systems Our annual Everyone Makes an Impact events take place   at Boston Scientific sites around the world to celebrate   patients who overcome health challenges and highlight  how each and every employee is helping to advance   patient care.
","('Product_Design_And_Lifecycle_Management', 0.4907052516937256)","('Product_Quality_And_Safety', 0.10811413079500198)","('Customer_Welfare', 0.10000472515821457)","('NON-ESG', 0.4907052516937256)","('NON-ESG', 0.10811413079500198)","('NON-ESG', 0.10000472515821457)"
Line 154,"In 2020, thousands of employees across   the globe attended a virtual event, and several patients  joined to talk about how their lives changed after being  successfully treated with Boston Scientific solutions.ELEVATING QUALITY: EVERYONE MAKES AN IMPACT  Valentina Arango of Bogota,  Colombia discussed how  doctors used the SpyGlass™   DS Direct Visualization   System  to treat potentially  cancerous liver fibrosis,   destroy stones in her   intrahepatic duct and   collect a biopsy.
","('Employee_Health_And_Safety', 0.23723113536834717)","('Access_And_Affordability', 0.21522866189479828)","('Employee_Engagement_Inclusion_And_Diversity', 0.07221286743879318)","('NON-ESG', 0.23723113536834717)","('NON-ESG', 0.21522866189479828)","('NON-ESG', 0.07221286743879318)"
Line 155,"Rahul Mathur, an employee  in our Gurgaon, India office  was successfully treated for  a cardiac condition with a   Promus ELITE™ stent.
","('Employee_Health_And_Safety', 0.602351725101471)","('Critical_Incident_Risk_Management', 0.07842618227005005)","('Access_And_Affordability', 0.04821566864848137)","(['Operational Eco-Efficiency'], 0.602351725101471)","('NON-ESG', 0.07842618227005005)","('NON-ESG', 0.04821566864848137)"
Line 156,"He  talked about what it feels  like to be helped by a  device he knows was made  with quality and care.
","('Product_Design_And_Lifecycle_Management', 0.3843831717967987)","('Employee_Health_And_Safety', 0.15171003341674805)","('Access_And_Affordability', 0.1472151279449463)","('NON-ESG', 0.3843831717967987)","('NON-ESG', 0.15171003341674805)","('NON-ESG', 0.1472151279449463)"
Line 157,"PRODUCT INNOVATION:           LISTENING TO OUR CUSTOMERS	 Boston	Scientific	2020	Performance	Report		 Pre-Clinical Sciences We conduct extensive research into the safety and efficacy  of our devices before progressing to human clinical trials.
","('Product_Quality_And_Safety', 0.41234803199768066)","('Selling_Practices_And_Product_Labeling', 0.1248849406838417)","('Product_Design_And_Lifecycle_Management', 0.11980687081813812)","('NON-ESG', 0.41234803199768066)","('NON-ESG', 0.1248849406838417)","('NON-ESG', 0.11980687081813812)"
Line 158,"This pre-clinical research sets stringent standards that  govern our training practices, product testing and regulatory  compliance.
","('Product_Quality_And_Safety', 0.3980391025543213)","('Management_Of_Legal_And_Regulatory_Framework', 0.19389277696609497)","('Business_Ethics', 0.175587996840477)","('NON-ESG', 0.3980391025543213)","('NON-ESG', 0.19389277696609497)","('NON-ESG', 0.175587996840477)"
Line 159,"In 2020, we made significant investments   in our Research and Technology Center in Minnesota,   including the latest in advanced imaging technology to  help ensure device compatibility — an investment that   will enhance R&D initiatives across all our businesses.To meet the highest safety standards, on occasion we   use animal testing in our R&D efforts.
","('Product_Quality_And_Safety', 0.9113237261772156)","('Employee_Health_And_Safety', 0.02017858996987343)","('Selling_Practices_And_Product_Labeling', 0.006327861454337835)","(['Product Quality & Recall Management'], 0.9113237261772156)","('NON-ESG', 0.02017858996987343)","('NON-ESG', 0.006327861454337835)"
Line 160,"For instance, when  we use new materials in medical devices, the U.S. Food   and Drug Administration (FDA) may require evidence   of animal testing prior to human clinical trials.
","('Selling_Practices_And_Product_Labeling', 0.22526973485946655)","('Customer_Welfare', 0.16172412037849426)","('Product_Quality_And_Safety', 0.12730970978736877)","('NON-ESG', 0.22526973485946655)","('NON-ESG', 0.16172412037849426)","('NON-ESG', 0.12730970978736877)"
Line 161,"Boston   Scientific is committed to the humane care and treatment  of laboratory animals.
","('Ecological_Impacts', 0.21340471506118774)","('Waste_And_Hazardous_Materials_Management', 0.1948051154613495)","('Employee_Health_And_Safety', 0.06197403371334076)","('NON-ESG', 0.21340471506118774)","('NON-ESG', 0.1948051154613495)","('NON-ESG', 0.06197403371334076)"
Line 162,"Whenever it is feasible, appropriate  and scientifically valid, we use alternative testing.
","('Competitive_Behavior', 0.509825587272644)","('Management_Of_Legal_And_Regulatory_Framework', 0.18734966218471527)","('Business_Ethics', 0.042225029319524765)","(['Business Ethics'], 0.509825587272644)","('NON-ESG', 0.18734966218471527)","('NON-ESG', 0.042225029319524765)"
Line 163,"Our   facilities meet applicable laws and regulatory standards,  often exceeding the latter.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9446470141410828)","('Business_Ethics', 0.011847583577036858)","('Product_Quality_And_Safety', 0.006848379038274288)","(['Corporate Governance'], 0.9446470141410828)","('NON-ESG', 0.011847583577036858)","('NON-ESG', 0.006848379038274288)"
Line 164,"We are routinely audited by  internal experts and government agencies, including   by the FDA, the U.S. Department of Agriculture, and   the Association for Assessment and Accreditation of   Laboratory Animal Care.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3092353343963623)","('Product_Quality_And_Safety', 0.2660783529281616)","('Access_And_Affordability', 0.07596305757761002)","('NON-ESG', 0.3092353343963623)","('NON-ESG', 0.2660783529281616)","('NON-ESG', 0.07596305757761002)"
Line 165,"Clinical Trials  Our clinical trials are scientifically rigorous and generate   the data we need to document that Boston Scientific   products are safe and effective.
","('Customer_Welfare', 0.23965805768966675)","('Product_Quality_And_Safety', 0.2035701870918274)","('Selling_Practices_And_Product_Labeling', 0.13586053252220154)","('NON-ESG', 0.23965805768966675)","('NON-ESG', 0.2035701870918274)","('NON-ESG', 0.13586053252220154)"
Line 166,"We disclose the outcome   of all primary and pre-specified secondary endpoints   in trials we sponsor, regardless of whether the results   are positive, negative or inconclusive.
","('Competitive_Behavior', 0.6594663858413696)","('Management_Of_Legal_And_Regulatory_Framework', 0.04776233807206154)","('Business_Ethics', 0.042209647595882416)","(['Business Ethics'], 0.6594663858413696)","('NON-ESG', 0.04776233807206154)","('NON-ESG', 0.042209647595882416)"
Line 167,"Our clinical teams   adhere to criteria established by the International   Committee of Medical Journal Editors for authorship   on clinical trial publications.
","('Management_Of_Legal_And_Regulatory_Framework', 0.36166685819625854)","('Access_And_Affordability', 0.14217092096805573)","('Competitive_Behavior', 0.12140057235956192)","('NON-ESG', 0.36166685819625854)","('NON-ESG', 0.14217092096805573)","('NON-ESG', 0.12140057235956192)"
Line 168,"In publications pertaining   to research that has been supported by Boston Scientific,  our teams disclose the company’s involvement, whether   as a sponsor or supporter.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6348673701286316)","('GHG_Emissions', 0.04840278625488281)","('Access_And_Affordability', 0.04214806482195854)","(['Corporate Governance'], 0.6348673701286316)","('NON-ESG', 0.04840278625488281)","('NON-ESG', 0.04214806482195854)"
Line 169,"In 2020, we strengthened and refined our operating   procedures to ensure we meet or exceed EU MDR   requirements by the required deadlines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8775374889373779)","('Business_Ethics', 0.016045590862631798)","('Product_Quality_And_Safety', 0.015616487711668015)","(['Corporate Governance'], 0.8775374889373779)","('NON-ESG', 0.016045590862631798)","('NON-ESG', 0.015616487711668015)"
Line 170,"119 active trials    in    6,655 patients    enrolled globallyOur	Mission  Patient	Spotlight	 Table	of	Contents	 A	Message	to	 Company	Profile	 Transforming	Care	 Investing	in		 Advancing	 Protecting	the	 Creating	Value	   	 	 	 Stakeholders		 	 	 Our	People	 Possibilities	 Environment	 Responsibly	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyBuilding Digital   Capability Our recent investments in digital platforms gave us   capabilities that were critical for providing remote   customer support in 2020.
","('Access_And_Affordability', 0.5048099160194397)","('Customer_Welfare', 0.08466125279664993)","('Management_Of_Legal_And_Regulatory_Framework', 0.04436667636036873)","(['Health Outcome Contribution'], 0.5048099160194397)","('NON-ESG', 0.08466125279664993)","('NON-ESG', 0.04436667636036873)"
Line 171,"119 active trials    in    6,655 patients    enrolled globallyOur	Mission  Patient	Spotlight	 Table	of	Contents	 A	Message	to	 Company	Profile	 Transforming	Care	 Investing	in		 Advancing	 Protecting	the	 Creating	Value	   	 	 	 Stakeholders		 	 	 Our	People	 Possibilities	 Environment	 Responsibly	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyBuilding Digital   Capability Our recent investments in digital platforms gave us   capabilities that were critical for providing remote   customer support in 2020.
","('Business_Model_Resilience', 0.27135950326919556)","('Product_Design_And_Lifecycle_Management', 0.16043129563331604)","('Data_Security', 0.10282985121011734)","('NON-ESG', 0.27135950326919556)","('NON-ESG', 0.16043129563331604)","('NON-ESG', 0.10282985121011734)"
Line 172,"Highlights include:     Aided practitioners remotely using our augmented   reality platform  to offer expert guidance on product   use and assist with setup and troubleshooting for   devices and procedures.
","('Product_Design_And_Lifecycle_Management', 0.48916327953338623)","('Product_Quality_And_Safety', 0.2219916731119156)","('Customer_Welfare', 0.05517604202032089)","('NON-ESG', 0.48916327953338623)","('NON-ESG', 0.2219916731119156)","('NON-ESG', 0.05517604202032089)"
Line 173,"Partnered with a wearable technology company to   pilot a smart glasses device that enables 225 customers  in Latin America to receive real-time remote guidance  from Boston Scientific clinical specialists — assistance   that helped nearly 1,200 patients.
","('Access_And_Affordability', 0.25515037775039673)","('Customer_Welfare', 0.12591524422168732)","('Competitive_Behavior', 0.09808824956417084)","('NON-ESG', 0.25515037775039673)","('NON-ESG', 0.12591524422168732)","('NON-ESG', 0.09808824956417084)"
Line 174,"Developed and launched provider tools and resources    for re-engaging with patients in the wake of the   pandemic.
","('Access_And_Affordability', 0.602748453617096)","('Critical_Incident_Risk_Management', 0.10595213621854782)","('Systemic_Risk_Management', 0.0273266788572073)","(['Health Outcome Contribution'], 0.602748453617096)","('NON-ESG', 0.10595213621854782)","('NON-ESG', 0.0273266788572073)"
Line 175,"Offered on-demand webinars  and telehealth resources  for providers on COVID-19-related legislation, regulations  and protocols.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9656320810317993)","('Energy_Management', 0.002882861066609621)","('Access_And_Affordability', 0.0023201715666800737)","(['Corporate Governance'], 0.9656320810317993)","('NON-ESG', 0.002882861066609621)","('NON-ESG', 0.0023201715666800737)"
Line 176,"Used our Heart Connect ™ system to conduct over   13,000 remote follow-up device checks with customers.
","('Data_Security', 0.2653047442436218)","('Customer_Privacy', 0.21895048022270203)","('Business_Ethics', 0.07917333394289017)","('NON-ESG', 0.2653047442436218)","('NON-ESG', 0.21895048022270203)","('NON-ESG', 0.07917333394289017)"
Line 177,"The company’s digital capabilities also allowed many  employees to work remotely during the pandemic.
","('Data_Security', 0.23066231608390808)","('Energy_Management', 0.08894091099500656)","('Systemic_Risk_Management', 0.08021524548530579)","('NON-ESG', 0.23066231608390808)","('NON-ESG', 0.08894091099500656)","('NON-ESG', 0.08021524548530579)"
Line 178,"We  established new operating procedures and launched   online tools so our employees could collaborate virtually  with colleagues inside and outside the company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23397836089134216)","('Director_Removal', 0.15361586213111877)","('Labor_Practices', 0.11673540621995926)","('NON-ESG', 0.23397836089134216)","('NON-ESG', 0.15361586213111877)","('NON-ESG', 0.11673540621995926)"
Line 179,"We are working closely with the FDA on their  new Digital Health Software Precertification  Pilot Program .
","('Management_Of_Legal_And_Regulatory_Framework', 0.7322952747344971)","('Product_Quality_And_Safety', 0.05125854164361954)","('Competitive_Behavior', 0.03331119939684868)","(['Corporate Governance'], 0.7322952747344971)","('NON-ESG', 0.05125854164361954)","('NON-ESG', 0.03331119939684868)"
Line 180,"The goal of the program is to offer precertified companies a streamlined premarket  review that will ultimately result in faster patient access  to safe and effective software-based medical innovations.ACCELERATING DIGITAL SOLUTIONS Our augmented  reality platform   connects customers   to expert live   support.
","('Access_And_Affordability', 0.814941942691803)","('Critical_Incident_Risk_Management', 0.020148800686001778)","('Energy_Management', 0.019628234207630157)","(['Health Outcome Contribution'], 0.814941942691803)","('NON-ESG', 0.020148800686001778)","('NON-ESG', 0.019628234207630157)"
Line 181,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Innovation in a Virtual World Throughout 2020, we remained steadfast in our   commitment to transform lives.
","('Access_And_Affordability', 0.24586433172225952)","('Business_Model_Resilience', 0.1670428216457367)","('Customer_Welfare', 0.10125993192195892)","('NON-ESG', 0.24586433172225952)","('NON-ESG', 0.1670428216457367)","('NON-ESG', 0.10125993192195892)"
Line 182,"Using virtual platforms,   we continued internal innovation initiatives such as:    Recognize Success , a program that celebrates   contributions by teams that have innovated to   improve quality, efficiency and agility at Boston   Scientific.
","('Product_Design_And_Lifecycle_Management', 0.4286743700504303)","('Business_Model_Resilience', 0.1657828688621521)","('Competitive_Behavior', 0.06826181709766388)","('NON-ESG', 0.4286743700504303)","('NON-ESG', 0.1657828688621521)","('NON-ESG', 0.06826181709766388)"
Line 183,"Recognize Development Excellence , an initiative   that honors cross-functional teams that develop   meaningful innovations for customers, patients   and our company.
","('Product_Design_And_Lifecycle_Management', 0.20046129822731018)","('Access_And_Affordability', 0.12501776218414307)","('Employee_Engagement_Inclusion_And_Diversity', 0.10672013461589813)","('NON-ESG', 0.20046129822731018)","('NON-ESG', 0.12501776218414307)","('NON-ESG', 0.10672013461589813)"
Line 184,"ImagineIF , an internal venture capital-style   approach to funding breakthrough employee   ideas which could have a positive impact on   any aspect of our company.
","('Business_Model_Resilience', 0.5205239057540894)","('Competitive_Behavior', 0.11796645075082779)","('Systemic_Risk_Management', 0.10235444456338882)","(['Codes of Business Conduct'], 0.5205239057540894)","('NON-ESG', 0.11796645075082779)","('NON-ESG', 0.10235444456338882)"
Line 185,"In addition, Boston Scientific launched the COVIDea   portal in March to collect employee ideas on how   to help slow the spread of the coronavirus and   support relief efforts.
","('Critical_Incident_Risk_Management', 0.1309109479188919)","('Access_And_Affordability', 0.09447849541902542)","('Employee_Health_And_Safety', 0.08635389059782028)","('NON-ESG', 0.1309109479188919)","('NON-ESG', 0.09447849541902542)","('NON-ESG', 0.08635389059782028)"
Line 186,"We received more than 100   submissions and pursued several proposals to   develop and donate personal protective equipment   and medical equipment, many of which are featured   in this report.
","('Employee_Health_And_Safety', 0.9114834070205688)","('Critical_Incident_Risk_Management', 0.01166540663689375)","('Product_Design_And_Lifecycle_Management', 0.010432165116071701)","(['Operational Eco-Efficiency'], 0.9114834070205688)","('NON-ESG', 0.01166540663689375)","('NON-ESG', 0.010432165116071701)"
Line 187,"SUPPORTING DIGITAL INNOVATION:   THE CONNECTED PATIENT CHALLENGE Digital health solutions that improve patient and   caregiver quality of life at home was the theme of   the fifth annual Boston Scientific Connected Patient  Challenge .
","('Access_And_Affordability', 0.5828174352645874)","('Product_Design_And_Lifecycle_Management', 0.054657142609357834)","('Employee_Health_And_Safety', 0.04371166229248047)","(['Health Outcome Contribution'], 0.5828174352645874)","('NON-ESG', 0.054657142609357834)","('NON-ESG', 0.04371166229248047)"
Line 188,"The external competition, co-sponsored   by Massachusetts Life Sciences Center and others,   promotes the development of digital innovation to   address complex health care challenges.
","('Competitive_Behavior', 0.9425503015518188)","('Customer_Welfare', 0.006118119694292545)","('Business_Model_Resilience', 0.005203586537390947)","(['Business Ethics'], 0.9425503015518188)","('NON-ESG', 0.006118119694292545)","('NON-ESG', 0.005203586537390947)"
Line 189,"In early 2020,  six finalists participated in a live pitch event with life   science professionals and industry experts.
","('Management_Of_Legal_And_Regulatory_Framework', 0.1342683583498001)","('Business_Model_Resilience', 0.13260413706302643)","('GHG_Emissions', 0.09192904084920883)","('NON-ESG', 0.1342683583498001)","('NON-ESG', 0.13260413706302643)","('NON-ESG', 0.09192904084920883)"
Line 190,"The   winning submission was the VaGenie , a connected   pelvic floor muscle training device that can help   prevent issues related to having a weak pelvic floor,   including incontinence and lower back pain.In October, Boston   Scientific hosted our  annual Recognize   Success event, where   we celebrated cross-   functional teams that   are making outstanding  contributions to improve  quality, patient care   and operational   effectiveness.
","('Employee_Health_And_Safety', 0.8889490962028503)","('Employee_Engagement_Inclusion_And_Diversity', 0.018783822655677795)","('Access_And_Affordability', 0.0102754607796669)","(['Operational Eco-Efficiency'], 0.8889490962028503)","('NON-ESG', 0.018783822655677795)","('NON-ESG', 0.0102754607796669)"
Line 191,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyCollaborating with   Customers  Boston Scientific is deeply committed to helping   health care providers meet patient needs.
","('Access_And_Affordability', 0.5910782217979431)","('Customer_Welfare', 0.06580930948257446)","('Employee_Health_And_Safety', 0.03198457509279251)","(['Health Outcome Contribution'], 0.5910782217979431)","('NON-ESG', 0.06580930948257446)","('NON-ESG', 0.03198457509279251)"
Line 192,"We gather   customer feedback in several ways to inspire future   product iterations and develop solutions collaboratively.
","('Product_Design_And_Lifecycle_Management', 0.8238605260848999)","('Business_Model_Resilience', 0.027785537764430046)","('Customer_Welfare', 0.022896168753504753)","(['Product Stewardship'], 0.8238605260848999)","('NON-ESG', 0.027785537764430046)","('NON-ESG', 0.022896168753504753)"
Line 193,"For example, our anatomical model lab in Minnesota   enables engineers and physicians to evaluate new   product concepts on-site or remotely using new   collaboration and visualization tools.
","('Product_Design_And_Lifecycle_Management', 0.9201160669326782)","('Customer_Welfare', 0.01731708087027073)","('Product_Quality_And_Safety', 0.011320918798446655)","(['Product Stewardship'], 0.9201160669326782)","('NON-ESG', 0.01731708087027073)","('NON-ESG', 0.011320918798446655)"
Line 194,"Through the Motion Medical joint innovation accelerator   with the Mayo Clinic, we made progress developing  minimally invasive treatments for conditions that impede  quality and longevity of life.
","('Access_And_Affordability', 0.29642555117607117)","('Employee_Health_And_Safety', 0.2458517849445343)","('Customer_Welfare', 0.06882660835981369)","('NON-ESG', 0.29642555117607117)","('NON-ESG', 0.2458517849445343)","('NON-ESG', 0.06882660835981369)"
Line 195,"In 2020, we refined two   prototype devices, one for patients with cancer and   another for patients with structural heart disease.
","('Employee_Health_And_Safety', 0.2003936469554901)","('Access_And_Affordability', 0.13380542397499084)","('Product_Quality_And_Safety', 0.09571156650781631)","('NON-ESG', 0.2003936469554901)","('NON-ESG', 0.13380542397499084)","('NON-ESG', 0.09571156650781631)"
Line 196,"In   2021, these projects are proceeding to final verification,  validation and preclinical testing.To support demand for ventilators and personal protective equipment (PPE), we teamed up with customers and health  care industry peers to develop and distribute innovative solutions to address critical medical needs in our communities.
","('Employee_Health_And_Safety', 0.4591692388057709)","('Product_Design_And_Lifecycle_Management', 0.12160118669271469)","('Critical_Incident_Risk_Management', 0.08182181417942047)","('NON-ESG', 0.4591692388057709)","('NON-ESG', 0.12160118669271469)","('NON-ESG', 0.08182181417942047)"
Line 197,"Nearly 3,000  Coventor   resuscitators were delivered to  health care providers INNOVATING WITH URGENCY DURING THE PANDEMIC Ventilator Alternatives.
","('Critical_Incident_Risk_Management', 0.6630653142929077)","('Access_And_Affordability', 0.05687538906931877)","('Air_Quality', 0.04760594293475151)","(['Risk & Crisis Management'], 0.6630653142929077)","('NON-ESG', 0.05687538906931877)","('NON-ESG', 0.04760594293475151)"
Line 198,"We collaborated with the   University of Minnesota Bakken Medical Device Center  and industry partners to bring the Coventor  resuscitator  to market, with less than 60 days from concept meeting  to production completion.
","('Product_Design_And_Lifecycle_Management', 0.2649085819721222)","('Customer_Welfare', 0.2631908655166626)","('Competitive_Behavior', 0.0746612548828125)","('NON-ESG', 0.2649085819721222)","('NON-ESG', 0.2631908655166626)","('NON-ESG', 0.0746612548828125)"
Line 199,"The machine pumps a   resuscitation bag at regular intervals, replacing the   need for manual respiration in emergency settings.
","('Critical_Incident_Risk_Management', 0.8788670897483826)","('Employee_Health_And_Safety', 0.06942765414714813)","('Access_And_Affordability', 0.005686304531991482)","(['Risk & Crisis Management'], 0.8788670897483826)","('NON-ESG', 0.06942765414714813)","('NON-ESG', 0.005686304531991482)"
Line 200,"After receiving FDA Emergency Use Authorization in  April 2020, our partnership delivered nearly 3,000   Coventor resuscitators to health care providers.
","('Critical_Incident_Risk_Management', 0.9710330367088318)","('Employee_Health_And_Safety', 0.004290787503123283)","('Air_Quality', 0.003164884401485324)","(['Risk & Crisis Management'], 0.9710330367088318)","('NON-ESG', 0.004290787503123283)","('NON-ESG', 0.003164884401485324)"
Line 201,"PPE.
","('Data_Security', 0.0892757922410965)","('Management_Of_Legal_And_Regulatory_Framework', 0.0824914425611496)","('Energy_Management', 0.07633934170007706)","('NON-ESG', 0.0892757922410965)","('NON-ESG', 0.0824914425611496)","('NON-ESG', 0.07633934170007706)"
Line 202,"Working with Stanford University and an international   coalition of medical experts, clinicians and industry leaders,   we developed the Pneumask ™ Face Shield in 38 days   and received FDA Emergency Use Authorization shortly  thereafter.
","('Critical_Incident_Risk_Management', 0.9665204882621765)","('Employee_Health_And_Safety', 0.006876147817820311)","('Air_Quality', 0.0034950526896864176)","(['Risk & Crisis Management'], 0.9665204882621765)","('NON-ESG', 0.006876147817820311)","('NON-ESG', 0.0034950526896864176)"
Line 203,"The device combines a full-face mask and a  Boston Scientific custom-molded adapter that attaches   to a medical-grade air filter.
","('Air_Quality', 0.4635072648525238)","('Employee_Health_And_Safety', 0.1037471815943718)","('Product_Quality_And_Safety', 0.07400612533092499)","('NON-ESG', 0.4635072648525238)","('NON-ESG', 0.1037471815943718)","('NON-ESG', 0.07400612533092499)"
Line 204,"We donated over 1,500   Pneumask Face Shields to hospitals across the United  States and have given other manufacturers access to  design details for future production.
","('Product_Design_And_Lifecycle_Management', 0.8027027249336243)","('Energy_Management', 0.04296635836362839)","('Product_Quality_And_Safety', 0.036525338888168335)","(['Product Stewardship'], 0.8027027249336243)","('NON-ESG', 0.04296635836362839)","('NON-ESG', 0.036525338888168335)"
Line 205,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyINNOVATION COLLABORATION Boston Scientific collaborates with a variety of  academic institutions, research organizations  and accelerators around the globe to   promote innovations in health care, including: gBETA  Medtech , a free Minnesota-based accelerator  that helps early-stage health care startups.
","('Access_And_Affordability', 0.42542368173599243)","('Customer_Welfare', 0.1118871420621872)","('Product_Design_And_Lifecycle_Management', 0.05062663555145264)","('NON-ESG', 0.42542368173599243)","('NON-ESG', 0.1118871420621872)","('NON-ESG', 0.05062663555145264)"
Line 206,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyINNOVATION COLLABORATION Boston Scientific collaborates with a variety of  academic institutions, research organizations  and accelerators around the globe to   promote innovations in health care, including: gBETA  Medtech , a free Minnesota-based accelerator  that helps early-stage health care startups.
","('Access_And_Affordability', 0.41470688581466675)","('Customer_Welfare', 0.09474959969520569)","('Business_Model_Resilience', 0.0495624765753746)","('NON-ESG', 0.41470688581466675)","('NON-ESG', 0.09474959969520569)","('NON-ESG', 0.0495624765753746)"
Line 207,"MEDX Xelerator , a medical device and digital health  incubator, based in Israel, that’s focused on innovations  across multiple disease states.
","('Product_Design_And_Lifecycle_Management', 0.533353328704834)","('Customer_Welfare', 0.10498220473527908)","('Energy_Management', 0.04158395156264305)","(['Product Stewardship'], 0.533353328704834)","('NON-ESG', 0.10498220473527908)","('NON-ESG', 0.04158395156264305)"
Line 208,"PracticePoint , a membership-based health care R&D  facility operating at Worcester Polytechnic Institute in  Massachusetts.
","('Access_And_Affordability', 0.6405550837516785)","('Customer_Welfare', 0.04944664612412453)","('Energy_Management', 0.03162375092506409)","(['Health Outcome Contribution'], 0.6405550837516785)","('NON-ESG', 0.04944664612412453)","('NON-ESG', 0.03162375092506409)"
Line 209,"BioInnovate , a program at the National University of  Ireland Galway that fosters medical device innovation  using a needs based approach from Stanford University  Biodesign.
","('Product_Design_And_Lifecycle_Management', 0.7448071241378784)","('Customer_Welfare', 0.037373676896095276)","('Supply_Chain_Management', 0.03235675394535065)","(['Product Stewardship'], 0.7448071241378784)","('NON-ESG', 0.037373676896095276)","('NON-ESG', 0.03235675394535065)"
Line 210,"Avicenna Alliance , an industry and academic   collaboration to promote an EU framework embracing  in-silico methods, computer modeling and simulation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24250660836696625)","('Competitive_Behavior', 0.15238791704177856)","('Access_And_Affordability', 0.11598462611436844)","('NON-ESG', 0.24250660836696625)","('NON-ESG', 0.15238791704177856)","('NON-ESG', 0.11598462611436844)"
Line 211,"HuaXi-Boston Scientific Joint Innovation Center ,   a collaboration with Huaxi Hospital in Chengdu, China  launched in September 2020 to bring innovative   solutions to patients via remote education.
","('Access_And_Affordability', 0.8448529243469238)","('Critical_Incident_Risk_Management', 0.015089957043528557)","('Energy_Management', 0.013280264101922512)","(['Health Outcome Contribution'], 0.8448529243469238)","('NON-ESG', 0.015089957043528557)","('NON-ESG', 0.013280264101922512)"
Line 212,"Medical Device Innovation Consortium , a public-   private partnership with the FDA to advance solutions  that promote patient access to innovative medical  technologies.
","('Access_And_Affordability', 0.40286320447921753)","('Customer_Welfare', 0.13997580111026764)","('Product_Design_And_Lifecycle_Management', 0.08529409021139145)","('NON-ESG', 0.40286320447921753)","('NON-ESG', 0.13997580111026764)","('NON-ESG', 0.08529409021139145)"
Line 213,"Boston Scientific R&D employees testing new components for the ROTAPRO™ Rotational Atherectomy System in the  anatomical model lab.Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyGlobal Customer Care In 2020, our global customer care team expanded its  framework and capabilities to improve customer support.
","('Customer_Welfare', 0.24529200792312622)","('Access_And_Affordability', 0.19774939119815826)","('Product_Design_And_Lifecycle_Management', 0.10468385368585587)","('NON-ESG', 0.24529200792312622)","('NON-ESG', 0.19774939119815826)","('NON-ESG', 0.10468385368585587)"
Line 214,"These enhancements enabled us to shift more resources   to manage customer relationships, anticipate product  needs and advise on solutions.
","('Product_Design_And_Lifecycle_Management', 0.89179527759552)","('Business_Model_Resilience', 0.023263519629836082)","('Customer_Welfare', 0.01650734804570675)","(['Product Stewardship'], 0.89179527759552)","('NON-ESG', 0.023263519629836082)","('NON-ESG', 0.01650734804570675)"
Line 215,"We introduced Salesforce.com Service Cloud in 16   countries to better serve customers and increase   online collaboration.
","('Data_Security', 0.1728484034538269)","('Product_Design_And_Lifecycle_Management', 0.12277156114578247)","('Competitive_Behavior', 0.11340589821338654)","('NON-ESG', 0.1728484034538269)","('NON-ESG', 0.12277156114578247)","('NON-ESG', 0.11340589821338654)"
Line 216,"In the EU, we invested in technology to increase   automated ordering to more than 80 percent of   volume, allowing employees to spend less time   handling orders and more time talking with   customers about their needs.
","('Product_Design_And_Lifecycle_Management', 0.3632490336894989)","('Customer_Welfare', 0.12621696293354034)","('Energy_Management', 0.10536972433328629)","('NON-ESG', 0.3632490336894989)","('NON-ESG', 0.12621696293354034)","('NON-ESG', 0.10536972433328629)"
Line 217,"Using robotic process automation shipping, we   reduced cycle time for sales and sales support   agents and improved field inventory levels.
","('Supply_Chain_Management', 0.1865449994802475)","('Competitive_Behavior', 0.1336125284433365)","('Energy_Management', 0.1251107007265091)","('NON-ESG', 0.1865449994802475)","('NON-ESG', 0.1336125284433365)","('NON-ESG', 0.1251107007265091)"
Line 218,"PERSPECTIVES ON ADVANCING CUSTOMER CARE:           HANS WILLEMS More than 750  dedicated   Customer Care team members  across 40  unique sites“ Technology solutions represent a huge  opportunity for our customers to provide  better care to patients.
","('Access_And_Affordability', 0.30862438678741455)","('Customer_Welfare', 0.17401403188705444)","('Product_Design_And_Lifecycle_Management', 0.08159133791923523)","('NON-ESG', 0.30862438678741455)","('NON-ESG', 0.17401403188705444)","('NON-ESG', 0.08159133791923523)"
Line 219,"Our teams are  focused on what’s going to help providers  and patients the most.”        Hans Willems , vice president, Global Customer Care   and EMEA Supply Chain 	 Boston	Scientific	2020	Performance	Report		 21	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyValue-Based Health Care  A global Boston Scientific team  is dedicated to studying  health economics to demonstrate the value of our   technologies and increase market access for providers   and patients through policy and reimbursement advocacy.
","('Supply_Chain_Management', 0.8655959367752075)","('Product_Design_And_Lifecycle_Management', 0.018089771270751953)","('Customer_Welfare', 0.016719456762075424)","(['Supply Chain Management'], 0.8655959367752075)","('NON-ESG', 0.018089771270751953)","('NON-ESG', 0.016719456762075424)"
Line 220,"Our teams are  focused on what’s going to help providers  and patients the most.”        Hans Willems , vice president, Global Customer Care   and EMEA Supply Chain 	 Boston	Scientific	2020	Performance	Report		 21	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyValue-Based Health Care  A global Boston Scientific team  is dedicated to studying  health economics to demonstrate the value of our   technologies and increase market access for providers   and patients through policy and reimbursement advocacy.
","('Access_And_Affordability', 0.7693546414375305)","('Management_Of_Legal_And_Regulatory_Framework', 0.07221368700265884)","('Product_Quality_And_Safety', 0.018596302717924118)","(['Health Outcome Contribution'], 0.7693546414375305)","('NON-ESG', 0.07221368700265884)","('NON-ESG', 0.018596302717924118)"
Line 221,"Chronic conditions among an aging population present  challenges to health care access and affordability.
","('Access_And_Affordability', 0.875966489315033)","('Employee_Health_And_Safety', 0.01590493507683277)","('Product_Quality_And_Safety', 0.013776891864836216)","(['Health Outcome Contribution'], 0.875966489315033)","('NON-ESG', 0.01590493507683277)","('NON-ESG', 0.013776891864836216)"
Line 222,"A study  in the Journal of the American Heart Association  showed  significant cost savings when patients who are at risk for stroke due to atrial fibrillation undergo a one-time,  minimally invasive procedure to implant the WATCHMAN™  Left Atrial Appendage Closure Device rather than receive  lifelong anticoagulant treatment.
","('Employee_Health_And_Safety', 0.33381932973861694)","('Access_And_Affordability', 0.2168745994567871)","('Critical_Incident_Risk_Management', 0.05716270953416824)","('NON-ESG', 0.33381932973861694)","('NON-ESG', 0.2168745994567871)","('NON-ESG', 0.05716270953416824)"
Line 223,"We use a combination of science and technology to   help identify patients who are likely to become sick or  experience a sudden health event, giving providers   more opportunities to take preventive action and   keep patients healthier at more affordable costs.
","('Employee_Health_And_Safety', 0.7633086442947388)","('Critical_Incident_Risk_Management', 0.07048782706260681)","('Access_And_Affordability', 0.03473605215549469)","(['Operational Eco-Efficiency'], 0.7633086442947388)","('NON-ESG', 0.07048782706260681)","('NON-ESG', 0.03473605215549469)"
Line 224,"The Boston Scientific HeartLogic™ Heart Failure Diagnostic   technology is embedded within implantable defibrillators  and uses multiple sensors to collect and analyze patient   physiological data.
","('Employee_Health_And_Safety', 0.5288584232330322)","('Critical_Incident_Risk_Management', 0.21479564905166626)","('Access_And_Affordability', 0.037161074578762054)","(['Operational Eco-Efficiency'], 0.5288584232330322)","('NON-ESG', 0.21479564905166626)","('NON-ESG', 0.037161074578762054)"
Line 225,"The technology has been proven   to predict heart failure events an average of 34 days   before they happen , which enables proactive care and  helps reduce patient hospitalizations and readmissions.
","('Employee_Health_And_Safety', 0.6788355112075806)","('Critical_Incident_Risk_Management', 0.1051778569817543)","('Access_And_Affordability', 0.025469329208135605)","(['Operational Eco-Efficiency'], 0.6788355112075806)","('NON-ESG', 0.1051778569817543)","('NON-ESG', 0.025469329208135605)"
Line 226,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Investing in   Our People At Boston Scientific, we are fortunate to  have approximately 38,000 employees  around the world whose constant focus  is developing solutions that change   and save lives.
","('Access_And_Affordability', 0.308916836977005)","('Human_Rights_And_Community_Relations', 0.11756736040115356)","('Employee_Engagement_Inclusion_And_Diversity', 0.0797891691327095)","('NON-ESG', 0.308916836977005)","('NON-ESG', 0.11756736040115356)","('NON-ESG', 0.0797891691327095)"
Line 227,"Their talent and collective passion define us as a  company, and our performance as a business is   built on their diversity of thought and experiences.
","('Employee_Engagement_Inclusion_And_Diversity', 0.953831672668457)","('Employee_Health_And_Safety', 0.00379068567417562)","('Human_Rights_And_Community_Relations', 0.0036523586604744196)","(['Human Capital Development'], 0.953831672668457)","('NON-ESG', 0.00379068567417562)","('NON-ESG', 0.0036523586604744196)"
Line 228,"Our business practices reflect our belief that   innovation thrives when employees are highly   engaged in their jobs and communities, and with   one another.
","('Employee_Engagement_Inclusion_And_Diversity', 0.40321987867355347)","('Business_Model_Resilience', 0.09972873330116272)","('Competitive_Behavior', 0.07733889669179916)","('NON-ESG', 0.40321987867355347)","('NON-ESG', 0.09972873330116272)","('NON-ESG', 0.07733889669179916)"
Line 229,"We invest in our people so they can  solve problems and advance promising ideas,   and we recognize and reward them for their   contributions.
","('Human_Rights_And_Community_Relations', 0.24314145743846893)","('Business_Model_Resilience', 0.14048852026462555)","('Business_Ethics', 0.07056473195552826)","('NON-ESG', 0.24314145743846893)","('NON-ESG', 0.14048852026462555)","('NON-ESG', 0.07056473195552826)"
Line 230,"Inspiring   possibilityPURPOSE Innovating through  diversityHUMANITY Discovering through  collaborationSCIENCE	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   In 2020, Stephanie Pittman, who has been with Boston  Scientific for 10 years, took on the role of vice president of  Global Talent Management and HR Planning in 2020.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9328798055648804)","('Business_Model_Resilience', 0.007558397948741913)","('Access_And_Affordability', 0.007086914498358965)","(['Human Capital Development'], 0.9328798055648804)","('NON-ESG', 0.007558397948741913)","('NON-ESG', 0.007086914498358965)"
Line 231,"Inspiring   possibilityPURPOSE Innovating through  diversityHUMANITY Discovering through  collaborationSCIENCE	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   In 2020, Stephanie Pittman, who has been with Boston  Scientific for 10 years, took on the role of vice president of  Global Talent Management and HR Planning in 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5926302075386047)","('Human_Rights_And_Community_Relations', 0.05354924872517586)","('Systemic_Risk_Management', 0.03690788149833679)","(['Corporate Governance'], 0.5926302075386047)","('NON-ESG', 0.05354924872517586)","('NON-ESG', 0.03690788149833679)"
Line 232,"“ Our global workforce expects meaningful  work with career advancement   opportunities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9518260955810547)","('Labor_Practices', 0.005896103102713823)","('Employee_Health_And_Safety', 0.005278913304209709)","(['Human Capital Development'], 0.9518260955810547)","('NON-ESG', 0.005896103102713823)","('NON-ESG', 0.005278913304209709)"
Line 233,"We are enhancing our   workforce planning strategy and   development capabilities to meet those  needs both now and in the future.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8033503890037537)","('Business_Model_Resilience', 0.040348175913095474)","('Access_And_Affordability', 0.02173992246389389)","(['Human Capital Development'], 0.8033503890037537)","('NON-ESG', 0.040348175913095474)","('NON-ESG', 0.02173992246389389)"
Line 234,"This  includes expanding virtual learning   offerings, investing in digitally enabled  analytics and increasing the ways we   listen to gain insight and take action.”  Stephanie Pittman , vice president, Global Talent   Management and HR PlanningSUSTAINABLE DEVELOPMENT GOALS: meaningful innovation high performancediversityglobal collaborationTalent and   Company Culture Our competitive edge comes from our employees’   collective talent and shared sense of purpose.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9137526154518127)","('Business_Model_Resilience', 0.009727049618959427)","('Employee_Health_And_Safety', 0.007712310180068016)","(['Human Capital Development'], 0.9137526154518127)","('NON-ESG', 0.009727049618959427)","('NON-ESG', 0.007712310180068016)"
Line 235,"We   foster a values-driven culture where engagement and  inclusion thrive and diversity of thought, background   and perspective elevate collaboration.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9724215269088745)","('Human_Rights_And_Community_Relations', 0.0024346602149307728)","('Employee_Health_And_Safety', 0.002357425633817911)","(['Human Capital Development'], 0.9724215269088745)","('NON-ESG', 0.0024346602149307728)","('NON-ESG', 0.002357425633817911)"
Line 236,"This culture   helps produce our greatest breakthroughs and is   the foundation of our success.
","('Business_Model_Resilience', 0.42296284437179565)","('Employee_Engagement_Inclusion_And_Diversity', 0.09934400022029877)","('Competitive_Behavior', 0.06266231834888458)","('NON-ESG', 0.42296284437179565)","('NON-ESG', 0.09934400022029877)","('NON-ESG', 0.06266231834888458)"
Line 237,"The core values  we   demonstrate across the company are embedded in   our talent management systems.
","('Employee_Engagement_Inclusion_And_Diversity', 0.951232373714447)","('Business_Model_Resilience', 0.005111253820359707)","('Employee_Health_And_Safety', 0.004208956379443407)","(['Human Capital Development'], 0.951232373714447)","('NON-ESG', 0.005111253820359707)","('NON-ESG', 0.004208956379443407)"
Line 238,"winning spirit caringOur Core ValuesTALENT MANAGEMENT INSIGHTS:           STEPHANIE PITTMAN	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyGlobal Strategic Talent   Management and Planning Our efforts to recruit, promote and retain diverse talent   are focused on cultivating inclusive behaviors and building  an organization that prioritizes continuous learning and   the following:    Talent management and planning: apply   analytics and insights to hire and develop   diverse, high-potential talent and facilitate   their movement to new roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9671064615249634)","('Employee_Health_And_Safety', 0.0028050709515810013)","('Business_Model_Resilience', 0.0027050580829381943)","(['Human Capital Development'], 0.9671064615249634)","('NON-ESG', 0.0028050709515810013)","('NON-ESG', 0.0027050580829381943)"
Line 239,"winning spirit caringOur Core ValuesTALENT MANAGEMENT INSIGHTS:           STEPHANIE PITTMAN	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyGlobal Strategic Talent   Management and Planning Our efforts to recruit, promote and retain diverse talent   are focused on cultivating inclusive behaviors and building  an organization that prioritizes continuous learning and   the following:    Talent management and planning: apply   analytics and insights to hire and develop   diverse, high-potential talent and facilitate   their movement to new roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9561161994934082)","('Employee_Health_And_Safety', 0.003271187888458371)","('Business_Model_Resilience', 0.0031858852598816156)","(['Human Capital Development'], 0.9561161994934082)","('NON-ESG', 0.003271187888458371)","('NON-ESG', 0.0031858852598816156)"
Line 240,"Manager development: improve managers’   performance and career coaching capabilities,   inclusive leadership behaviors and agility in  adapting to change.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7745044827461243)","('Business_Model_Resilience', 0.036086007952690125)","('Human_Rights_And_Community_Relations', 0.0272985827177763)","(['Human Capital Development'], 0.7745044827461243)","('NON-ESG', 0.036086007952690125)","('NON-ESG', 0.0272985827177763)"
Line 241,"Culture and engagement: measure the   employee experience through data and   ongoing dialogue and act on the results.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7535986304283142)","('Human_Rights_And_Community_Relations', 0.09638293087482452)","('Employee_Health_And_Safety', 0.027317576110363007)","(['Human Capital Development'], 0.7535986304283142)","('NON-ESG', 0.09638293087482452)","('NON-ESG', 0.027317576110363007)"
Line 242,"Employee growth and development: provide   development opportunities for all employees,  as well as tailored programs for top leaders   and key talent; this includes accelerating   meaningful advancement opportunities for  women and multicultural talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.967832088470459)","('Employee_Health_And_Safety', 0.002725068014115095)","('Human_Rights_And_Community_Relations', 0.002277707913890481)","(['Human Capital Development'], 0.967832088470459)","('NON-ESG', 0.002725068014115095)","('NON-ESG', 0.002277707913890481)"
Line 243,"Our progress in talent management included the transition   to what we have named, “Performance Development  Coaching (PDC) 2.0,” an ongoing people development  approach.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8457694053649902)","('Human_Rights_And_Community_Relations', 0.019763384014368057)","('Business_Model_Resilience', 0.01343014370650053)","(['Human Capital Development'], 0.8457694053649902)","('NON-ESG', 0.019763384014368057)","('NON-ESG', 0.01343014370650053)"
Line 244,"Slated for companywide adoption in 2021, PDC  2.0 enables employees to receive continuous coaching and  to request performance feedback from supervisors and  colleagues as projects are completed and evaluated.
","('Employee_Engagement_Inclusion_And_Diversity', 0.18576936423778534)","('Human_Rights_And_Community_Relations', 0.1835903376340866)","('Labor_Practices', 0.12302109599113464)","('NON-ESG', 0.18576936423778534)","('NON-ESG', 0.1835903376340866)","('NON-ESG', 0.12302109599113464)"
Line 245,"Recruit.
","('Employee_Engagement_Inclusion_And_Diversity', 0.33377355337142944)","('Data_Security', 0.07282218337059021)","('Customer_Welfare', 0.057750947773456573)","('NON-ESG', 0.33377355337142944)","('NON-ESG', 0.07282218337059021)","('NON-ESG', 0.057750947773456573)"
Line 246,"Develop.
","('Business_Model_Resilience', 0.15012292563915253)","('Product_Design_And_Lifecycle_Management', 0.12899670004844666)","('Employee_Engagement_Inclusion_And_Diversity', 0.10172994434833527)","('NON-ESG', 0.15012292563915253)","('NON-ESG', 0.12899670004844666)","('NON-ESG', 0.10172994434833527)"
Line 247,"Promote.
","('Competitive_Behavior', 0.15859276056289673)","('Human_Rights_And_Community_Relations', 0.10736209154129028)","('Business_Ethics', 0.08586036413908005)","('NON-ESG', 0.15859276056289673)","('NON-ESG', 0.10736209154129028)","('NON-ESG', 0.08586036413908005)"
Line 248,"Retain.
","('Competitive_Behavior', 0.14544567465782166)","('Employee_Engagement_Inclusion_And_Diversity', 0.14391979575157166)","('Customer_Privacy', 0.09696463495492935)","('NON-ESG', 0.14544567465782166)","('NON-ESG', 0.14391979575157166)","('NON-ESG', 0.09696463495492935)"
Line 249,"PIVOTING TO PDC 2.FROM:    Formal review meetings twice a year     Comprehensive feedback  limited to   scheduled reviews    Companywide  timing    Structured  review eventsTO:    Ongoing feedback  as needed     Brief feedback  and coaching conversations relevant  to current work     Supervisor or direct report  initiates discussions   as needed     Feedback and coaching intervals integrated  into   regular work meetings, reinforcing ongoing   development conversations	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Employee Growth and Development Boston Scientific provides tools and training for continuous  learning so every employee can envision greater possibilities  for their career.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4304318428039551)","('Access_And_Affordability', 0.1172804906964302)","('Business_Ethics', 0.04747277870774269)","('NON-ESG', 0.4304318428039551)","('NON-ESG', 0.1172804906964302)","('NON-ESG', 0.04747277870774269)"
Line 250,"PIVOTING TO PDC 2.FROM:    Formal review meetings twice a year     Comprehensive feedback  limited to   scheduled reviews    Companywide  timing    Structured  review eventsTO:    Ongoing feedback  as needed     Brief feedback  and coaching conversations relevant  to current work     Supervisor or direct report  initiates discussions   as needed     Feedback and coaching intervals integrated  into   regular work meetings, reinforcing ongoing   development conversations	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Employee Growth and Development Boston Scientific provides tools and training for continuous  learning so every employee can envision greater possibilities  for their career.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7320753335952759)","('Access_And_Affordability', 0.052933383733034134)","('Employee_Health_And_Safety', 0.04848073422908783)","(['Human Capital Development'], 0.7320753335952759)","('NON-ESG', 0.052933383733034134)","('NON-ESG', 0.04848073422908783)"
Line 251,"We offer more than 150 professional and technical  courses , including on-the-job training, skills-based   education and programs for employees who have   the potential to hold leadership positions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9064264893531799)","('Labor_Practices', 0.012183872982859612)","('Employee_Health_And_Safety', 0.009200001135468483)","(['Human Capital Development'], 0.9064264893531799)","('NON-ESG', 0.012183872982859612)","('NON-ESG', 0.009200001135468483)"
Line 252,"Responding to the realities of the pandemic, the   company ramped up virtual training and   development .
","('Critical_Incident_Risk_Management', 0.4117334187030792)","('Physical_Impacts_Of_Climate_Change', 0.1649477332830429)","('Systemic_Risk_Management', 0.06542915105819702)","('NON-ESG', 0.4117334187030792)","('NON-ESG', 0.1649477332830429)","('NON-ESG', 0.06542915105819702)"
Line 253,"People at all levels of the company   now have access to more than 100 new and expanded  webinars, online courses and on-demand training.
","('Access_And_Affordability', 0.4435233771800995)","('Employee_Engagement_Inclusion_And_Diversity', 0.14539790153503418)","('Product_Quality_And_Safety', 0.053199853748083115)","('NON-ESG', 0.4435233771800995)","('NON-ESG', 0.14539790153503418)","('NON-ESG', 0.053199853748083115)"
Line 254,"564K hours  spent by non-manufacturing employees in 2020 virtual and classroom training  150+ professional and technical    courses  offered     100+ new and expanded    webinars, online courses and    on-demand training	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Multicultural (U.S. and Puerto Rico) 2017 201817.8%19.6% 201920.8% 202021.4%Fostering a Diverse,   Equitable and   Inclusive Culture To promote equity and cultivate an enduring culture   of inclusion, we must hold ourselves accountable as an   organization.
","('Access_And_Affordability', 0.45427075028419495)","('Employee_Engagement_Inclusion_And_Diversity', 0.11944875866174698)","('Employee_Health_And_Safety', 0.06717497110366821)","('NON-ESG', 0.45427075028419495)","('NON-ESG', 0.11944875866174698)","('NON-ESG', 0.06717497110366821)"
Line 255,"564K hours  spent by non-manufacturing employees in 2020 virtual and classroom training  150+ professional and technical    courses  offered     100+ new and expanded    webinars, online courses and    on-demand training	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Multicultural (U.S. and Puerto Rico) 2017 201817.8%19.6% 201920.8% 202021.4%Fostering a Diverse,   Equitable and   Inclusive Culture To promote equity and cultivate an enduring culture   of inclusion, we must hold ourselves accountable as an   organization.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9693211317062378)","('Human_Rights_And_Community_Relations', 0.003394025843590498)","('Business_Model_Resilience', 0.002475256333127618)","(['Human Capital Development'], 0.9693211317062378)","('NON-ESG', 0.003394025843590498)","('NON-ESG', 0.002475256333127618)"
Line 256,"We have made steady progress , and at   the beginning of 2020, we set our diversity, equity   and inclusion goals even higher with three new bold   measures to accelerate the representation of women   and multicultural talent in our workforce.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9764556288719177)","('Employee_Health_And_Safety', 0.001955523155629635)","('Human_Rights_And_Community_Relations', 0.0016007166123017669)","(['Human Capital Development'], 0.9764556288719177)","('NON-ESG', 0.001955523155629635)","('NON-ESG', 0.0016007166123017669)"
Line 257,"Based on our   belief that the only acceptable trajectory for diverse   representation is up, we call these goals “3Up by 2023.” Increase our goal of   representation of   women  at the   supervisory and   managerial level to   at least 43 percent —   an increase of   3 percentage pointsIncrease our goal of    representation of   multicultural talent   at the supervisory   and managerial level   to at least 23 percent —   an increase of   3 percentage pointsTop 10%: Continue to  be in the top 10 percent  globally as a recognized  leader for workplace  inclusion3UP BY REPRESENTATION AT ALL LEVELS SUPERVISORY AND MANAGERIAL LEVEL REPRESENTATIONDE&I EFFORTS ACROSS BOSTON  SCIENTIFIC ALIGN WITH FOUR  STRATEGIC PILLARS Multicultural (U.S. and Puerto Rico) 2017 201830.7%31.7% 201933.2% 202034.0% Women (Global) 2017 201837.4%38.4% 201938.1% 202039.9% 2020Women (Global) 2017 201845.5%46.5% 201947.0% 202047.4%Greater representation and   inclusivity  is about progress over  time, not overnight.
","('Employee_Engagement_Inclusion_And_Diversity', 0.972140908241272)","('Employee_Health_And_Safety', 0.002637675730511546)","('Labor_Practices', 0.002251615282148123)","(['Human Capital Development'], 0.972140908241272)","('NON-ESG', 0.002637675730511546)","('NON-ESG', 0.002251615282148123)"
Line 258,"Based on our   belief that the only acceptable trajectory for diverse   representation is up, we call these goals “3Up by 2023.” Increase our goal of   representation of   women  at the   supervisory and   managerial level to   at least 43 percent —   an increase of   3 percentage pointsIncrease our goal of    representation of   multicultural talent   at the supervisory   and managerial level   to at least 23 percent —   an increase of   3 percentage pointsTop 10%: Continue to  be in the top 10 percent  globally as a recognized  leader for workplace  inclusion3UP BY REPRESENTATION AT ALL LEVELS SUPERVISORY AND MANAGERIAL LEVEL REPRESENTATIONDE&I EFFORTS ACROSS BOSTON  SCIENTIFIC ALIGN WITH FOUR  STRATEGIC PILLARS Multicultural (U.S. and Puerto Rico) 2017 201830.7%31.7% 201933.2% 202034.0% Women (Global) 2017 201837.4%38.4% 201938.1% 202039.9% 2020Women (Global) 2017 201845.5%46.5% 201947.0% 202047.4%Greater representation and   inclusivity  is about progress over  time, not overnight.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9700708389282227)","('Competitive_Behavior', 0.0023722851183265448)","('Employee_Health_And_Safety', 0.0022845850326120853)","(['Human Capital Development'], 0.9700708389282227)","('NON-ESG', 0.0023722851183265448)","('NON-ESG', 0.0022845850326120853)"
Line 259,"Learn more   about why DE&I is a business   imperative for Boston Scientific.
","('Business_Model_Resilience', 0.44756969809532166)","('Supply_Chain_Management', 0.11199335753917694)","('Systemic_Risk_Management', 0.07491985708475113)","('NON-ESG', 0.44756969809532166)","('NON-ESG', 0.11199335753917694)","('NON-ESG', 0.07491985708475113)"
Line 260,"CAREER     CULTURE  COMMERCE    COMMUNITY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In 2020, four Boston Scientific  employees were selected to  participate in the CEO Action  for Racial Equity , a fellowship  that provides representatives of CEO Action for Diversity  & Inclusion signatories an opportunity to advance racial  equity through public policy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9756976366043091)","('Employee_Health_And_Safety', 0.002090276451781392)","('Business_Model_Resilience', 0.0016181761166080832)","(['Human Capital Development'], 0.9756976366043091)","('NON-ESG', 0.002090276451781392)","('NON-ESG', 0.0016181761166080832)"
Line 261,"CAREER     CULTURE  COMMERCE    COMMUNITY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In 2020, four Boston Scientific  employees were selected to  participate in the CEO Action  for Racial Equity , a fellowship  that provides representatives of CEO Action for Diversity  & Inclusion signatories an opportunity to advance racial  equity through public policy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9583925604820251)","('Human_Rights_And_Community_Relations', 0.004863715264946222)","('Access_And_Affordability', 0.0035266822669655085)","(['Human Capital Development'], 0.9583925604820251)","('NON-ESG', 0.004863715264946222)","('NON-ESG', 0.0035266822669655085)"
Line 262,"The fellowship is governed  by the CEO Action for Racial Equity Governing Committee,  a group of 20 CEOs who represent multiple industries  and regions, including Boston Scientific Chairman and  CEO Mike Mahoney, a founding signatory of CEO Action.
","('Director_Removal', 0.20657509565353394)","('Management_Of_Legal_And_Regulatory_Framework', 0.19374918937683105)","('Systemic_Risk_Management', 0.09439430385828018)","('NON-ESG', 0.20657509565353394)","('NON-ESG', 0.19374918937683105)","('NON-ESG', 0.09439430385828018)"
Line 263,"“  This fellowship aligns  with my own values   and enables me to   take responsibility —   as a white woman   of privilege — in  the journey to advance racial equity.”       Caroline Jacobsen , manager, Health EconomicsCEO ACTION FOR RACIAL EQUITY FELLOWSHIP  Our ability to fulfill our mission   will always depend on a team   that includes a diversity of people,  ideas and skills.
","('Employee_Engagement_Inclusion_And_Diversity', 0.973479151725769)","('Human_Rights_And_Community_Relations', 0.002533170860260725)","('Employee_Health_And_Safety', 0.002239072462543845)","(['Human Capital Development'], 0.973479151725769)","('NON-ESG', 0.002533170860260725)","('NON-ESG', 0.002239072462543845)"
Line 264,"The company took  steps to accelerate DE&I progress    in 2020 by expanding many of   our programs to ensure individuals  have equitable opportunities for  growth.
","('Employee_Engagement_Inclusion_And_Diversity', 0.46093741059303284)","('Human_Rights_And_Community_Relations', 0.15823787450790405)","('Access_And_Affordability', 0.05543132871389389)","('NON-ESG', 0.46093741059303284)","('NON-ESG', 0.15823787450790405)","('NON-ESG', 0.05543132871389389)"
Line 265,"Unconscious bias training   is mandatory for all employees,   as is expanded diverse hiring   practices.
","('Employee_Engagement_Inclusion_And_Diversity', 0.972488522529602)","('Labor_Practices', 0.002140347147360444)","('Competitive_Behavior', 0.0021217078901827335)","(['Human Capital Development'], 0.972488522529602)","('NON-ESG', 0.002140347147360444)","('NON-ESG', 0.0021217078901827335)"
Line 266,"To help our organization  be more deliberate in our approach  to DE&I, we increased training   for all leaders on topics such as  microagressions, modeling inclusive  behaviors, history of racism, allyship  and moving from “color blind to  color brave.” CHAMPIONING DE&I	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Advancing Multicultural Talent To address the need for more Black, Hispanic and Latinx   employees at the manager and supervisor levels, we  expanded our diverse hiring and training programs and  increased our investment in ally and mentorship initiatives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9618832468986511)","('Access_And_Affordability', 0.0039666504599153996)","('Human_Rights_And_Community_Relations', 0.0037398873828351498)","(['Human Capital Development'], 0.9618832468986511)","('NON-ESG', 0.0039666504599153996)","('NON-ESG', 0.0037398873828351498)"
Line 267,"To help our organization  be more deliberate in our approach  to DE&I, we increased training   for all leaders on topics such as  microagressions, modeling inclusive  behaviors, history of racism, allyship  and moving from “color blind to  color brave.” CHAMPIONING DE&I	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Advancing Multicultural Talent To address the need for more Black, Hispanic and Latinx   employees at the manager and supervisor levels, we  expanded our diverse hiring and training programs and  increased our investment in ally and mentorship initiatives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9754933714866638)","('Employee_Health_And_Safety', 0.001660586567595601)","('Business_Model_Resilience', 0.0014975982485339046)","(['Human Capital Development'], 0.9754933714866638)","('NON-ESG', 0.001660586567595601)","('NON-ESG', 0.0014975982485339046)"
Line 268,"We also designed new programs specifically for Black,   Hispanic and Latinx employees who build our medical  devices to prepare them for business roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.972783625125885)","('Human_Rights_And_Community_Relations', 0.001979999942705035)","('Employee_Health_And_Safety', 0.0018407360184937716)","(['Human Capital Development'], 0.972783625125885)","('NON-ESG', 0.001979999942705035)","('NON-ESG', 0.0018407360184937716)"
Line 269,"These   programs are expected to launch in 2021.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7674626111984253)","('GHG_Emissions', 0.0335388146340847)","('Physical_Impacts_Of_Climate_Change', 0.02329760417342186)","(['Corporate Governance'], 0.7674626111984253)","('NON-ESG', 0.0335388146340847)","('NON-ESG', 0.02329760417342186)"
Line 270,"Inclusion Resources The DE&I dashboard we developed in 2019 proved to   be a valuable analytics tool in 2020 as we took stock of   where we can address shortcomings and make measurable  improvements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.18806101381778717)","('Systemic_Risk_Management', 0.14590740203857422)","('Business_Model_Resilience', 0.1193404570221901)","('NON-ESG', 0.18806101381778717)","('NON-ESG', 0.14590740203857422)","('NON-ESG', 0.1193404570221901)"
Line 271,"Our leaders use DE&I analytics to better   understand representation trends in their organizations  and identify ways to improve hiring, promotion and   attrition metrics.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9586445093154907)","('Labor_Practices', 0.007181723136454821)","('Competitive_Behavior', 0.0028916203882545233)","(['Human Capital Development'], 0.9586445093154907)","('NON-ESG', 0.007181723136454821)","('NON-ESG', 0.0028916203882545233)"
Line 272,"Over the course of the year, we expanded our virtual   inclusion resources.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9116156697273254)","('Access_And_Affordability', 0.014550983905792236)","('Employee_Health_And_Safety', 0.008449619635939598)","(['Human Capital Development'], 0.9116156697273254)","('NON-ESG', 0.014550983905792236)","('NON-ESG', 0.008449619635939598)"
Line 273,"Inclusion toolkit.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9300369620323181)","('Human_Rights_And_Community_Relations', 0.014427989721298218)","('Employee_Health_And_Safety', 0.006954751908779144)","(['Human Capital Development'], 0.9300369620323181)","('NON-ESG', 0.014427989721298218)","('NON-ESG', 0.006954751908779144)"
Line 274,"The online toolkit encourages   employees to take the I Act On Pledge  and complete  an assessment to determine their inclusion IQ.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9708786606788635)","('Employee_Health_And_Safety', 0.002449503866955638)","('Human_Rights_And_Community_Relations', 0.0024175262078642845)","(['Human Capital Development'], 0.9708786606788635)","('NON-ESG', 0.002449503866955638)","('NON-ESG', 0.0024175262078642845)"
Line 275,"It offers  on-demand DE&I tools as well as learning modules   on topics such as unconscious bias training, modeling   inclusive behaviors and anti-racism.
","('Employee_Engagement_Inclusion_And_Diversity', 0.928321897983551)","('Human_Rights_And_Community_Relations', 0.007235544268041849)","('Competitive_Behavior', 0.006592814810574055)","(['Human Capital Development'], 0.928321897983551)","('NON-ESG', 0.007235544268041849)","('NON-ESG', 0.006592814810574055)"
Line 276,"Candid conversations.
","('Customer_Privacy', 0.09052127599716187)","('Business_Ethics', 0.0879487693309784)","('Employee_Engagement_Inclusion_And_Diversity', 0.0768231526017189)","('NON-ESG', 0.09052127599716187)","('NON-ESG', 0.0879487693309784)","('NON-ESG', 0.0768231526017189)"
Line 277,"The Candid Conversations   podcast is an interview series that builds on our   inclusion training and Real Talk listening sessions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9536440968513489)","('Human_Rights_And_Community_Relations', 0.00635303882881999)","('Employee_Health_And_Safety', 0.004037547390908003)","(['Human Capital Development'], 0.9536440968513489)","('NON-ESG', 0.00635303882881999)","('NON-ESG', 0.004037547390908003)"
Line 278,"In 2020, we expanded opportunities for people at   all levels of the organization to tell their stories   and offer perspectives on handling issues such   as parenting during the pandemic, racial injustice   and mental health.
","('Employee_Engagement_Inclusion_And_Diversity', 0.38307657837867737)","('Human_Rights_And_Community_Relations', 0.2947714924812317)","('Employee_Health_And_Safety', 0.08109890669584274)","('NON-ESG', 0.38307657837867737)","('NON-ESG', 0.2947714924812317)","('NON-ESG', 0.08109890669584274)"
Line 279,"As racial inequity and injustice   dominated the dialogue in and   outside the company, we took steps  to engage in necessary, sometimes  uncomfortable, conversations to  break the silence about race and  identity.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9388198852539062)","('Human_Rights_And_Community_Relations', 0.011721798218786716)","('Employee_Health_And_Safety', 0.006956612225621939)","(['Human Capital Development'], 0.9388198852539062)","('NON-ESG', 0.011721798218786716)","('NON-ESG', 0.006956612225621939)"
Line 280,"Leaders and our HR and   DE&I teams led more than 200   hours of Real Talk listening sessions,  engaging employees throughout   the organization in dialogue on the  root causes of racism.
","('Business_Ethics', 0.46915170550346375)","('Employee_Engagement_Inclusion_And_Diversity', 0.24492943286895752)","('Human_Rights_And_Community_Relations', 0.04165136441588402)","('NON-ESG', 0.46915170550346375)","('NON-ESG', 0.24492943286895752)","('NON-ESG', 0.04165136441588402)"
Line 281,"We covered  topics such as what it’s like to be  Black in corporate America, white  privilege as well as disparities in   the workplace and barriers to   diversity.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9752291440963745)","('Employee_Health_And_Safety', 0.0017926202854141593)","('Human_Rights_And_Community_Relations', 0.0016478694742545485)","(['Human Capital Development'], 0.9752291440963745)","('NON-ESG', 0.0017926202854141593)","('NON-ESG', 0.0016478694742545485)"
Line 282,"Rob Morton (left), and his mentor  Matt Lavelle, vice president,   Operations (right) held one of   the first Real Talk sessions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.31587550044059753)","('Business_Model_Resilience', 0.12031596899032593)","('Competitive_Behavior', 0.08214392513036728)","('NON-ESG', 0.31587550044059753)","('NON-ESG', 0.12031596899032593)","('NON-ESG', 0.08214392513036728)"
Line 283,"Employees engaged in 200+ hours of “Real Talk” REAL TALK IN ” Things like race have a negative stigma associated with  being talked about at work.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9432461857795715)","('Labor_Practices', 0.010253521613776684)","('Employee_Health_And_Safety', 0.0048529403284192085)","(['Human Capital Development'], 0.9432461857795715)","('NON-ESG', 0.010253521613776684)","('NON-ESG', 0.0048529403284192085)"
Line 284,"If sharing our conversation  influences just one person then it was a success.”      Rob Morton , senior scientific communications specialist, Medical Affairs	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Learning from our Employee   Resource Groups Employee Resource Groups (ERGs)  are vital collaborators   in our DE&I strategy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.28625839948654175)","('Employee_Health_And_Safety', 0.1281646341085434)","('Human_Rights_And_Community_Relations', 0.12658406794071198)","('NON-ESG', 0.28625839948654175)","('NON-ESG', 0.1281646341085434)","('NON-ESG', 0.12658406794071198)"
Line 285,"If sharing our conversation  influences just one person then it was a success.”      Rob Morton , senior scientific communications specialist, Medical Affairs	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Learning from our Employee   Resource Groups Employee Resource Groups (ERGs)  are vital collaborators   in our DE&I strategy.
","('Business_Model_Resilience', 0.16457977890968323)","('Human_Rights_And_Community_Relations', 0.0923009067773819)","('Employee_Engagement_Inclusion_And_Diversity', 0.07694509625434875)","('NON-ESG', 0.16457977890968323)","('NON-ESG', 0.0923009067773819)","('NON-ESG', 0.07694509625434875)"
Line 286,"ERGs are voluntary, company-sponsored  groups of employees who champion opportunity for all in  our work environment and provide feedback to executive  leaders through the company’s Global Council for Inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9465011954307556)","('Human_Rights_And_Community_Relations', 0.008721834979951382)","('Employee_Health_And_Safety', 0.006677550729364157)","(['Human Capital Development'], 0.9465011954307556)","('NON-ESG', 0.008721834979951382)","('NON-ESG', 0.006677550729364157)"
Line 287,"ERGs are typically formed around specific dimensions of  diversity, for example, gender, race, veteran status, sexual  orientation or life stage.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9744083881378174)","('Employee_Health_And_Safety', 0.0020328264217823744)","('Human_Rights_And_Community_Relations', 0.0017843593377619982)","(['Human Capital Development'], 0.9744083881378174)","('NON-ESG', 0.0020328264217823744)","('NON-ESG', 0.0017843593377619982)"
Line 288,"All employees are welcome and  encouraged to join any ERG.
","('Employee_Engagement_Inclusion_And_Diversity', 0.32487815618515015)","('Director_Removal', 0.13464438915252686)","('Labor_Practices', 0.0698380246758461)","('NON-ESG', 0.32487815618515015)","('NON-ESG', 0.13464438915252686)","('NON-ESG', 0.0698380246758461)"
Line 289,"In 2020, Boston Scientific leaders and employees   participated in our first global ERG summit.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21681924164295197)","('Business_Model_Resilience', 0.09742845594882965)","('Human_Rights_And_Community_Relations', 0.08318018168210983)","('NON-ESG', 0.21681924164295197)","('NON-ESG', 0.09742845594882965)","('NON-ESG', 0.08318018168210983)"
Line 290,"We   examined the impact that the pandemic has had on  our employees, particularly through the lens of diversity,  equity and inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9716848731040955)","('Human_Rights_And_Community_Relations', 0.0024429038166999817)","('Employee_Health_And_Safety', 0.002407374093309045)","(['Human Capital Development'], 0.9716848731040955)","('NON-ESG', 0.0024429038166999817)","('NON-ESG', 0.002407374093309045)"
Line 291,"More than 850 members of the  company gathered virtually for panels and breakout   sessions to share perspectives on inclusion and   belonging.GLOBAL ERG SUMMIT: INCLUSION AND BELONGING  DURING THE COVID-19 PANDEMIC 6,000+ employees   across nine ERGs  110  chapters globally 42  chapters outside the U.S. 11  virtual chapters  Precious Morton  joined Boston Scientific in 2007 and  founded the Spencer, Indiana chapter of Bridge, our ERG  focused on developing a community of Black leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9495574831962585)","('Human_Rights_And_Community_Relations', 0.007661590352654457)","('Employee_Health_And_Safety', 0.004955096170306206)","(['Human Capital Development'], 0.9495574831962585)","('NON-ESG', 0.007661590352654457)","('NON-ESG', 0.004955096170306206)"
Line 292,"She is now a quality manager in Alpharetta, Georgia and  the global lead of Bridge.
","('Systemic_Risk_Management', 0.20879773795604706)","('Supply_Chain_Management', 0.20294182002544403)","('Business_Model_Resilience', 0.19720204174518585)","('NON-ESG', 0.20879773795604706)","('NON-ESG', 0.20294182002544403)","('NON-ESG', 0.19720204174518585)"
Line 293,"To recognize her contributions  to DE&I, the Boston Scientific Global Council for Inclusion   honored Precious with a 2020 Diversity, Equity and  Inclusion Impact Award for her leadership and courage  in bringing Black employees together to support one  another and give voice to racism and injustice to drive  meaningful change inside and outside the company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9699600338935852)","('Human_Rights_And_Community_Relations', 0.0030476092360913754)","('Employee_Health_And_Safety', 0.003041270887479186)","(['Human Capital Development'], 0.9699600338935852)","('NON-ESG', 0.0030476092360913754)","('NON-ESG', 0.003041270887479186)"
Line 294,"“  Everyone should be heard and accepted  for who they are.
","('Employee_Engagement_Inclusion_And_Diversity', 0.25012916326522827)","('Human_Rights_And_Community_Relations', 0.15133069455623627)","('Director_Removal', 0.10653483122587204)","('NON-ESG', 0.25012916326522827)","('NON-ESG', 0.15133069455623627)","('NON-ESG', 0.10653483122587204)"
Line 295,"People need a sense of  belonging and purpose.
","('Employee_Engagement_Inclusion_And_Diversity', 0.321897029876709)","('Human_Rights_And_Community_Relations', 0.2886330485343933)","('Customer_Privacy', 0.05307377129793167)","('NON-ESG', 0.321897029876709)","('NON-ESG', 0.2886330485343933)","('NON-ESG', 0.05307377129793167)"
Line 296,"I affectionately  call my Bridge colleagues The Fam,   because they are my family.
","('Director_Removal', 0.14694486558437347)","('Business_Ethics', 0.13907237350940704)","('Employee_Engagement_Inclusion_And_Diversity', 0.12999263405799866)","('NON-ESG', 0.14694486558437347)","('NON-ESG', 0.13907237350940704)","('NON-ESG', 0.12999263405799866)"
Line 297,"The ERGs at  Boston Scientific give us a safe space in a  not-so-safe world.
","('Employee_Health_And_Safety', 0.3165190815925598)","('Access_And_Affordability', 0.17997652292251587)","('Critical_Incident_Risk_Management', 0.08972591161727905)","('NON-ESG', 0.3165190815925598)","('NON-ESG', 0.17997652292251587)","('NON-ESG', 0.08972591161727905)"
Line 298,"We learn from one   another, and we make a positive impact  on the company and on our communities.”           Precious Morton , quality manager, PathologyERG PERSPECTIVE FROM BRIDGE:           DEVELOPING A COMMUNITY OF BLACK LEADERS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly The COVID-19 pulse survey gauged whether employees felt supported during the pandemic and allowed us to quickly   adapt companywide efforts as necessary.
","('Human_Rights_And_Community_Relations', 0.5778852105140686)","('Access_And_Affordability', 0.12730784714221954)","('Employee_Engagement_Inclusion_And_Diversity', 0.06203017383813858)","(['Community Relations'], 0.5778852105140686)","('NON-ESG', 0.12730784714221954)","('NON-ESG', 0.06203017383813858)"
Line 299,"We learn from one   another, and we make a positive impact  on the company and on our communities.”           Precious Morton , quality manager, PathologyERG PERSPECTIVE FROM BRIDGE:           DEVELOPING A COMMUNITY OF BLACK LEADERS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly The COVID-19 pulse survey gauged whether employees felt supported during the pandemic and allowed us to quickly   adapt companywide efforts as necessary.
","('Physical_Impacts_Of_Climate_Change', 0.4098522365093231)","('Critical_Incident_Risk_Management', 0.17328625917434692)","('Systemic_Risk_Management', 0.1396264135837555)","('NON-ESG', 0.4098522365093231)","('NON-ESG', 0.17328625917434692)","('NON-ESG', 0.1396264135837555)"
Line 300,"Distributed to a representative sampling of approximately 9,000 indirect   labor * employees , and with an 80 percent participation rate , feedback showed that employees: Trust    senior leaders  and believe   they care about  employee  well-being.
","('Labor_Practices', 0.49422892928123474)","('Employee_Engagement_Inclusion_And_Diversity', 0.18368765711784363)","('Employee_Health_And_Safety', 0.09478447586297989)","('NON-ESG', 0.49422892928123474)","('NON-ESG', 0.18368765711784363)","('NON-ESG', 0.09478447586297989)"
Line 301,"Value    frequent,   transparent  COVID-19   communications.Feel  they   have access to   helpful resources  and information,   although some   had difficulty   finding certain  well-being   resources.Appreciate   the flexibility in  where and when  they work, although  some expressed  workload concerns.
","('Access_And_Affordability', 0.22178331017494202)","('Management_Of_Legal_And_Regulatory_Framework', 0.20124231278896332)","('Human_Rights_And_Community_Relations', 0.11070559173822403)","('NON-ESG', 0.22178331017494202)","('NON-ESG', 0.20124231278896332)","('NON-ESG', 0.11070559173822403)"
Line 302,"COVID-19 PULSE SURVEY PEOPLE LEADERSHIP SURVEY 2020: EMPLOYEES RATE MANAGERS ON LEADERSHIP BEHAVIORS  *Those	with	one	or	more	direct	reports	responding		Each year, we offer   employees an    opportunity to rate their  manager’s performance  against a range of   leadership behaviors.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7684574723243713)","('Employee_Health_And_Safety', 0.03474951535463333)","('Human_Rights_And_Community_Relations', 0.02669454924762249)","(['Human Capital Development'], 0.7684574723243713)","('NON-ESG', 0.03474951535463333)","('NON-ESG', 0.02669454924762249)"
Line 303,"More than 26,000   employees  invited   to give survey feedback   on 4,800 people   leaders .
","('Employee_Engagement_Inclusion_And_Diversity', 0.6716412305831909)","('Business_Model_Resilience', 0.04620090499520302)","('Director_Removal', 0.04446538910269737)","(['Human Capital Development'], 0.6716412305831909)","('NON-ESG', 0.04620090499520302)","('NON-ESG', 0.04446538910269737)"
Line 304,"77% employee   response rate .
","('Employee_Health_And_Safety', 0.501563549041748)","('Critical_Incident_Risk_Management', 0.35383397340774536)","('Access_And_Affordability', 0.01847333274781704)","(['Operational Eco-Efficiency'], 0.501563549041748)","('NON-ESG', 0.35383397340774536)","('NON-ESG', 0.01847333274781704)"
Line 305,"95% of participating  managers * received a  personalized feedback  report.* Indirect	labor	includes	employees	who	are	 not	directly	involved	in	the	manufacturing	 of	products.
","('Labor_Practices', 0.9572344422340393)","('Employee_Health_And_Safety', 0.004554572515189648)","('Director_Removal', 0.004435251466929913)","(['Labor Practice Indicators'], 0.9572344422340393)","('NON-ESG', 0.004554572515189648)","('NON-ESG', 0.004435251466929913)"
Line 306,"Listening to Our People Our people have a prominent voice in how we   conduct business and the actions we take as a   global citizen.
","('Human_Rights_And_Community_Relations', 0.45537447929382324)","('Business_Model_Resilience', 0.19531525671482086)","('Employee_Engagement_Inclusion_And_Diversity', 0.06649396568536758)","('NON-ESG', 0.45537447929382324)","('NON-ESG', 0.19531525671482086)","('NON-ESG', 0.06649396568536758)"
Line 307,"To support this work, we invested in   an on-demand, pulse survey tool that allows us to  gather feedback on timely topics that can quickly   be turned into action.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3276764750480652)","('Access_And_Affordability', 0.10774577409029007)","('Business_Model_Resilience', 0.07735902070999146)","('NON-ESG', 0.3276764750480652)","('NON-ESG', 0.10774577409029007)","('NON-ESG', 0.07735902070999146)"
Line 308,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Benefits to Fit   People’s Lives Employee benefits at Boston Scientific reflect our belief  that well-being, financial health and security are essential  for a productive and collaborative workforce.
","('Employee_Health_And_Safety', 0.360919326543808)","('Access_And_Affordability', 0.2290443480014801)","('Employee_Engagement_Inclusion_And_Diversity', 0.11516319960355759)","('NON-ESG', 0.360919326543808)","('NON-ESG', 0.2290443480014801)","('NON-ESG', 0.11516319960355759)"
Line 309,"We strive to  offer benefits that are valued by our employees, promote  well-being and support life-work integration.
","('Employee_Health_And_Safety', 0.2903231978416443)","('Human_Rights_And_Community_Relations', 0.2188870757818222)","('Employee_Engagement_Inclusion_And_Diversity', 0.18643295764923096)","('NON-ESG', 0.2903231978416443)","('NON-ESG', 0.2188870757818222)","('NON-ESG', 0.18643295764923096)"
Line 310,"Our Global  Benefits to Fit Your Life  program provides employees   with a broad range of offerings to support and improve  their lives.
","('Access_And_Affordability', 0.3375967741012573)","('Employee_Health_And_Safety', 0.20543810725212097)","('Employee_Engagement_Inclusion_And_Diversity', 0.12242535501718521)","('NON-ESG', 0.3375967741012573)","('NON-ESG', 0.20543810725212097)","('NON-ESG', 0.12242535501718521)"
Line 311,"Compensation At Boston Scientific, we pay for performance.
","('Labor_Practices', 0.3712901771068573)","('Business_Ethics', 0.3543953597545624)","('Management_Of_Legal_And_Regulatory_Framework', 0.04232439026236534)","('NON-ESG', 0.3712901771068573)","('NON-ESG', 0.3543953597545624)","('NON-ESG', 0.04232439026236534)"
Line 312,"Where   it is relevant to an employee’s responsibilities and in   compliance with applicable law, we offer both a base   salary and variable compensation.
","('Labor_Practices', 0.9538702964782715)","('Management_Of_Legal_And_Regulatory_Framework', 0.007166157476603985)","('Employee_Engagement_Inclusion_And_Diversity', 0.005342930555343628)","(['Labor Practice Indicators'], 0.9538702964782715)","('NON-ESG', 0.007166157476603985)","('NON-ESG', 0.005342930555343628)"
Line 313,"Our variable pay   components include annual bonus programs, long-term  incentive stock awards, and one-time performance and  recognition rewards for highly successful projects and  breakthrough performance.
","('Labor_Practices', 0.6392911076545715)","('Management_Of_Legal_And_Regulatory_Framework', 0.07139892131090164)","('Business_Ethics', 0.06862998753786087)","(['Labor Practice Indicators'], 0.6392911076545715)","('NON-ESG', 0.07139892131090164)","('NON-ESG', 0.06862998753786087)"
Line 314,"Equal Pay for Equal Work: Pay Equity We pay people equally for equal work .
","('Labor_Practices', 0.9703842401504517)","('Employee_Engagement_Inclusion_And_Diversity', 0.0029440780635923147)","('Director_Removal', 0.002459780080243945)","(['Labor Practice Indicators'], 0.9703842401504517)","('NON-ESG', 0.0029440780635923147)","('NON-ESG', 0.002459780080243945)"
Line 315,"Our compensation  experts regularly benchmark salaries and conduct   companywide and external parity audits.
","('Labor_Practices', 0.6829001903533936)","('Management_Of_Legal_And_Regulatory_Framework', 0.0857435017824173)","('Business_Ethics', 0.08026547729969025)","(['Labor Practice Indicators'], 0.6829001903533936)","('NON-ESG', 0.0857435017824173)","('NON-ESG', 0.08026547729969025)"
Line 316,"We contract   with an independent third party to assess pay equity   across all positions using regression analysis.
","('Labor_Practices', 0.27825990319252014)","('Management_Of_Legal_And_Regulatory_Framework', 0.20555873215198517)","('Competitive_Behavior', 0.16392990946769714)","('NON-ESG', 0.27825990319252014)","('NON-ESG', 0.20555873215198517)","('NON-ESG', 0.16392990946769714)"
Line 317,"This   data-driven approach controls for variables that   influence compensation such as job position, tenure,   years of experience and location.
","('Labor_Practices', 0.5206080675125122)","('Employee_Engagement_Inclusion_And_Diversity', 0.3557788133621216)","('Employee_Health_And_Safety', 0.019540050998330116)","(['Labor Practice Indicators'], 0.5206080675125122)","('NON-ESG', 0.3557788133621216)","('NON-ESG', 0.019540050998330116)"
Line 318,"We use the results  to identify any potential pay disparities, and we address   these accordingly.
","('Labor_Practices', 0.8618928790092468)","('Business_Ethics', 0.02535165287554264)","('Competitive_Behavior', 0.016734620556235313)","(['Labor Practice Indicators'], 0.8618928790092468)","('NON-ESG', 0.02535165287554264)","('NON-ESG', 0.016734620556235313)"
Line 319,"In our last assessment, conducted   in 2019, we continued to see 99+ percent pay equity   for gender globally and 99+ percent pay equity for   multicultural talent in the United States, including   Puerto Rico.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9610138535499573)","('Access_And_Affordability', 0.003931271843612194)","('Labor_Practices', 0.003720825305208564)","(['Human Capital Development'], 0.9610138535499573)","('NON-ESG', 0.003931271843612194)","('NON-ESG', 0.003720825305208564)"
Line 320,"Our compensation team will conduct   another third-party global pay assessment in 2021.
","('Labor_Practices', 0.9137969017028809)","('Business_Ethics', 0.01886937953531742)","('Management_Of_Legal_And_Regulatory_Framework', 0.014363612979650497)","(['Labor Practice Indicators'], 0.9137969017028809)","('NON-ESG', 0.01886937953531742)","('NON-ESG', 0.014363612979650497)"
Line 321,"99%+  pay  equity             Employer of Choice Awards  Boston Scientific is committed to be an   employer of choice for globally diverse   talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9699541926383972)","('Access_And_Affordability', 0.0026136974338442087)","('Employee_Health_And_Safety', 0.0021840925328433514)","(['Human Capital Development'], 0.9699541926383972)","('NON-ESG', 0.0026136974338442087)","('NON-ESG', 0.0021840925328433514)"
Line 322,"We participate in external   benchmarking surveys that candidly  assess our progress and ensure we are doing all we   can to achieve our goals.
","('Business_Model_Resilience', 0.22496943175792694)","('Human_Rights_And_Community_Relations', 0.17547810077667236)","('Management_Of_Legal_And_Regulatory_Framework', 0.10110535472631454)","('NON-ESG', 0.22496943175792694)","('NON-ESG', 0.17547810077667236)","('NON-ESG', 0.10110535472631454)"
Line 323,"Visit our awards page  to   learn more about the recognition we received in 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.22915957868099213)","('Business_Ethics', 0.12475007027387619)","('Ecological_Impacts', 0.08072277903556824)","('NON-ESG', 0.22915957868099213)","('NON-ESG', 0.12475007027387619)","('NON-ESG', 0.08072277903556824)"
Line 324,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   As employees adjusted to life and work during the   pandemic, we moved quickly to help them and their   families by shortening meeting times, holding managers   accountable for supporting their teams with flexible  hours, and regularly communicating available resources.
","('Employee_Health_And_Safety', 0.48814284801483154)","('Access_And_Affordability', 0.22892026603221893)","('Human_Rights_And_Community_Relations', 0.06052039936184883)","('NON-ESG', 0.48814284801483154)","('NON-ESG', 0.22892026603221893)","('NON-ESG', 0.06052039936184883)"
Line 325,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   As employees adjusted to life and work during the   pandemic, we moved quickly to help them and their   families by shortening meeting times, holding managers   accountable for supporting their teams with flexible  hours, and regularly communicating available resources.
","('Access_And_Affordability', 0.18894396722316742)","('Ecological_Impacts', 0.13378220796585083)","('Supply_Chain_Management', 0.07776627689599991)","('NON-ESG', 0.18894396722316742)","('NON-ESG', 0.13378220796585083)","('NON-ESG', 0.07776627689599991)"
Line 326,"Through employee surveys and listening session s with  working parents and other caregivers, we continued to  assess how best to support our workforce.
","('Access_And_Affordability', 0.6864810585975647)","('Employee_Health_And_Safety', 0.08444632589817047)","('Human_Rights_And_Community_Relations', 0.04681815579533577)","(['Health Outcome Contribution'], 0.6864810585975647)","('NON-ESG', 0.08444632589817047)","('NON-ESG', 0.04681815579533577)"
Line 327,"As a result,  we added new benefits  and expanded other offerings:      expanded no-cost, virtual offerings for general   medicine and mental health support.
","('Access_And_Affordability', 0.593285322189331)","('Employee_Health_And_Safety', 0.06287817656993866)","('Customer_Welfare', 0.05907795950770378)","(['Health Outcome Contribution'], 0.593285322189331)","('NON-ESG', 0.06287817656993866)","('NON-ESG', 0.05907795950770378)"
Line 328,"doubled the time available under our Personal   Leave of Absence policy, and made it available to   use in half- or full-day increments.
","('Labor_Practices', 0.7954412698745728)","('Management_Of_Legal_And_Regulatory_Framework', 0.04127350077033043)","('Director_Removal', 0.030355820432305336)","(['Labor Practice Indicators'], 0.7954412698745728)","('NON-ESG', 0.04127350077033043)","('NON-ESG', 0.030355820432305336)"
Line 329,"increased child and adult care-giving benefits,   including adding more caregiver resources and   offering home schooling support such as virtual   tutoring, learning pods and return-to-school guides.
","('Access_And_Affordability', 0.917204737663269)","('Product_Quality_And_Safety', 0.008943953551352024)","('Employee_Health_And_Safety', 0.006794490851461887)","(['Health Outcome Contribution'], 0.917204737663269)","('NON-ESG', 0.008943953551352024)","('NON-ESG', 0.006794490851461887)"
Line 330,"modified our financial benefits for people facing   economic hardship.
","('Human_Rights_And_Community_Relations', 0.3321130871772766)","('Labor_Practices', 0.16459177434444427)","('Access_And_Affordability', 0.1620679348707199)","('NON-ESG', 0.3321130871772766)","('NON-ESG', 0.16459177434444427)","('NON-ESG', 0.1620679348707199)"
Line 331,"launched an internal well-being website and well-   being circles to provide employees opportunities to  connect over shared interests and circumstances.A BOOST IN PANDEMIC BENEFITS  Covered COVID-19 testing .
","('Access_And_Affordability', 0.48446381092071533)","('Human_Rights_And_Community_Relations', 0.230918750166893)","('Employee_Health_And_Safety', 0.10323502123355865)","('NON-ESG', 0.48446381092071533)","('NON-ESG', 0.230918750166893)","('NON-ESG', 0.10323502123355865)"
Line 332,"Doubled backup child care and elder care  days.
","('Access_And_Affordability', 0.8100962042808533)","('Employee_Health_And_Safety', 0.0265013687312603)","('Critical_Incident_Risk_Management', 0.017463862895965576)","(['Health Outcome Contribution'], 0.8100962042808533)","('NON-ESG', 0.0265013687312603)","('NON-ESG', 0.017463862895965576)"
Line 333,"Upheld flex work hours  and U.S. Flex Fridays.
","('Labor_Practices', 0.8868308067321777)","('Employee_Health_And_Safety', 0.03291648253798485)","('Waste_And_Hazardous_Materials_Management', 0.0062456196174025536)","(['Labor Practice Indicators'], 0.8868308067321777)","('NON-ESG', 0.03291648253798485)","('NON-ESG', 0.0062456196174025536)"
Line 334,"Revised policies  to support workplace flexibility.
","('Labor_Practices', 0.5417823791503906)","('Employee_Engagement_Inclusion_And_Diversity', 0.21096332371234894)","('Management_Of_Legal_And_Regulatory_Framework', 0.04966781288385391)","(['Labor Practice Indicators'], 0.5417823791503906)","('NON-ESG', 0.21096332371234894)","('NON-ESG', 0.04966781288385391)"
Line 335,"Expanded personal leave .
","('Labor_Practices', 0.5343953371047974)","('Business_Ethics', 0.0863613486289978)","('Customer_Privacy', 0.07565131783485413)","(['Labor Practice Indicators'], 0.5343953371047974)","('NON-ESG', 0.0863613486289978)","('NON-ESG', 0.07565131783485413)"
Line 336,"Enhanced global employee assistance programs .
","('Employee_Health_And_Safety', 0.4208918511867523)","('Labor_Practices', 0.21955926716327667)","('Employee_Engagement_Inclusion_And_Diversity', 0.12855930626392365)","('NON-ESG', 0.4208918511867523)","('NON-ESG', 0.21955926716327667)","('NON-ESG', 0.12855930626392365)"
Line 337,"Expanded counseling  benefit.
","('Access_And_Affordability', 0.7838975191116333)","('Employee_Engagement_Inclusion_And_Diversity', 0.026953672990202904)","('Employee_Health_And_Safety', 0.022312475368380547)","(['Health Outcome Contribution'], 0.7838975191116333)","('NON-ESG', 0.026953672990202904)","('NON-ESG', 0.022312475368380547)"
Line 338,"Introduced well-being  tools and resources,   including podcasts, webinars and interaction   opportunities.
","('Access_And_Affordability', 0.5944015979766846)","('Employee_Health_And_Safety', 0.09059356153011322)","('Human_Rights_And_Community_Relations', 0.05908631533384323)","(['Health Outcome Contribution'], 0.5944015979766846)","('NON-ESG', 0.09059356153011322)","('NON-ESG', 0.05908631533384323)"
Line 339,"Launched virtual well-being circles .
","('Access_And_Affordability', 0.39593666791915894)","('Employee_Health_And_Safety', 0.14823190867900848)","('Human_Rights_And_Community_Relations', 0.06769639998674393)","('NON-ESG', 0.39593666791915894)","('NON-ESG', 0.14823190867900848)","('NON-ESG', 0.06769639998674393)"
Line 340,"Expanded telehealth  options.
","('Energy_Management', 0.13203465938568115)","('Customer_Welfare', 0.12869808077812195)","('Competitive_Behavior', 0.10471734404563904)","('NON-ESG', 0.13203465938568115)","('NON-ESG', 0.12869808077812195)","('NON-ESG', 0.10471734404563904)"
Line 341,"Expanded 24/7 emotional support .COVID-19: BENEFITS EXPANSION AND UPDATES	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyWORKPLACE STRATEGY:           NOEL FINNERTY “ The dual challenges   of climate change   and a global pandemic   have made designing  safe, sustainable and efficient workplaces even more important  for companies and their employees.”      Noel Finnerty , director, Global Real Estate and   Facilities Prioritizing Employee  Health and Safety Boston Scientific takes a global approach to prioritizing,  delivering and monitoring employee safety at all our offices  and facilities.
","('Physical_Impacts_Of_Climate_Change', 0.9429398775100708)","('Business_Model_Resilience', 0.010799599811434746)","('Critical_Incident_Risk_Management', 0.005965064279735088)","(['Climate Change'], 0.9429398775100708)","('NON-ESG', 0.010799599811434746)","('NON-ESG', 0.005965064279735088)"
Line 342,"Expanded 24/7 emotional support .COVID-19: BENEFITS EXPANSION AND UPDATES	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyWORKPLACE STRATEGY:           NOEL FINNERTY “ The dual challenges   of climate change   and a global pandemic   have made designing  safe, sustainable and efficient workplaces even more important  for companies and their employees.”      Noel Finnerty , director, Global Real Estate and   Facilities Prioritizing Employee  Health and Safety Boston Scientific takes a global approach to prioritizing,  delivering and monitoring employee safety at all our offices  and facilities.
","('Employee_Health_And_Safety', 0.9839833974838257)","('Critical_Incident_Risk_Management', 0.001987988129258156)","('Employee_Engagement_Inclusion_And_Diversity', 0.0019490898121148348)","(['Operational Eco-Efficiency'], 0.9839833974838257)","('NON-ESG', 0.001987988129258156)","('NON-ESG', 0.0019490898121148348)"
Line 343,"We set health and safety goals called Total  Recordable Incident Rate (TRIR) targets for every Boston  Scientific operations site.
","('Employee_Health_And_Safety', 0.965117335319519)","('Critical_Incident_Risk_Management', 0.01315493043512106)","('Product_Quality_And_Safety', 0.002090471563860774)","(['Operational Eco-Efficiency'], 0.965117335319519)","('NON-ESG', 0.01315493043512106)","('NON-ESG', 0.002090471563860774)"
Line 344,"Our global Employee Health and  Safety (EHS) Operations Council reviews their performance  monthly to discuss trends and risks, as well as opportunities  for improvement.
","('Employee_Health_And_Safety', 0.9830596446990967)","('Employee_Engagement_Inclusion_And_Diversity', 0.0018720742082223296)","('Critical_Incident_Risk_Management', 0.0016841680044308305)","(['Operational Eco-Efficiency'], 0.9830596446990967)","('NON-ESG', 0.0018720742082223296)","('NON-ESG', 0.0016841680044308305)"
Line 345,"In accordance with the Boston Scientific Environment,  Health and Safety Policy , we integrate multiple health and  safety metrics in our monitoring systems at the local and  global levels.
","('Employee_Health_And_Safety', 0.9680950045585632)","('Product_Quality_And_Safety', 0.006715064402669668)","('Critical_Incident_Risk_Management', 0.002636284800246358)","(['Operational Eco-Efficiency'], 0.9680950045585632)","('NON-ESG', 0.006715064402669668)","('NON-ESG', 0.002636284800246358)"
Line 346,"The policy is supported by our global EHS  Essentials, which sets 143 specific expectations across 25  health- and safety-related programs.
","('Employee_Health_And_Safety', 0.465437650680542)","('Product_Quality_And_Safety', 0.3932298421859741)","('Product_Design_And_Lifecycle_Management', 0.017871743068099022)","('NON-ESG', 0.465437650680542)","('NON-ESG', 0.3932298421859741)","('NON-ESG', 0.017871743068099022)"
Line 347,"Our Occupational Health Council provided valuable   employee assistance during the pandemic.
","('Employee_Health_And_Safety', 0.96834397315979)","('Critical_Incident_Risk_Management', 0.006649211049079895)","('Access_And_Affordability', 0.002943861996755004)","(['Operational Eco-Efficiency'], 0.96834397315979)","('NON-ESG', 0.006649211049079895)","('NON-ESG', 0.002943861996755004)"
Line 348,"They   established a centralized helpline, staffed by Boston   Scientific physicians and occupational health nurses to   help guide employees with COVID-19-related queries.
","('Employee_Health_And_Safety', 0.9357352256774902)","('Access_And_Affordability', 0.008504513651132584)","('Labor_Practices', 0.006470262538641691)","(['Operational Eco-Efficiency'], 0.9357352256774902)","('NON-ESG', 0.008504513651132584)","('NON-ESG', 0.006470262538641691)"
Line 349,"We also offered voluntary COVID-19 testing to our on-site  employees to help reassure them of the effectiveness   of our protective processes.
","('Employee_Health_And_Safety', 0.21226073801517487)","('Product_Quality_And_Safety', 0.15699724853038788)","('Labor_Practices', 0.12218830734491348)","('NON-ESG', 0.21226073801517487)","('NON-ESG', 0.15699724853038788)","('NON-ESG', 0.12218830734491348)"
Line 350,"We conducted a workplace survey of more than 25,000  employees to ask about their remote work experience  during the pandemic and their preferences moving  forward.
","('Employee_Health_And_Safety', 0.45242294669151306)","('Labor_Practices', 0.1257677525281906)","('Employee_Engagement_Inclusion_And_Diversity', 0.09896595776081085)","('NON-ESG', 0.45242294669151306)","('NON-ESG', 0.1257677525281906)","('NON-ESG', 0.09896595776081085)"
Line 351,"Responses showed that working remotely has  changed many employees’ thinking about their ability   to work effectively from home and has made them   more receptive to different types of office environments.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23203401267528534)","('Employee_Health_And_Safety', 0.21400567889213562)","('Labor_Practices', 0.17903688549995422)","('NON-ESG', 0.23203401267528534)","('NON-ESG', 0.21400567889213562)","('NON-ESG', 0.17903688549995422)"
Line 352,"We incorporated survey insights into a Global Design  Guidelines Update that addresses on-site protocols as   well as work-from-home practices.
","('Product_Design_And_Lifecycle_Management', 0.27388429641723633)","('Product_Quality_And_Safety', 0.1413068324327469)","('Business_Model_Resilience', 0.08628661930561066)","('NON-ESG', 0.27388429641723633)","('NON-ESG', 0.1413068324327469)","('NON-ESG', 0.08628661930561066)"
Line 353,"In 2020, we navigated the ongoing   challenges of the pandemic in the various  countries where our employees live and   work.
","('Employee_Health_And_Safety', 0.2547449767589569)","('Critical_Incident_Risk_Management', 0.15707528591156006)","('Physical_Impacts_Of_Climate_Change', 0.13150973618030548)","('NON-ESG', 0.2547449767589569)","('NON-ESG', 0.15707528591156006)","('NON-ESG', 0.13150973618030548)"
Line 354,"Boston Scientific took immediate action to develop global COVID-19 guidance,   restrictions and workplace protocols , including:    Flexible work arrangements  for employees   who could work from home.
","('Labor_Practices', 0.9250794053077698)","('Employee_Health_And_Safety', 0.02199525199830532)","('Employee_Engagement_Inclusion_And_Diversity', 0.008521182462573051)","(['Labor Practice Indicators'], 0.9250794053077698)","('NON-ESG', 0.02199525199830532)","('NON-ESG', 0.008521182462573051)"
Line 355,"Travel restrictions and protocols .
","('Labor_Practices', 0.13121096789836884)","('Customer_Privacy', 0.12068118155002594)","('Management_Of_Legal_And_Regulatory_Framework', 0.11454199254512787)","('NON-ESG', 0.13121096789836884)","('NON-ESG', 0.12068118155002594)","('NON-ESG', 0.11454199254512787)"
Line 356,"Company and site safety protocols .
","('Employee_Health_And_Safety', 0.6180243492126465)","('Product_Quality_And_Safety', 0.1420922577381134)","('Critical_Incident_Risk_Management', 0.06508127599954605)","(['Operational Eco-Efficiency'], 0.6180243492126465)","('NON-ESG', 0.1420922577381134)","('NON-ESG', 0.06508127599954605)"
Line 357,"Workstation reconfiguration .
","('Product_Design_And_Lifecycle_Management', 0.3038487732410431)","('Energy_Management', 0.14556585252285004)","('Data_Security', 0.09448942542076111)","('NON-ESG', 0.3038487732410431)","('NON-ESG', 0.14556585252285004)","('NON-ESG', 0.09448942542076111)"
Line 358,"Limited sales visits  to critical cases.
","('Supply_Chain_Management', 0.12872697412967682)","('Customer_Welfare', 0.11981071531772614)","('Selling_Practices_And_Product_Labeling', 0.08278480917215347)","('NON-ESG', 0.12872697412967682)","('NON-ESG', 0.11981071531772614)","('NON-ESG', 0.08278480917215347)"
Line 359,"Accelerated capabilities to provide remote   physician support .
","('Access_And_Affordability', 0.18935717642307281)","('Critical_Incident_Risk_Management', 0.18592078983783722)","('Energy_Management', 0.14548833668231964)","('NON-ESG', 0.18935717642307281)","('NON-ESG', 0.18592078983783722)","('NON-ESG', 0.14548833668231964)"
Line 360,"Advanced cleaning protocols .
","('Product_Design_And_Lifecycle_Management', 0.2566412091255188)","('Waste_And_Hazardous_Materials_Management', 0.15033432841300964)","('Water_And_Wastewater_Management', 0.09231594204902649)","('NON-ESG', 0.2566412091255188)","('NON-ESG', 0.15033432841300964)","('NON-ESG', 0.09231594204902649)"
Line 361,"COVID-19 employee resources  website.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7826854586601257)","('Employee_Health_And_Safety', 0.07277652621269226)","('Labor_Practices', 0.031234443187713623)","(['Human Capital Development'], 0.7826854586601257)","('NON-ESG', 0.07277652621269226)","('NON-ESG', 0.031234443187713623)"
Line 362,"Office space modifications  and new building   procedures .
","('Ecological_Impacts', 0.22318598628044128)","('Management_Of_Legal_And_Regulatory_Framework', 0.11427470296621323)","('Business_Model_Resilience', 0.07846056669950485)","('NON-ESG', 0.22318598628044128)","('NON-ESG', 0.11427470296621323)","('NON-ESG', 0.07846056669950485)"
Line 363,"COVID-19 testing and personal protective   equipment (PPE)  for employees.
","('Employee_Health_And_Safety', 0.9432333707809448)","('Product_Design_And_Lifecycle_Management', 0.006712597329169512)","('Critical_Incident_Risk_Management', 0.006304518785327673)","(['Operational Eco-Efficiency'], 0.9432333707809448)","('NON-ESG', 0.006712597329169512)","('NON-ESG', 0.006304518785327673)"
Line 364,"COVID-19 contact tracing .
","('Customer_Privacy', 0.7228379845619202)","('Data_Security', 0.06397835910320282)","('Business_Ethics', 0.03819890692830086)","(['Privacy Protection'], 0.7228379845619202)","('NON-ESG', 0.06397835910320282)","('NON-ESG', 0.03819890692830086)"
Line 365,"Augmented platforms for remote practitioner   case support .
","('Management_Of_Legal_And_Regulatory_Framework', 0.6326557397842407)","('Competitive_Behavior', 0.1331014186143875)","('Business_Ethics', 0.04274975508451462)","(['Corporate Governance'], 0.6326557397842407)","('NON-ESG', 0.1331014186143875)","('NON-ESG', 0.04274975508451462)"
Line 366,"TOTAL RECORDABLE INCIDENT RATE (TRIR)  2020:  0.47 TRIR   (0.47 injuries per   100 employees)2030 Goal:  0.25 TRIR (0.25 injuries per 100  employees) 4,655 employee calls  to our physicians and nurses in 2020  5,482 COVID-19 tests  for on-site employees in 2020  	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Advancing possibilitiesPURPOSE Combating inequitiesHUMANITY Improving outcomesSCIENCE Advancing   Possibilities Our commitment to transforming lives  inspires us to address inequities in the  world around us.
","('Employee_Health_And_Safety', 0.9806235432624817)","('Critical_Incident_Risk_Management', 0.004263635259121656)","('Employee_Engagement_Inclusion_And_Diversity', 0.0016871900297701359)","(['Operational Eco-Efficiency'], 0.9806235432624817)","('NON-ESG', 0.004263635259121656)","('NON-ESG', 0.0016871900297701359)"
Line 367,"TOTAL RECORDABLE INCIDENT RATE (TRIR)  2020:  0.47 TRIR   (0.47 injuries per   100 employees)2030 Goal:  0.25 TRIR (0.25 injuries per 100  employees) 4,655 employee calls  to our physicians and nurses in 2020  5,482 COVID-19 tests  for on-site employees in 2020  	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Advancing possibilitiesPURPOSE Combating inequitiesHUMANITY Improving outcomesSCIENCE Advancing   Possibilities Our commitment to transforming lives  inspires us to address inequities in the  world around us.
","('Systemic_Risk_Management', 0.788340151309967)","('Business_Model_Resilience', 0.064309261739254)","('Supply_Chain_Management', 0.027183575555682182)","(['Risk & Crisis Management'], 0.788340151309967)","('NON-ESG', 0.064309261739254)","('NON-ESG', 0.027183575555682182)"
Line 368,"Boston Scientific collaborates with local communities,  nonprofit organizations and providers to understand  and address disparities within underrepresented   populations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5720822811126709)","('Human_Rights_And_Community_Relations', 0.20087900757789612)","('Competitive_Behavior', 0.03666456416249275)","(['Human Capital Development'], 0.5720822811126709)","('NON-ESG', 0.20087900757789612)","('NON-ESG', 0.03666456416249275)"
Line 369,"Whether we are improving treatment  disparities for Black, Hispanic and Latinx people,   providing students access to STEM opportunities,   or empowering employees to take action in their  communities, we are advancing possibilities for   societal good.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9461022615432739)","('Access_And_Affordability', 0.00886305421590805)","('Human_Rights_And_Community_Relations', 0.007499106228351593)","(['Human Capital Development'], 0.9461022615432739)","('NON-ESG', 0.00886305421590805)","('NON-ESG', 0.007499106228351593)"
Line 370,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Confronting Health   Inequities For more than 15 years, Boston Scientific has worked   to eliminate health care inequities in underserved   communities through our industry-leading program   Close the Gap .
","('Access_And_Affordability', 0.9439346790313721)","('Human_Rights_And_Community_Relations', 0.00540952431038022)","('Product_Quality_And_Safety', 0.004908144474029541)","(['Health Outcome Contribution'], 0.9439346790313721)","('NON-ESG', 0.00540952431038022)","('NON-ESG', 0.004908144474029541)"
Line 371,"More recently, and as the pandemic   exposed the severity of treatment disparities and   systemic barriers to care, we stepped up our efforts  to   help providers identify and serve diverse populations.
","('Systemic_Risk_Management', 0.6057862639427185)","('Access_And_Affordability', 0.07393234223127365)","('Employee_Engagement_Inclusion_And_Diversity', 0.046891648322343826)","(['Risk & Crisis Management'], 0.6057862639427185)","('NON-ESG', 0.07393234223127365)","('NON-ESG', 0.046891648322343826)"
Line 372,"Through Close the Gap, Boston Scientific launched a   public awareness campaign focused on health inequities  related to heart and vascular disease outcomes in the U.S. The campaign augments the work we’re doing with local  health care providers and major health systems.
","('Employee_Health_And_Safety', 0.42900794744491577)","('Access_And_Affordability', 0.209560364484787)","('Critical_Incident_Risk_Management', 0.05592462792992592)","('NON-ESG', 0.42900794744491577)","('NON-ESG', 0.209560364484787)","('NON-ESG', 0.05592462792992592)"
Line 373,"This  includes sharing community-specific disparity data and  patient education materials to help address the treatment  gaps  among patients who identify as women and people  of color.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9097686409950256)","('Access_And_Affordability', 0.022277362644672394)","('Human_Rights_And_Community_Relations', 0.00846940465271473)","(['Human Capital Development'], 0.9097686409950256)","('NON-ESG', 0.022277362644672394)","('NON-ESG', 0.00846940465271473)"
Line 374,"SUSTAINABLE DEVELOPMENT GOALS:  HEALTH EQUITY CHAMPION:           PAIGE BINGHAM   In 2020, Paige Bingham became the national program  director of Close the Gap.
","('Access_And_Affordability', 0.18856936693191528)","('Business_Model_Resilience', 0.14748108386993408)","('Human_Rights_And_Community_Relations', 0.13828425109386444)","('NON-ESG', 0.18856936693191528)","('NON-ESG', 0.14748108386993408)","('NON-ESG', 0.13828425109386444)"
Line 375,"A longtime health equity   champion, Paige offers insights on the team’s work to  address treatment disparities and increase diversity in  clinical trials .
","('Employee_Engagement_Inclusion_And_Diversity', 0.9692771434783936)","('Employee_Health_And_Safety', 0.0022261503618210554)","('Customer_Welfare', 0.002009822055697441)","(['Human Capital Development'], 0.9692771434783936)","('NON-ESG', 0.0022261503618210554)","('NON-ESG', 0.002009822055697441)"
Line 376,"“ The Boston Scientific Close the Gap   program empowers physicians with data  and epidemiological insights to identify  local treatment gaps and customizable   resources to reach vulnerable populations.
","('Access_And_Affordability', 0.48469966650009155)","('Human_Rights_And_Community_Relations', 0.20249216258525848)","('Employee_Engagement_Inclusion_And_Diversity', 0.06491957604885101)","('NON-ESG', 0.48469966650009155)","('NON-ESG', 0.20249216258525848)","('NON-ESG', 0.06491957604885101)"
Line 377,"This approach helps to inform and activate  measurable change to save lives.”      Paige Bingham , national program director, Close   the Gap  In 2020, Boston Scientific launched a public awareness campaign focused on health inequity awareness.
","('Employee_Health_And_Safety', 0.41381099820137024)","('Access_And_Affordability', 0.1807059496641159)","('Critical_Incident_Risk_Management', 0.15113376080989838)","('NON-ESG', 0.41381099820137024)","('NON-ESG', 0.1807059496641159)","('NON-ESG', 0.15113376080989838)"
Line 378,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Addressing the Gaps: COVID-19 Heart Study The most vulnerable populations are at the greatest risk  for conditions such as heart disease, but they are the least  studied in large-scale clinical trials.
","('Access_And_Affordability', 0.5080704092979431)","('Employee_Health_And_Safety', 0.11910513043403625)","('Human_Rights_And_Community_Relations', 0.05755218118429184)","(['Health Outcome Contribution'], 0.5080704092979431)","('NON-ESG', 0.11910513043403625)","('NON-ESG', 0.05755218118429184)"
Line 379,"According to census  data, Black Americans represent 13.4 percent of the U.S.  population, yet peer-reviewed research shows they make  up only 5 to 7 percent of clinical trial participants.1 In 2020,  we began work with Yale/Yale-New Haven Hospital   Center for Outcomes Research and Evaluation (Yale-CORE)  to increase the diversity of representation in the Boston  Scientific COVID-19 Heart Study , developed to better   understand how COVID-19 affects people with heart   conditions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9640361666679382)","('Employee_Health_And_Safety', 0.0035754020791500807)","('Labor_Practices', 0.002220387337729335)","(['Human Capital Development'], 0.9640361666679382)","('NON-ESG', 0.0035754020791500807)","('NON-ESG', 0.002220387337729335)"
Line 380,"1  Clark	LT,	Watkins	L, 	Piña	IL,	et	al.
","('Management_Of_Legal_And_Regulatory_Framework', 0.38596346974372864)","('Competitive_Behavior', 0.13661789894104004)","('GHG_Emissions', 0.06736665219068527)","('NON-ESG', 0.38596346974372864)","('NON-ESG', 0.13661789894104004)","('NON-ESG', 0.06736665219068527)"
Line 381,"Increasing	diversity	in	clinical	trials: 	Overcoming	critical	barriers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9181404709815979)","('Competitive_Behavior', 0.007176058366894722)","('Customer_Welfare', 0.006106581073254347)","(['Human Capital Development'], 0.9181404709815979)","('NON-ESG', 0.007176058366894722)","('NON-ESG', 0.006106581073254347)"
Line 382,"Curr Probl Cardiol .
","('Customer_Welfare', 0.32399335503578186)","('Selling_Practices_And_Product_Labeling', 0.10551024228334427)","('Access_And_Affordability', 0.0909915491938591)","('NON-ESG', 0.32399335503578186)","('NON-ESG', 0.10551024228334427)","('NON-ESG', 0.0909915491938591)"
Line 383,"2019	May;44(5):148-72.
","('Management_Of_Legal_And_Regulatory_Framework', 0.34254980087280273)","('Business_Model_Resilience', 0.09043025970458984)","('Competitive_Behavior', 0.0767550989985466)","('NON-ESG', 0.34254980087280273)","('NON-ESG', 0.09043025970458984)","('NON-ESG', 0.0767550989985466)"
Line 384,"Paul Underwood, MD, and medical   director at Boston Scientific, has been  working to reduce health disparities for  women and people of color since 1990.
","('Employee_Engagement_Inclusion_And_Diversity', 0.778814971446991)","('Employee_Health_And_Safety', 0.10097598284482956)","('Access_And_Affordability', 0.020594945177435875)","(['Human Capital Development'], 0.778814971446991)","('NON-ESG', 0.10097598284482956)","('NON-ESG', 0.020594945177435875)"
Line 385,"He made it his mission to fight racism .
","('Employee_Engagement_Inclusion_And_Diversity', 0.7944002151489258)","('Human_Rights_And_Community_Relations', 0.03376607969403267)","('Business_Ethics', 0.02724333666265011)","(['Human Capital Development'], 0.7944002151489258)","('NON-ESG', 0.03376607969403267)","('NON-ESG', 0.02724333666265011)"
Line 386,"“ The data show that the most  vulnerable populations have  the greatest risk of heart   disease but are the least   studied in large-scale clinical   trials.
","('Access_And_Affordability', 0.39220336079597473)","('Employee_Health_And_Safety', 0.2129136025905609)","('Critical_Incident_Risk_Management', 0.07697855681180954)","('NON-ESG', 0.39220336079597473)","('NON-ESG', 0.2129136025905609)","('NON-ESG', 0.07697855681180954)"
Line 387,"The opportunities   to make an impact are   fantastic when we use   objective data to guide the  way.
","('Business_Model_Resilience', 0.530734121799469)","('Access_And_Affordability', 0.07308843731880188)","('Human_Rights_And_Community_Relations', 0.05681830272078514)","(['Codes of Business Conduct'], 0.530734121799469)","('NON-ESG', 0.07308843731880188)","('NON-ESG', 0.05681830272078514)"
Line 388,"I am so proud to be   working for a company   taking tangible actions to  battle systemic racism.”           Paul Underwood, MD ,   medical director, Boston ScientificIN THE UNITED STATES: 13.4% of the population   is Black Only 5-7% of clinical trial   participants are BlackA 40-YEAR BATTLE AGAINST RACISM	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Playing Our Part:   Combating Racism  Racism in the United States and around the world   was front and center in 2020 as we witnessed the tragic   death of George Floyd, preceded by those of Breonna  Taylor, Ahmaud Arbery and so many others.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5219830870628357)","('Business_Ethics', 0.22564679384231567)","('Employee_Health_And_Safety', 0.039092276245355606)","(['Human Capital Development'], 0.5219830870628357)","('NON-ESG', 0.22564679384231567)","('NON-ESG', 0.039092276245355606)"
Line 389,"I am so proud to be   working for a company   taking tangible actions to  battle systemic racism.”           Paul Underwood, MD ,   medical director, Boston ScientificIN THE UNITED STATES: 13.4% of the population   is Black Only 5-7% of clinical trial   participants are BlackA 40-YEAR BATTLE AGAINST RACISM	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Playing Our Part:   Combating Racism  Racism in the United States and around the world   was front and center in 2020 as we witnessed the tragic   death of George Floyd, preceded by those of Breonna  Taylor, Ahmaud Arbery and so many others.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5800719857215881)","('Business_Ethics', 0.1480139195919037)","('Human_Rights_And_Community_Relations', 0.03950239717960358)","(['Human Capital Development'], 0.5800719857215881)","('NON-ESG', 0.1480139195919037)","('NON-ESG', 0.03950239717960358)"
Line 390,"The Boston  Scientific Executive Committee issued an open letter    reaffirming the company’s commitment to contribute   to a more equitable and inclusive society where all people  feel safe and valued and have a voice.
","('Human_Rights_And_Community_Relations', 0.558162271976471)","('Employee_Engagement_Inclusion_And_Diversity', 0.1807515025138855)","('Access_And_Affordability', 0.09217766672372818)","(['Community Relations'], 0.558162271976471)","('NON-ESG', 0.1807515025138855)","('NON-ESG', 0.09217766672372818)"
Line 391,"As part of that  pledge, Boston Scientific is donating $3.5 million over a  multiyear period to combat inequity, systemic racism   and injustice in our communities.
","('Business_Ethics', 0.7588034868240356)","('Human_Rights_And_Community_Relations', 0.07463962584733963)","('Employee_Engagement_Inclusion_And_Diversity', 0.03030494973063469)","(['Business Ethics'], 0.7588034868240356)","('NON-ESG', 0.07463962584733963)","('NON-ESG', 0.03030494973063469)"
Line 392,"We are also accelerating  our internal diversity, equity and inclusion programs,   which include initiatives that address discrimination   and racism.$3.5 million to combat  racism and advance social justiceCOMBATING RACISM STRATEGY Community Expand the conversation on   anti-racism and support social   justice organizations Economic Empowerment   Accelerate the development of   Black-owned businesses Education   Educate and create professional   opportunities for Black youth Health Care Disparities   Address health care disparities in   the community Government/Policies Advocate for change	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblySupporting   Our Communities The work we do is about caring for human life, and   it draws us into the communities where we live and   work.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9657856225967407)","('Employee_Health_And_Safety', 0.0036881736014038324)","('Human_Rights_And_Community_Relations', 0.0029588034376502037)","(['Human Capital Development'], 0.9657856225967407)","('NON-ESG', 0.0036881736014038324)","('NON-ESG', 0.0029588034376502037)"
Line 393,"We are also accelerating  our internal diversity, equity and inclusion programs,   which include initiatives that address discrimination   and racism.$3.5 million to combat  racism and advance social justiceCOMBATING RACISM STRATEGY Community Expand the conversation on   anti-racism and support social   justice organizations Economic Empowerment   Accelerate the development of   Black-owned businesses Education   Educate and create professional   opportunities for Black youth Health Care Disparities   Address health care disparities in   the community Government/Policies Advocate for change	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblySupporting   Our Communities The work we do is about caring for human life, and   it draws us into the communities where we live and   work.
","('Human_Rights_And_Community_Relations', 0.9315484762191772)","('Access_And_Affordability', 0.016188479959964752)","('Ecological_Impacts', 0.004642842803150415)","(['Community Relations'], 0.9315484762191772)","('NON-ESG', 0.016188479959964752)","('NON-ESG', 0.004642842803150415)"
Line 394,"Our employees help us shape the way we care for  the world around us.
","('Human_Rights_And_Community_Relations', 0.3957805037498474)","('Business_Model_Resilience', 0.09272894263267517)","('Employee_Engagement_Inclusion_And_Diversity', 0.07823701202869415)","('NON-ESG', 0.3957805037498474)","('NON-ESG', 0.09272894263267517)","('NON-ESG', 0.07823701202869415)"
Line 395,"In 2020, employee engagement   expanded to 54 countries and philanthropic contributions  focused on the coronavirus pandemic, social justice   and natural disasters.
","('Human_Rights_And_Community_Relations', 0.863572895526886)","('Access_And_Affordability', 0.02560875192284584)","('Management_Of_Legal_And_Regulatory_Framework', 0.01811525970697403)","(['Community Relations'], 0.863572895526886)","('NON-ESG', 0.02560875192284584)","('NON-ESG', 0.01811525970697403)"
Line 396,"Our global community engagement   is focused on three key areas:  BSC CONTRIBUTIONS AND ENGAGEMENT 54 countries Employee community engagement $70 million Contributions for medical research,  fellowships, educational and charitable  giving $1.2 million Boston Scientific Foundation contributions +1,700 nonprofits supported with donations or grant funding       Advancing education    To develop diverse talent who   will create health solutions   for generations to come, we  support science, technology,  engineering and math (STEM)  programming for underserved  5- to 18-year-old students  around the world.
","('Access_And_Affordability', 0.44432517886161804)","('Human_Rights_And_Community_Relations', 0.2560041546821594)","('Employee_Engagement_Inclusion_And_Diversity', 0.0704328864812851)","('NON-ESG', 0.44432517886161804)","('NON-ESG', 0.2560041546821594)","('NON-ESG', 0.0704328864812851)"
Line 397,"Our global community engagement   is focused on three key areas:  BSC CONTRIBUTIONS AND ENGAGEMENT 54 countries Employee community engagement $70 million Contributions for medical research,  fellowships, educational and charitable  giving $1.2 million Boston Scientific Foundation contributions +1,700 nonprofits supported with donations or grant funding       Advancing education    To develop diverse talent who   will create health solutions   for generations to come, we  support science, technology,  engineering and math (STEM)  programming for underserved  5- to 18-year-old students  around the world.
","('Access_And_Affordability', 0.9455545544624329)","('Product_Quality_And_Safety', 0.004823183175176382)","('Human_Rights_And_Community_Relations', 0.00455474155023694)","(['Health Outcome Contribution'], 0.9455545544624329)","('NON-ESG', 0.004823183175176382)","('NON-ESG', 0.00455474155023694)"
Line 398,"Advancing health    To decrease health disparities   in chronic diseases among  underserved communities,   we aim to provide access to  quality care, support disease  prevention and help prepare  children for a healthy journey  into adulthood.
","('Access_And_Affordability', 0.9454942941665649)","('Product_Quality_And_Safety', 0.005386213306337595)","('Critical_Incident_Risk_Management', 0.004925468470901251)","(['Health Outcome Contribution'], 0.9454942941665649)","('NON-ESG', 0.005386213306337595)","('NON-ESG', 0.004925468470901251)"
Line 399,"Advancing community    To improve life in their local   communities, we empower   our employees to donate their  talent and resources through  our strategic matching gifts   and volunteer programs.
","('Human_Rights_And_Community_Relations', 0.6866368055343628)","('Access_And_Affordability', 0.09166612476110458)","('Employee_Engagement_Inclusion_And_Diversity', 0.077999547123909)","(['Community Relations'], 0.6866368055343628)","('NON-ESG', 0.09166612476110458)","('NON-ESG', 0.077999547123909)"
Line 400,"3	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Relief Efforts  When an event occurs that devastates one of our   communities, Boston Scientific works to ensure employee  safety, assess impact and determine how the company   can support relief efforts.
","('Employee_Health_And_Safety', 0.9609790444374084)","('Critical_Incident_Risk_Management', 0.01618443801999092)","('Employee_Engagement_Inclusion_And_Diversity', 0.002164534293115139)","(['Operational Eco-Efficiency'], 0.9609790444374084)","('NON-ESG', 0.01618443801999092)","('NON-ESG', 0.002164534293115139)"
Line 401,"For example, in 2020, the   company coordinated and encouraged employee   donations to help people affected by the wildfires in   Australia and California, Hurricane Laura, the explosion   in Beirut, the coronavirus epidemic as well as victims   of social injustice and racial inequity.
","('Human_Rights_And_Community_Relations', 0.9150311946868896)","('Employee_Engagement_Inclusion_And_Diversity', 0.01633669063448906)","('Access_And_Affordability', 0.008998445235192776)","(['Community Relations'], 0.9150311946868896)","('NON-ESG', 0.01633669063448906)","('NON-ESG', 0.008998445235192776)"
Line 402,"Employees who   chose to donate to these efforts received a matching   financial contribution from Boston Scientific.EMPLOYEE ACTION AFTER BEIRUT BLAST In August 2020, an explosion in Beirut killed more   than 200 people, injured more than 7,500 and left   an estimated 300,000 people homeless.
","('Critical_Incident_Risk_Management', 0.6636968851089478)","('Employee_Health_And_Safety', 0.222110778093338)","('Air_Quality', 0.02451459690928459)","(['Risk & Crisis Management'], 0.6636968851089478)","('NON-ESG', 0.222110778093338)","('NON-ESG', 0.02451459690928459)"
Line 403,"Boston   Scientific Peripheral Interventions Training Manager  Rawad Abou Dihn, who has a nursing background,  quickly rallied colleagues and friends to turn the   entrance of a local building into an emergency wound  clinic.
","('Critical_Incident_Risk_Management', 0.8962858319282532)","('Employee_Health_And_Safety', 0.054681647568941116)","('Access_And_Affordability', 0.009532135911285877)","(['Risk & Crisis Management'], 0.8962858319282532)","('NON-ESG', 0.054681647568941116)","('NON-ESG', 0.009532135911285877)"
Line 404,"The team provided critical aid to an average   of 100 people daily and helped reduce the tremendous  strain on hospitals overwhelmed with critically wounded  people and COVID-19 patients.
","('Critical_Incident_Risk_Management', 0.8376023173332214)","('Employee_Health_And_Safety', 0.061725545674562454)","('Access_And_Affordability', 0.030649278312921524)","(['Risk & Crisis Management'], 0.8376023173332214)","('NON-ESG', 0.061725545674562454)","('NON-ESG', 0.030649278312921524)"
Line 405,"Boston	Scientific	2020	Performance	Report		 4035% annual increase of   employees participating in global  matching gifts program  Tarek El Rahbani led local efforts to support Boston   Scientific employees and operations in Beirut following  the explosion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.39455941319465637)","('Labor_Practices', 0.2292485386133194)","('Director_Removal', 0.051011987030506134)","('NON-ESG', 0.39455941319465637)","('NON-ESG', 0.2292485386133194)","('NON-ESG', 0.051011987030506134)"
Line 406,"“ As a Lebanese Boston Scientific employee,   I am grateful for the support we received  from colleagues around the world and   proud of the quick actions taken by   Rawad and volunteers.
","('Human_Rights_And_Community_Relations', 0.3436214029788971)","('Employee_Health_And_Safety', 0.1159248799085617)","('Management_Of_Legal_And_Regulatory_Framework', 0.09412974119186401)","('NON-ESG', 0.3436214029788971)","('NON-ESG', 0.1159248799085617)","('NON-ESG', 0.09412974119186401)"
Line 407,"Our commitment   to our caring core value  is evidenced by   how our employees responded with   compassion and integrity.”            Tarek El Rahbani,  managing director, Middle East,  North Africa, Turkey and Central AsiaPERSPECTIVE FROM BEIRUT           TAREK EL RAHBANI	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In Marlborough, Massachusetts , employees made and  donated masks and other items to local nursing homes,  hospitals and homeless shelters.
","('Human_Rights_And_Community_Relations', 0.5771668553352356)","('Employee_Health_And_Safety', 0.08191411197185516)","('Business_Ethics', 0.06232620030641556)","(['Community Relations'], 0.5771668553352356)","('NON-ESG', 0.08191411197185516)","('NON-ESG', 0.06232620030641556)"
Line 408,"Our commitment   to our caring core value  is evidenced by   how our employees responded with   compassion and integrity.”            Tarek El Rahbani,  managing director, Middle East,  North Africa, Turkey and Central AsiaPERSPECTIVE FROM BEIRUT           TAREK EL RAHBANI	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In Marlborough, Massachusetts , employees made and  donated masks and other items to local nursing homes,  hospitals and homeless shelters.
","('Access_And_Affordability', 0.42393144965171814)","('Employee_Health_And_Safety', 0.2828814387321472)","('Human_Rights_And_Community_Relations', 0.04187596216797829)","('NON-ESG', 0.42393144965171814)","('NON-ESG', 0.2828814387321472)","('NON-ESG', 0.04187596216797829)"
Line 409,"In Galway, Ireland , employees lifted spirits by donating  critical supplies, including gloves, masks, coveralls and  boxes of chocolate Easter eggs, to local nursing homes.In Singapore , employees packed and donated more  than 350 kits filled with essential items such as hand   sanitizer, face shields and healthy snacks to local   nursing home residents and health care workers.+ + =$18 million+   Global relief efforts$1 million+    Charitable donations$13 million +  Face shields,   other innovations$4 million+    Personal Protective   Equipment (PPE)   PITCHING IN WITH PPE GLOBALLYCOVID-19 RELIEF BY THE NUMBERS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In an urgent 2020 undertaking called Project Shield ,  Boston Scientific employees assembled and donated one  million face shields in just over one month.
","('Employee_Health_And_Safety', 0.32389354705810547)","('Access_And_Affordability', 0.17744141817092896)","('Product_Quality_And_Safety', 0.16158998012542725)","('NON-ESG', 0.32389354705810547)","('NON-ESG', 0.17744141817092896)","('NON-ESG', 0.16158998012542725)"
Line 410,"In Galway, Ireland , employees lifted spirits by donating  critical supplies, including gloves, masks, coveralls and  boxes of chocolate Easter eggs, to local nursing homes.In Singapore , employees packed and donated more  than 350 kits filled with essential items such as hand   sanitizer, face shields and healthy snacks to local   nursing home residents and health care workers.+ + =$18 million+   Global relief efforts$1 million+    Charitable donations$13 million +  Face shields,   other innovations$4 million+    Personal Protective   Equipment (PPE)   PITCHING IN WITH PPE GLOBALLYCOVID-19 RELIEF BY THE NUMBERS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In an urgent 2020 undertaking called Project Shield ,  Boston Scientific employees assembled and donated one  million face shields in just over one month.
","('Employee_Health_And_Safety', 0.9127459526062012)","('Critical_Incident_Risk_Management', 0.02241417020559311)","('Product_Design_And_Lifecycle_Management', 0.008044314570724964)","(['Operational Eco-Efficiency'], 0.9127459526062012)","('NON-ESG', 0.02241417020559311)","('NON-ESG', 0.008044314570724964)"
Line 411,"In Galway, Ireland , employees lifted spirits by donating  critical supplies, including gloves, masks, coveralls and  boxes of chocolate Easter eggs, to local nursing homes.In Singapore , employees packed and donated more  than 350 kits filled with essential items such as hand   sanitizer, face shields and healthy snacks to local   nursing home residents and health care workers.+ + =$18 million+   Global relief efforts$1 million+    Charitable donations$13 million +  Face shields,   other innovations$4 million+    Personal Protective   Equipment (PPE)   PITCHING IN WITH PPE GLOBALLYCOVID-19 RELIEF BY THE NUMBERS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly In an urgent 2020 undertaking called Project Shield ,  Boston Scientific employees assembled and donated one  million face shields in just over one month.
","('Labor_Practices', 0.14089778065681458)","('Management_Of_Legal_And_Regulatory_Framework', 0.1065925881266594)","('Access_And_Affordability', 0.0989127978682518)","('NON-ESG', 0.14089778065681458)","('NON-ESG', 0.1065925881266594)","('NON-ESG', 0.0989127978682518)"
Line 412,"Urology Research  and Development (R&D) Project Manager Alissa Brandon  came up with the idea and collaborated with colleagues to  launch the initiative .
","('Ecological_Impacts', 0.28274044394493103)","('Access_And_Affordability', 0.14173132181167603)","('Employee_Engagement_Inclusion_And_Diversity', 0.07491233199834824)","('NON-ESG', 0.28274044394493103)","('NON-ESG', 0.14173132181167603)","('NON-ESG', 0.07491233199834824)"
Line 413,"The effort rapidly expanded to include:    12 Boston Scientific sites.
","('Ecological_Impacts', 0.6772520542144775)","('GHG_Emissions', 0.11223757266998291)","('Access_And_Affordability', 0.023641781881451607)","(['Natural Capital'], 0.6772520542144775)","('NON-ESG', 0.11223757266998291)","('NON-ESG', 0.023641781881451607)"
Line 414,"More than 400 employees around the world contributing  their time and expertise.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4389312267303467)","('Employee_Health_And_Safety', 0.08822651207447052)","('Product_Design_And_Lifecycle_Management', 0.05496478080749512)","('NON-ESG', 0.4389312267303467)","('NON-ESG', 0.08822651207447052)","('NON-ESG', 0.05496478080749512)"
Line 415,"They also collaborated with the grassroots organization  GetUsPPE , to deliver the PPE to health care facilities in   more than 40 U.S. states and territories.
","('Access_And_Affordability', 0.7524316906929016)","('Critical_Incident_Risk_Management', 0.02544434927403927)","('Employee_Health_And_Safety', 0.023196039721369743)","(['Health Outcome Contribution'], 0.7524316906929016)","('NON-ESG', 0.02544434927403927)","('NON-ESG', 0.023196039721369743)"
Line 416,"“   This shows what can be  accomplished when a team  with a lot of heart and  know-how comes together  to collaborate.
","('Business_Model_Resilience', 0.25837481021881104)","('Employee_Engagement_Inclusion_And_Diversity', 0.1448138803243637)","('Product_Design_And_Lifecycle_Management', 0.07935040444135666)","('NON-ESG', 0.25837481021881104)","('NON-ESG', 0.1448138803243637)","('NON-ESG', 0.07935040444135666)"
Line 417,"So many  people stepped up to contribute and help scale this project to  where it is today.
","('Human_Rights_And_Community_Relations', 0.4482018053531647)","('Access_And_Affordability', 0.07461776584386826)","('Business_Model_Resilience', 0.060848601162433624)","('NON-ESG', 0.4482018053531647)","('NON-ESG', 0.07461776584386826)","('NON-ESG', 0.060848601162433624)"
Line 418,"I am grateful for our caring  team who demonstrated heroic hustle.”          Alissa Brandon , R&D manager, Urology COMMUNITY ENGAGEMENT SPOTLIGHT:           PROTECTING OUR HEALTH CARE HEROES	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Global Signature Health Grant Program The World Health Organization is estimating a shortage  of 19 million health care workers in low- and lower-middle  income countries by 2030.
","('Access_And_Affordability', 0.5021823048591614)","('Human_Rights_And_Community_Relations', 0.1728600561618805)","('Employee_Engagement_Inclusion_And_Diversity', 0.041655585169792175)","(['Health Outcome Contribution'], 0.5021823048591614)","('NON-ESG', 0.1728600561618805)","('NON-ESG', 0.041655585169792175)"
Line 419,"I am grateful for our caring  team who demonstrated heroic hustle.”          Alissa Brandon , R&D manager, Urology COMMUNITY ENGAGEMENT SPOTLIGHT:           PROTECTING OUR HEALTH CARE HEROES	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Global Signature Health Grant Program The World Health Organization is estimating a shortage  of 19 million health care workers in low- and lower-middle  income countries by 2030.
","('Labor_Practices', 0.45513105392456055)","('Employee_Health_And_Safety', 0.19287019968032837)","('Access_And_Affordability', 0.074371337890625)","('NON-ESG', 0.45513105392456055)","('NON-ESG', 0.19287019968032837)","('NON-ESG', 0.074371337890625)"
Line 420,"Recognizing this crisis early   on, Boston Scientific launched a Global Signature Health  Grant Program in 2016.
","('Systemic_Risk_Management', 0.1878480315208435)","('Management_Of_Legal_And_Regulatory_Framework', 0.12432337552309036)","('Physical_Impacts_Of_Climate_Change', 0.09473264962434769)","('NON-ESG', 0.1878480315208435)","('NON-ESG', 0.12432337552309036)","('NON-ESG', 0.09473264962434769)"
Line 421,"Since then, we have partnered   with nonprofit organizations that are working globally   to increase the number of trained health care workers   and improve the quality and availability of chronic   disease screenings.
","('Employee_Health_And_Safety', 0.8889455795288086)","('Access_And_Affordability', 0.02481328882277012)","('Product_Quality_And_Safety', 0.012187447398900986)","(['Operational Eco-Efficiency'], 0.8889455795288086)","('NON-ESG', 0.02481328882277012)","('NON-ESG', 0.012187447398900986)"
Line 422,"The World Health Organization   is estimating a shortage   of 19 million  health care  workers in low- and lower-middle  income countries by MEXICO: Boston Scientific  supported Partners in Health  between 2017 and 2019 and   trained newly graduated   Mexican physicians in the   diagnosis and treatment of   chronic disease.COLOMBIA: New in 2020, we  support Project HOPE in its  work with the Ministry of  Health and local universities  to deliver chronic disease  training for providers caring  for millions of Venezuelan  refugees.SOUTH AFRICA: Our grant to  Project HOPE funded work   that trained health care   workers and created screening   protocols for diabetes and   hypertension from 2016 to  2018.
","('Employee_Health_And_Safety', 0.9166631102561951)","('Access_And_Affordability', 0.010428712703287601)","('Employee_Engagement_Inclusion_And_Diversity', 0.008417446166276932)","(['Operational Eco-Efficiency'], 0.9166631102561951)","('NON-ESG', 0.010428712703287601)","('NON-ESG', 0.008417446166276932)"
Line 423,"The World Health Organization   is estimating a shortage   of 19 million  health care  workers in low- and lower-middle  income countries by MEXICO: Boston Scientific  supported Partners in Health  between 2017 and 2019 and   trained newly graduated   Mexican physicians in the   diagnosis and treatment of   chronic disease.COLOMBIA: New in 2020, we  support Project HOPE in its  work with the Ministry of  Health and local universities  to deliver chronic disease  training for providers caring  for millions of Venezuelan  refugees.SOUTH AFRICA: Our grant to  Project HOPE funded work   that trained health care   workers and created screening   protocols for diabetes and   hypertension from 2016 to  2018.
","('Access_And_Affordability', 0.4059824049472809)","('Employee_Health_And_Safety', 0.17115981876850128)","('Product_Quality_And_Safety', 0.07865601032972336)","('NON-ESG', 0.4059824049472809)","('NON-ESG', 0.17115981876850128)","('NON-ESG', 0.07865601032972336)"
Line 424,"INDIA: Beginning in 2016, we  collaboratively developed  training tools with Project HOPE  that support the diagnosis and  treatment of chronic disease.
","('Employee_Health_And_Safety', 0.7606505751609802)","('Product_Quality_And_Safety', 0.04223185405135155)","('Access_And_Affordability', 0.029702531173825264)","(['Operational Eco-Efficiency'], 0.7606505751609802)","('NON-ESG', 0.04223185405135155)","('NON-ESG', 0.029702531173825264)"
Line 425,"New in 2020, our grant to  Population Services International  funds the creation of digital  tools that better identify and  follow patients living with   chronic disease.MALAYSIA: Since 2018, we have  supported Children’s HeartLink to  help create a regional center of  excellence for the diagnosis and   treatment of congenital heart  disease in children.GLOBAL SIGNATURE HEALTH GRANT COLLABORATIONS SINCE 2016 “ We are incredibly thankful for Boston  Scientific’s commitment to improving the  world’s health and for a partnership that   is helping people around the world access  the care they need.”           Rabih Torbay , president and CEO, Project HOPE Project HOPE Project HOPEProject HOPE, Population Services InternationalPartners in Health Children’s HeartLink	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyProject HOPE Aid in Colombia When Colombia declared COVID-19 a health emergency,  Project HOPE  redirected its efforts, and a portion of grant  funding, to work with the Ministry of Health, Departmental  Health Institute and local hospitals to train health care   workers and non-medical staff, conduct COVID-19 screenings  and distribute PPE.
","('Employee_Health_And_Safety', 0.43225935101509094)","('Access_And_Affordability', 0.11923699080944061)","('Product_Quality_And_Safety', 0.08273136615753174)","('NON-ESG', 0.43225935101509094)","('NON-ESG', 0.11923699080944061)","('NON-ESG', 0.08273136615753174)"
Line 426,"New in 2020, our grant to  Population Services International  funds the creation of digital  tools that better identify and  follow patients living with   chronic disease.MALAYSIA: Since 2018, we have  supported Children’s HeartLink to  help create a regional center of  excellence for the diagnosis and   treatment of congenital heart  disease in children.GLOBAL SIGNATURE HEALTH GRANT COLLABORATIONS SINCE 2016 “ We are incredibly thankful for Boston  Scientific’s commitment to improving the  world’s health and for a partnership that   is helping people around the world access  the care they need.”           Rabih Torbay , president and CEO, Project HOPE Project HOPE Project HOPEProject HOPE, Population Services InternationalPartners in Health Children’s HeartLink	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyProject HOPE Aid in Colombia When Colombia declared COVID-19 a health emergency,  Project HOPE  redirected its efforts, and a portion of grant  funding, to work with the Ministry of Health, Departmental  Health Institute and local hospitals to train health care   workers and non-medical staff, conduct COVID-19 screenings  and distribute PPE.
","('Access_And_Affordability', 0.834192156791687)","('Human_Rights_And_Community_Relations', 0.02101205661892891)","('Employee_Health_And_Safety', 0.015649477019906044)","(['Health Outcome Contribution'], 0.834192156791687)","('NON-ESG', 0.02101205661892891)","('NON-ESG', 0.015649477019906044)"
Line 427,"New in 2020, our grant to  Population Services International  funds the creation of digital  tools that better identify and  follow patients living with   chronic disease.MALAYSIA: Since 2018, we have  supported Children’s HeartLink to  help create a regional center of  excellence for the diagnosis and   treatment of congenital heart  disease in children.GLOBAL SIGNATURE HEALTH GRANT COLLABORATIONS SINCE 2016 “ We are incredibly thankful for Boston  Scientific’s commitment to improving the  world’s health and for a partnership that   is helping people around the world access  the care they need.”           Rabih Torbay , president and CEO, Project HOPE Project HOPE Project HOPEProject HOPE, Population Services InternationalPartners in Health Children’s HeartLink	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyProject HOPE Aid in Colombia When Colombia declared COVID-19 a health emergency,  Project HOPE  redirected its efforts, and a portion of grant  funding, to work with the Ministry of Health, Departmental  Health Institute and local hospitals to train health care   workers and non-medical staff, conduct COVID-19 screenings  and distribute PPE.
","('Critical_Incident_Risk_Management', 0.9627082943916321)","('Employee_Health_And_Safety', 0.008695113472640514)","('Access_And_Affordability', 0.004182248841971159)","(['Risk & Crisis Management'], 0.9627082943916321)","('NON-ESG', 0.008695113472640514)","('NON-ESG', 0.004182248841971159)"
Line 428,"5,616 people  screened for COVID-19.
","('Access_And_Affordability', 0.44504013657569885)","('Employee_Engagement_Inclusion_And_Diversity', 0.25282174348831177)","('Human_Rights_And_Community_Relations', 0.04647308215498924)","('NON-ESG', 0.44504013657569885)","('NON-ESG', 0.25282174348831177)","('NON-ESG', 0.04647308215498924)"
Line 429,"94 health care workers  trained.
","('Employee_Health_And_Safety', 0.908988356590271)","('Critical_Incident_Risk_Management', 0.01722828485071659)","('Labor_Practices', 0.010310112498700619)","(['Operational Eco-Efficiency'], 0.908988356590271)","('NON-ESG', 0.01722828485071659)","('NON-ESG', 0.010310112498700619)"
Line 430,"238 non-medical staff and local volunteers  trained in  hygiene promotion, infection protection and control,   and contact tracing.
","('Employee_Health_And_Safety', 0.8953741192817688)","('Critical_Incident_Risk_Management', 0.019225843250751495)","('Access_And_Affordability', 0.011382926255464554)","(['Operational Eco-Efficiency'], 0.8953741192817688)","('NON-ESG', 0.019225843250751495)","('NON-ESG', 0.011382926255464554)"
Line 431,"7,543 health consultations  provided.
","('Access_And_Affordability', 0.3330424726009369)","('Management_Of_Legal_And_Regulatory_Framework', 0.14164569973945618)","('Critical_Incident_Risk_Management', 0.06307957321405411)","('NON-ESG', 0.3330424726009369)","('NON-ESG', 0.14164569973945618)","('NON-ESG', 0.06307957321405411)"
Line 432,"415+ full sets of PPE  distributed.
","('Management_Of_Legal_And_Regulatory_Framework', 0.1830592006444931)","('Systemic_Risk_Management', 0.1684512197971344)","('Competitive_Behavior', 0.11283561587333679)","('NON-ESG', 0.1830592006444931)","('NON-ESG', 0.1684512197971344)","('NON-ESG', 0.11283561587333679)"
Line 433,"1,500 gloves  provided.
","('Employee_Health_And_Safety', 0.7497376203536987)","('Employee_Engagement_Inclusion_And_Diversity', 0.03834328055381775)","('Waste_And_Hazardous_Materials_Management', 0.028965149074792862)","(['Operational Eco-Efficiency'], 0.7497376203536987)","('NON-ESG', 0.03834328055381775)","('NON-ESG', 0.028965149074792862)"
Line 434,"500+ protective lenses  distributed.
","('Product_Design_And_Lifecycle_Management', 0.2789255976676941)","('Energy_Management', 0.11448796838521957)","('Product_Quality_And_Safety', 0.0729844719171524)","('NON-ESG', 0.2789255976676941)","('NON-ESG', 0.11448796838521957)","('NON-ESG', 0.0729844719171524)"
Line 435,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly STEM Education On-site events and in-person mentoring were put on   hold for much of the year, but Boston Scientific found   innovative ways to continue to bring STEM education   to underrepresented youth.
","('Access_And_Affordability', 0.6060490012168884)","('Employee_Engagement_Inclusion_And_Diversity', 0.14616641402244568)","('Customer_Welfare', 0.02572605013847351)","(['Health Outcome Contribution'], 0.6060490012168884)","('NON-ESG', 0.14616641402244568)","('NON-ESG', 0.02572605013847351)"
Line 436,"Around the world, STEM   volunteers used new technology to expose students to  careers in industries like ours.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8109208345413208)","('Product_Design_And_Lifecycle_Management', 0.02248826064169407)","('Business_Model_Resilience', 0.015135892666876316)","(['Human Capital Development'], 0.8109208345413208)","('NON-ESG', 0.02248826064169407)","('NON-ESG', 0.015135892666876316)"
Line 437,"China: In honor of Children’s Day, our STEM team   created “Know Your Body” videos, including How does   air pollution harm your lungs?
","('Air_Quality', 0.9717830419540405)","('Critical_Incident_Risk_Management', 0.0024705969262868166)","('Energy_Management', 0.002287530805915594)","(['Operational Eco-Efficiency'], 0.9717830419540405)","('NON-ESG', 0.0024705969262868166)","('NON-ESG', 0.002287530805915594)"
Line 438,"and Why lip color turns  darker when your heart does not feel well .
","('Employee_Engagement_Inclusion_And_Diversity', 0.381235808134079)","('Employee_Health_And_Safety', 0.10722426325082779)","('Product_Design_And_Lifecycle_Management', 0.06263359636068344)","('NON-ESG', 0.381235808134079)","('NON-ESG', 0.10722426325082779)","('NON-ESG', 0.06263359636068344)"
Line 439,"Puerto Rico: Employee volunteers gave elementary  school students a virtual tour of our Dorado plant   that featured an interactive pH experiment.
","('Product_Design_And_Lifecycle_Management', 0.3023117780685425)","('Employee_Health_And_Safety', 0.1565099060535431)","('Supply_Chain_Management', 0.12762488424777985)","('NON-ESG', 0.3023117780685425)","('NON-ESG', 0.1565099060535431)","('NON-ESG', 0.12762488424777985)"
Line 440,"High school  students also had the opportunity to interact with   an online panel of STEM experts and watch a video   simulating a product being implanted.
","('Product_Design_And_Lifecycle_Management', 0.6050691604614258)","('Customer_Welfare', 0.13055814802646637)","('Product_Quality_And_Safety', 0.05516864359378815)","(['Product Stewardship'], 0.6050691604614258)","('NON-ESG', 0.13055814802646637)","('NON-ESG', 0.05516864359378815)"
Line 441,"Ireland: To recognize Engineering Day, the team held   a contest in which 8- to 12-year-old students had the  chance to win a “STEM Day in a Box” that featured   content and experiments in chemistry, engineering,   physics and battery technology.
","('Access_And_Affordability', 0.24295490980148315)","('Employee_Engagement_Inclusion_And_Diversity', 0.20526503026485443)","('Product_Design_And_Lifecycle_Management', 0.07172811776399612)","('NON-ESG', 0.24295490980148315)","('NON-ESG', 0.20526503026485443)","('NON-ESG', 0.07172811776399612)"
Line 442,"More than 750   youngsters representing 46 schools in 25 towns   participated in the contest.
","('Employee_Engagement_Inclusion_And_Diversity', 0.38136225938796997)","('Access_And_Affordability', 0.25276851654052734)","('Management_Of_Legal_And_Regulatory_Framework', 0.04570164903998375)","('NON-ESG', 0.38136225938796997)","('NON-ESG', 0.25276851654052734)","('NON-ESG', 0.04570164903998375)"
Line 443,"Our Community Engagement team launched BSC   Buddies, a program that connects employees’   school-aged children online across different   geographies, cultures and languages.
","('Employee_Engagement_Inclusion_And_Diversity', 0.440603643655777)","('Human_Rights_And_Community_Relations', 0.2627604007720947)","('Access_And_Affordability', 0.09617036581039429)","('NON-ESG', 0.440603643655777)","('NON-ESG', 0.2627604007720947)","('NON-ESG', 0.09617036581039429)"
Line 444,"The 2020 pilot  paired 400 children from more than 20 countries.34,000 kits packed that   provided STEM activities, health  and wellness essentials, and other  necessities to populations in need  around the world BSC BUDDIES	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Prioritizing   our planetPURPOSE Making a global   commitmentHUMANITY Reducing our   climate impactsSCIENCEProtecting the   Environment Our commitment to improving patient  health comes with a responsibility to  protect the planet we all share.
","('Access_And_Affordability', 0.604681134223938)","('Employee_Health_And_Safety', 0.10951785743236542)","('Product_Quality_And_Safety', 0.05909270793199539)","(['Health Outcome Contribution'], 0.604681134223938)","('NON-ESG', 0.10951785743236542)","('NON-ESG', 0.05909270793199539)"
Line 445,"The 2020 pilot  paired 400 children from more than 20 countries.34,000 kits packed that   provided STEM activities, health  and wellness essentials, and other  necessities to populations in need  around the world BSC BUDDIES	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Prioritizing   our planetPURPOSE Making a global   commitmentHUMANITY Reducing our   climate impactsSCIENCEProtecting the   Environment Our commitment to improving patient  health comes with a responsibility to  protect the planet we all share.
","('Physical_Impacts_Of_Climate_Change', 0.884316086769104)","('Business_Model_Resilience', 0.028133464977145195)","('GHG_Emissions', 0.018280446529388428)","(['Climate Change'], 0.884316086769104)","('NON-ESG', 0.028133464977145195)","('NON-ESG', 0.018280446529388428)"
Line 446,"As we work to solve health care’s toughest   challenges, we are taking decisive action to   reduce our environmental impacts and achieve   carbon neutrality.
","('Physical_Impacts_Of_Climate_Change', 0.30618351697921753)","('Supply_Chain_Management', 0.09756235778331757)","('Business_Model_Resilience', 0.07825043797492981)","('NON-ESG', 0.30618351697921753)","('NON-ESG', 0.09756235778331757)","('NON-ESG', 0.07825043797492981)"
Line 447,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Responding to   Climate Change  Boston Scientific sets ambitious climate change goals,   and we are on track to meet our commitment to   achieve carbon neutrality  in all manufacturing and   key distribution sites by 2030.
","('Physical_Impacts_Of_Climate_Change', 0.945167601108551)","('Business_Model_Resilience', 0.010807006619870663)","('GHG_Emissions', 0.006743627600371838)","(['Climate Change'], 0.945167601108551)","('NON-ESG', 0.010807006619870663)","('NON-ESG', 0.006743627600371838)"
Line 448,"We became the first   medical device manufacturer to make such a pledge    in 2017.
","('Product_Design_And_Lifecycle_Management', 0.24436338245868683)","('Competitive_Behavior', 0.13906346261501312)","('Customer_Welfare', 0.11438169330358505)","('NON-ESG', 0.24436338245868683)","('NON-ESG', 0.13906346261501312)","('NON-ESG', 0.11438169330358505)"
Line 449,"Since the start of 2017, we have reduced our   carbon footprint by 50 percent.SUSTAINABLE DEVELOPMENT GOALS:   Ronan Coffey has led our Global Energy Management System (GEMS)  since 2018.
","('Energy_Management', 0.44608941674232483)","('GHG_Emissions', 0.1866857260465622)","('Physical_Impacts_Of_Climate_Change', 0.057167015969753265)","('NON-ESG', 0.44608941674232483)","('NON-ESG', 0.1866857260465622)","('NON-ESG', 0.057167015969753265)"
Line 450,"“ Carbon neutrality is the right thing to  do, and our C3 strategy is the right way  to do it.
","('GHG_Emissions', 0.3846106231212616)","('Management_Of_Legal_And_Regulatory_Framework', 0.14523187279701233)","('Competitive_Behavior', 0.11271356791257858)","('NON-ESG', 0.3846106231212616)","('NON-ESG', 0.14523187279701233)","('NON-ESG', 0.11271356791257858)"
Line 451,"Our Global Energy Management System has grown from being a new way to look at   energy consumption to being the actual language we  use to talk about energy management and carbon  emissions.
","('Energy_Management', 0.9802667498588562)","('Management_Of_Legal_And_Regulatory_Framework', 0.002428582636639476)","('Air_Quality', 0.0022415833082050085)","(['Operational Eco-Efficiency'], 0.9802667498588562)","('NON-ESG', 0.002428582636639476)","('NON-ESG', 0.0022415833082050085)"
Line 452,"GEMS is built into how we work.
","('Product_Design_And_Lifecycle_Management', 0.3045858144760132)","('Business_Model_Resilience', 0.14474810659885406)","('Employee_Engagement_Inclusion_And_Diversity', 0.07347463816404343)","('NON-ESG', 0.3045858144760132)","('NON-ESG', 0.14474810659885406)","('NON-ESG', 0.07347463816404343)"
Line 453,"Our teams  are making great progress around the world.”  Ronan Coffey,  global energy manager, Boston Scientific   C3 STRATEGY Cut    energy use emissions.Convert   to renewable energy  sources instead of   relying on fossil fuels.Compensate    with carbon credits and  offset projects for any  remaining unavoidable  emissions.A central component of the company’s carbon neutrality approach is our C3 energy strategy.
","('GHG_Emissions', 0.429726779460907)","('Energy_Management', 0.2553284466266632)","('Management_Of_Legal_And_Regulatory_Framework', 0.10376234352588654)","('NON-ESG', 0.429726779460907)","('NON-ESG', 0.2553284466266632)","('NON-ESG', 0.10376234352588654)"
Line 454,"Global and site teams   collaborate across Boston Scientific to meet its objectives: ACHIEVING CARBON NEUTRALITY:           RONAN COFFEY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 2013123k 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030Greenhouse Gas Emis sions: Tonnes C O₂ Equiv alents                                                                • Renew able thermal                                                    • Electriﬁc ation                                       • Renew able ener gy cr edit pur chases                           • Supplier r enew ables              • On-site solar installations • Power pur chase agr eements Scope 2:  Electricity Scope 1:  Natur al Gas% Renewable Energy2013–2030: RAMP TO CARBON NEUTRALITY Interim Goals: 50% renewable   electricity by 2021100% renewable   electricity by 202490% renewable   energy (all   sources) by 2027Boston Scientific is on track to achieving carbon neutrality   in all manufacturing and key distribution sites by 2020 HONORS In 2020, Boston Scientific was named  to the Dow Jones  Sustainability Index (DJSI) for North America, a well-   respected global benchmark for corporate responsibility.
","('Access_And_Affordability', 0.3215489685535431)","('Management_Of_Legal_And_Regulatory_Framework', 0.11901826411485672)","('GHG_Emissions', 0.10917719453573227)","('NON-ESG', 0.3215489685535431)","('NON-ESG', 0.11901826411485672)","('NON-ESG', 0.10917719453573227)"
Line 455,"Global and site teams   collaborate across Boston Scientific to meet its objectives: ACHIEVING CARBON NEUTRALITY:           RONAN COFFEY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 2013123k 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030Greenhouse Gas Emis sions: Tonnes C O₂ Equiv alents                                                                • Renew able thermal                                                    • Electriﬁc ation                                       • Renew able ener gy cr edit pur chases                           • Supplier r enew ables              • On-site solar installations • Power pur chase agr eements Scope 2:  Electricity Scope 1:  Natur al Gas% Renewable Energy2013–2030: RAMP TO CARBON NEUTRALITY Interim Goals: 50% renewable   electricity by 2021100% renewable   electricity by 202490% renewable   energy (all   sources) by 2027Boston Scientific is on track to achieving carbon neutrality   in all manufacturing and key distribution sites by 2020 HONORS In 2020, Boston Scientific was named  to the Dow Jones  Sustainability Index (DJSI) for North America, a well-   respected global benchmark for corporate responsibility.
","('Energy_Management', 0.9470536112785339)","('Management_Of_Legal_And_Regulatory_Framework', 0.013601929880678654)","('GHG_Emissions', 0.007879290729761124)","(['Operational Eco-Efficiency'], 0.9470536112785339)","('NON-ESG', 0.013601929880678654)","('NON-ESG', 0.007879290729761124)"
Line 456,"Global and site teams   collaborate across Boston Scientific to meet its objectives: ACHIEVING CARBON NEUTRALITY:           RONAN COFFEY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly 2013123k 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030Greenhouse Gas Emis sions: Tonnes C O₂ Equiv alents                                                                • Renew able thermal                                                    • Electriﬁc ation                                       • Renew able ener gy cr edit pur chases                           • Supplier r enew ables              • On-site solar installations • Power pur chase agr eements Scope 2:  Electricity Scope 1:  Natur al Gas% Renewable Energy2013–2030: RAMP TO CARBON NEUTRALITY Interim Goals: 50% renewable   electricity by 2021100% renewable   electricity by 202490% renewable   energy (all   sources) by 2027Boston Scientific is on track to achieving carbon neutrality   in all manufacturing and key distribution sites by 2020 HONORS In 2020, Boston Scientific was named  to the Dow Jones  Sustainability Index (DJSI) for North America, a well-   respected global benchmark for corporate responsibility.
","('Energy_Management', 0.9678617715835571)","('Management_Of_Legal_And_Regulatory_Framework', 0.007090477738529444)","('GHG_Emissions', 0.0022977387998253107)","(['Operational Eco-Efficiency'], 0.9678617715835571)","('NON-ESG', 0.007090477738529444)","('NON-ESG', 0.0022977387998253107)"
Line 457,"The list recognizes companies that deliver outstanding   economic, social and environmental performance.
","('Human_Rights_And_Community_Relations', 0.9021567702293396)","('Business_Model_Resilience', 0.01449546031653881)","('Ecological_Impacts', 0.00760991545394063)","(['Community Relations'], 0.9021567702293396)","('NON-ESG', 0.01449546031653881)","('NON-ESG', 0.00760991545394063)"
Line 458,"Visit our online awards page  to read more about our  environmental honors and distinctions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3515349328517914)","('Business_Ethics', 0.1392362117767334)","('Employee_Engagement_Inclusion_And_Diversity', 0.0674859955906868)","('NON-ESG', 0.3515349328517914)","('NON-ESG', 0.1392362117767334)","('NON-ESG', 0.0674859955906868)"
Line 459,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyGEMS KEY PERFORMANCE INDICATORS  Using the GEMS  approach developed in conjunction with the National University of Ireland, Galway, Boston Scientific is making measurable strides toward carbon neutrality.
","('Access_And_Affordability', 0.2307281494140625)","('Management_Of_Legal_And_Regulatory_Framework', 0.12854041159152985)","('Business_Model_Resilience', 0.11537550389766693)","('NON-ESG', 0.2307281494140625)","('NON-ESG', 0.12854041159152985)","('NON-ESG', 0.11537550389766693)"
Line 460,"We track   progress and report it publicly using five GEMS key performance indicators (KPIs).
","('Systemic_Risk_Management', 0.38802093267440796)","('Business_Model_Resilience', 0.17061030864715576)","('Human_Rights_And_Community_Relations', 0.052433259785175323)","('NON-ESG', 0.38802093267440796)","('NON-ESG', 0.17061030864715576)","('NON-ESG', 0.052433259785175323)"
Line 461,"2015 2016 2017 2018 2019 Carbon Footprint   Total amount of Scope 1 and Scope 2 greenhouse gas emissions 118,327   108,694   94,946   85,127   84,778   53,730   (MT CO2eq)  emitted into the atmosphere from manufacturing and distribution    sites.
","('GHG_Emissions', 0.9666702747344971)","('Ecological_Impacts', 0.004559621214866638)","('Air_Quality', 0.004348329734057188)","(['Climate Change'], 0.9666702747344971)","('NON-ESG', 0.004559621214866638)","('NON-ESG', 0.004348329734057188)"
Line 462,"Measured in tonnes of carbon equivalent.
","('GHG_Emissions', 0.3903656005859375)","('Energy_Management', 0.21882733702659607)","('Management_Of_Legal_And_Regulatory_Framework', 0.09669296443462372)","('NON-ESG', 0.3903656005859375)","('NON-ESG', 0.21882733702659607)","('NON-ESG', 0.09669296443462372)"
Line 463,"Energy Use  Total energy Boston Scientific Total MWh 370k  367k   364k   355k   368k   381k   (MWh)  consumes annually to    manufacture our products.
","('Energy_Management', 0.9715120196342468)","('Product_Design_And_Lifecycle_Management', 0.005274563562124968)","('Management_Of_Legal_And_Regulatory_Framework', 0.0019519480410963297)","(['Operational Eco-Efficiency'], 0.9715120196342468)","('NON-ESG', 0.005274563562124968)","('NON-ESG', 0.0019519480410963297)"
Line 464,"Normalized MWh/ 49   44   40   36   34   38    Million $ Revenue EM3 An energy management maturity model to establish where in 2.7 3.2 3.6 3.7 3.9 4.1   the “energy journey” each manufacturing site resides on a scale     of 0 to 5: (Minimal/Emerging/Developing/Advancing/Leading)        Green Real Estate   Percentage of Boston Scientific real estate that is independently 27% 28% 32% 32%* 41%* 42%   (% of total)  certified for energy efficiency by industry-leading bodies such as    LEED for design and Energy Star or ISO 50001 for building    operations.
","('Energy_Management', 0.979716956615448)","('Air_Quality', 0.0024005493614822626)","('Critical_Incident_Risk_Management', 0.0016489388654008508)","(['Operational Eco-Efficiency'], 0.979716956615448)","('NON-ESG', 0.0024005493614822626)","('NON-ESG', 0.0016489388654008508)"
Line 465,"Normalized MWh/ 49   44   40   36   34   38    Million $ Revenue EM3 An energy management maturity model to establish where in 2.7 3.2 3.6 3.7 3.9 4.1   the “energy journey” each manufacturing site resides on a scale     of 0 to 5: (Minimal/Emerging/Developing/Advancing/Leading)        Green Real Estate   Percentage of Boston Scientific real estate that is independently 27% 28% 32% 32%* 41%* 42%   (% of total)  certified for energy efficiency by industry-leading bodies such as    LEED for design and Energy Star or ISO 50001 for building    operations.
","('Product_Design_And_Lifecycle_Management', 0.17260277271270752)","('Product_Quality_And_Safety', 0.15134944021701813)","('Management_Of_Legal_And_Regulatory_Framework', 0.09193626046180725)","('NON-ESG', 0.17260277271270752)","('NON-ESG', 0.15134944021701813)","('NON-ESG', 0.09193626046180725)"
Line 466,"Renewable Energy   Percentage of total energy  Electricity Percent — — — 5% 11% 71%   (% of total)  consumed, generated from     renewable sources, with BSC    owning the renewable  All Sources Percent — — — 3% 6% 35%     attributes.
","('Energy_Management', 0.9795275330543518)","('Management_Of_Legal_And_Regulatory_Framework', 0.0024428009055554867)","('Product_Design_And_Lifecycle_Management', 0.001552597270347178)","(['Operational Eco-Efficiency'], 0.9795275330543518)","('NON-ESG', 0.0024428009055554867)","('NON-ESG', 0.001552597270347178)"
Line 467,"*	Prior	year	numbers	restated	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly2020 ENVIRONMENTAL ADVANCES Our Environmental   Impact  In 2020, we made significant progress in our C³ energy  strategy to achieve carbon neutrality across our   manufacturing and key distribution sites.
","('Business_Model_Resilience', 0.15287436544895172)","('Human_Rights_And_Community_Relations', 0.14002297818660736)","('Access_And_Affordability', 0.13843093812465668)","('NON-ESG', 0.15287436544895172)","('NON-ESG', 0.14002297818660736)","('NON-ESG', 0.13843093812465668)"
Line 468,"By addressing   the company’s energy consumption, carbon emissions   and environmental designs, we are reducing our   climate impacts.
","('Energy_Management', 0.8083852529525757)","('Physical_Impacts_Of_Climate_Change', 0.05398968979716301)","('GHG_Emissions', 0.030576791614294052)","(['Operational Eco-Efficiency'], 0.8083852529525757)","('NON-ESG', 0.05398968979716301)","('NON-ESG', 0.030576791614294052)"
Line 469,"67% reduction   in greenhouse gas emissions   since 71% of purchased electricity   from renewable  sources  94% of solid waste   diverted  from landfills Working with   sustainability-minded  customers, since 2017 , we increased    the number of patients reached by 20%  while reducing  our carbon footprint  by 50%   BIGGER REACH, SMALLER FOOTPRINT	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyCutting Our Carbon Footprint Tackling energy use is the first tier of our   C3 approach.
","('Waste_And_Hazardous_Materials_Management', 0.8949639201164246)","('GHG_Emissions', 0.02169523388147354)","('Water_And_Wastewater_Management', 0.019020987674593925)","(['Operational Eco-Efficiency'], 0.8949639201164246)","('NON-ESG', 0.02169523388147354)","('NON-ESG', 0.019020987674593925)"
Line 470,"67% reduction   in greenhouse gas emissions   since 71% of purchased electricity   from renewable  sources  94% of solid waste   diverted  from landfills Working with   sustainability-minded  customers, since 2017 , we increased    the number of patients reached by 20%  while reducing  our carbon footprint  by 50%   BIGGER REACH, SMALLER FOOTPRINT	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyCutting Our Carbon Footprint Tackling energy use is the first tier of our   C3 approach.
","('Energy_Management', 0.9526994228363037)","('Management_Of_Legal_And_Regulatory_Framework', 0.006568217650055885)","('Product_Design_And_Lifecycle_Management', 0.004706765990704298)","(['Operational Eco-Efficiency'], 0.9526994228363037)","('NON-ESG', 0.006568217650055885)","('NON-ESG', 0.004706765990704298)"
Line 471,"To improve energy use in our   existing sites and develop new construction  in an environmentally responsible manner, we adhere to  internationally recognized programs such as Leadership   in Energy and Environmental Design (LEED) or the ISO   50001 energy management system.
","('Energy_Management', 0.9779354333877563)","('Product_Design_And_Lifecycle_Management', 0.0023308328818529844)","('Management_Of_Legal_And_Regulatory_Framework', 0.0020401126239448786)","(['Operational Eco-Efficiency'], 0.9779354333877563)","('NON-ESG', 0.0023308328818529844)","('NON-ESG', 0.0020401126239448786)"
Line 472,"In 2020, Boston   Scientific green real estate increased to 42%, up from   27% in 2015, representing more than 3.8 million square   feet of total company real estate.
","('Energy_Management', 0.2411547303199768)","('Product_Design_And_Lifecycle_Management', 0.10988114774227142)","('Business_Model_Resilience', 0.10420618951320648)","('NON-ESG', 0.2411547303199768)","('NON-ESG', 0.10988114774227142)","('NON-ESG', 0.10420618951320648)"
Line 473,"At a minimum, all   newly constructed Boston Scientific buildings are   LEED certified.OUR GREEN REAL ESTATE EXPANDS    Energy Management System ISO 50001:   5 manufacturing sites, 1 distribution center    Leadership in Energy and Environmental   Design (LEED):  15 buildings   42% of Boston Scientific real   estate  is green — representing  3.8+ million square feet New commercial hub in Madrid, Spain .
","('Energy_Management', 0.697360634803772)","('Product_Design_And_Lifecycle_Management', 0.12275223433971405)","('Access_And_Affordability', 0.022547027096152306)","(['Operational Eco-Efficiency'], 0.697360634803772)","('NON-ESG', 0.12275223433971405)","('NON-ESG', 0.022547027096152306)"
Line 474,"Renovated flexible, collaborative workspace in Galway,  Ireland .New administration block in Clonmel, Ireland .
","('Management_Of_Legal_And_Regulatory_Framework', 0.15124429762363434)","('Energy_Management', 0.09482038021087646)","('Business_Model_Resilience', 0.08447933942079544)","('NON-ESG', 0.15124429762363434)","('NON-ESG', 0.09482038021087646)","('NON-ESG', 0.08447933942079544)"
Line 475,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyConverting to Renewable Energy Investing in and converting to renewable   energy sources is the second action area of the C3 strategy.
","('Energy_Management', 0.948987603187561)","('Management_Of_Legal_And_Regulatory_Framework', 0.006679687183350325)","('Product_Design_And_Lifecycle_Management', 0.005957603920251131)","(['Operational Eco-Efficiency'], 0.948987603187561)","('NON-ESG', 0.006679687183350325)","('NON-ESG', 0.005957603920251131)"
Line 476,"We monitor the percentage of the company’s energy generated from renewable sources,  whether the energy is generated on-site or purchased   from outside suppliers.
","('Energy_Management', 0.9793946146965027)","('Management_Of_Legal_And_Regulatory_Framework', 0.0021830208133906126)","('Air_Quality', 0.0017633255338296294)","(['Operational Eco-Efficiency'], 0.9793946146965027)","('NON-ESG', 0.0021830208133906126)","('NON-ESG', 0.0017633255338296294)"
Line 477,"In 2020, we stayed on track to   meet our objective of sourcing or generating 100 percent   of our electricity from renewable sources by 2024.
","('Energy_Management', 0.9535627961158752)","('Management_Of_Legal_And_Regulatory_Framework', 0.007994281128048897)","('Product_Design_And_Lifecycle_Management', 0.004876380320638418)","(['Operational Eco-Efficiency'], 0.9535627961158752)","('NON-ESG', 0.007994281128048897)","('NON-ESG', 0.004876380320638418)"
Line 478,"We   expect that by 2027, 90 percent of all energy at Boston   Scientific facilities, including electricity and natural gas,   will be renewable.
","('Energy_Management', 0.9595941305160522)","('Management_Of_Legal_And_Regulatory_Framework', 0.007349076215177774)","('GHG_Emissions', 0.006905905436724424)","(['Operational Eco-Efficiency'], 0.9595941305160522)","('NON-ESG', 0.007349076215177774)","('NON-ESG', 0.006905905436724424)"
Line 479,"Our Clonmel, Cork and Galway, Ireland facilities and   our Kerkrade, the Netherlands distribution center source   100 percent renewable energy.
","('Energy_Management', 0.9763756990432739)","('Management_Of_Legal_And_Regulatory_Framework', 0.002482332056388259)","('Product_Design_And_Lifecycle_Management', 0.0020372960716485977)","(['Operational Eco-Efficiency'], 0.9763756990432739)","('NON-ESG', 0.002482332056388259)","('NON-ESG', 0.0020372960716485977)"
Line 480,"Using hydroelectric, wind and solar power, our   manufacturing sites in Heredia and Coyol, Costa   Rica have been carbon-neutral since 2016.
","('Energy_Management', 0.8424239158630371)","('GHG_Emissions', 0.03221716731786728)","('Product_Design_And_Lifecycle_Management', 0.021453913301229477)","(['Operational Eco-Efficiency'], 0.8424239158630371)","('NON-ESG', 0.03221716731786728)","('NON-ESG', 0.021453913301229477)"
Line 481,"In our Marlborough and Quincy, Massachusetts locations,   we have on-site solar installations that generated a total   of 3.2 million kilowatt-hours of renewable electricity   in 2020.
","('Energy_Management', 0.9755067825317383)","('Management_Of_Legal_And_Regulatory_Framework', 0.003912577871233225)","('Water_And_Wastewater_Management', 0.0018218964105471969)","(['Operational Eco-Efficiency'], 0.9755067825317383)","('NON-ESG', 0.003912577871233225)","('NON-ESG', 0.0018218964105471969)"
Line 482,"An on-site solar installation at our Dorado,   Puerto Rico facility, slated for completion in mid-2021,   will deliver approximately 17 percent of the site’s   electricity needs.Compensating With Carbon Offsets Carbon offsetting is the final step we consider  taking to reach carbon neutrality.
","('Energy_Management', 0.8187861442565918)","('Management_Of_Legal_And_Regulatory_Framework', 0.07112325727939606)","('GHG_Emissions', 0.02984585240483284)","(['Operational Eco-Efficiency'], 0.8187861442565918)","('NON-ESG', 0.07112325727939606)","('NON-ESG', 0.02984585240483284)"
Line 483,"While our  primary focus is on cutting energy use and converting to clean energy sources, we compensate with  carbon offset projects when we have unavoidable carbon  emissions or cannot yet rely on renewable energy options.
","('Energy_Management', 0.9708482027053833)","('Management_Of_Legal_And_Regulatory_Framework', 0.006900494452565908)","('GHG_Emissions', 0.0026015681214630604)","(['Operational Eco-Efficiency'], 0.9708482027053833)","('NON-ESG', 0.006900494452565908)","('NON-ESG', 0.0026015681214630604)"
Line 484,"Potential projects are carefully assessed to ensure the  results will negate our remaining carbon emissions.
","('GHG_Emissions', 0.8825861215591431)","('Air_Quality', 0.04104078933596611)","('Management_Of_Legal_And_Regulatory_Framework', 0.015395495109260082)","(['Climate Change'], 0.8825861215591431)","('NON-ESG', 0.04104078933596611)","('NON-ESG', 0.015395495109260082)"
Line 485,"For example, Boston Scientific collaborated with the  eco-conscious platform Treedom  in 2020 to plant more  than 5,000 trees in Kenya.
","('Ecological_Impacts', 0.9363477826118469)","('GHG_Emissions', 0.007859575562179089)","('Human_Rights_And_Community_Relations', 0.006676613353192806)","(['Natural Capital'], 0.9363477826118469)","('NON-ESG', 0.007859575562179089)","('NON-ESG', 0.006676613353192806)"
Line 486,"The initiative will benefit local   communities and contribute to cleaner air in the region.
","('Air_Quality', 0.8983162045478821)","('Human_Rights_And_Community_Relations', 0.013170360587537289)","('Energy_Management', 0.010391403920948505)","(['Operational Eco-Efficiency'], 0.8983162045478821)","('NON-ESG', 0.013170360587537289)","('NON-ESG', 0.010391403920948505)"
Line 487,"Climate Risk Management Boston Scientific has begun integrating climate-related  financial disclosures into the way we manage climate-   related risks and opportunities.
","('Physical_Impacts_Of_Climate_Change', 0.9461976289749146)","('Business_Model_Resilience', 0.010983151383697987)","('GHG_Emissions', 0.005762857850641012)","(['Climate Change'], 0.9461976289749146)","('NON-ESG', 0.010983151383697987)","('NON-ESG', 0.005762857850641012)"
Line 488,"In 2021, we will complete   a comprehensive assessment of our business risks   associated with climate change.
","('Physical_Impacts_Of_Climate_Change', 0.9576531648635864)","('Business_Model_Resilience', 0.007854095660150051)","('GHG_Emissions', 0.0038198144175112247)","(['Climate Change'], 0.9576531648635864)","('NON-ESG', 0.007854095660150051)","('NON-ESG', 0.0038198144175112247)"
Line 489,"By 2027 , we expect 90% of all   energy used in Boston Scientific  facilities will be renewable 	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Conserving Water  Water is a critical shared resource, and we are committed   to managing its use responsibly.
","('Water_And_Wastewater_Management', 0.896548867225647)","('Energy_Management', 0.032462943345308304)","('Ecological_Impacts', 0.011363564059138298)","(['Operational Eco-Efficiency'], 0.896548867225647)","('NON-ESG', 0.032462943345308304)","('NON-ESG', 0.011363564059138298)"
Line 490,"While Boston Scientific  operations are not water intensive, we work to minimize  consumption and prepare for water supply challenges.
","('Water_And_Wastewater_Management', 0.9752145409584045)","('GHG_Emissions', 0.0029680831357836723)","('Energy_Management', 0.0024248850531876087)","(['Operational Eco-Efficiency'], 0.9752145409584045)","('NON-ESG', 0.0029680831357836723)","('NON-ESG', 0.0024248850531876087)"
Line 491,"Based on an assessment using the World Resources   Institute Aqueduct risk-mapping tool, we have determined  that 11 company locations are at low overall water-related  risk, and six facilities are in the low-to-medium risk   category.
","('Water_And_Wastewater_Management', 0.970413863658905)","('Waste_And_Hazardous_Materials_Management', 0.0027903588488698006)","('Ecological_Impacts', 0.002633636584505439)","(['Operational Eco-Efficiency'], 0.970413863658905)","('NON-ESG', 0.0027903588488698006)","('NON-ESG', 0.002633636584505439)"
Line 492,"Our efforts to assess water-related risks and  opportunities will expand in 2021 to include the company’s  significant commercial operations.
","('Water_And_Wastewater_Management', 0.9719924926757812)","('GHG_Emissions', 0.002770857186987996)","('Energy_Management', 0.0023025772534310818)","(['Operational Eco-Efficiency'], 0.9719924926757812)","('NON-ESG', 0.002770857186987996)","('NON-ESG', 0.0023025772534310818)"
Line 493,"Water usage at Boston  Scientific manufacturing and major distribution centers   is predominantly associated with employees, which   accounts for 69 percent of our total water consumption.
","('Water_And_Wastewater_Management', 0.9728642702102661)","('Energy_Management', 0.00359010836109519)","('GHG_Emissions', 0.0023662694729864597)","(['Operational Eco-Efficiency'], 0.9728642702102661)","('NON-ESG', 0.00359010836109519)","('NON-ESG', 0.0023662694729864597)"
Line 494,"Waste Management and Recycling  We are working to divert all non-hazardous waste   from landfills and incineration by 2030.
","('Waste_And_Hazardous_Materials_Management', 0.9847294688224792)","('Data_Security', 0.0011454374762251973)","('Water_And_Wastewater_Management', 0.0011124077718704939)","(['Operational Eco-Efficiency'], 0.9847294688224792)","('NON-ESG', 0.0011454374762251973)","('NON-ESG', 0.0011124077718704939)"
Line 495,"Boston Scientific   facilities will participate in the TRUE (Total Resource   Use and Efficiency) certification program to meet this   objective.
","('Energy_Management', 0.7043595314025879)","('Supply_Chain_Management', 0.08305557072162628)","('Product_Design_And_Lifecycle_Management', 0.08194377273321152)","(['Operational Eco-Efficiency'], 0.7043595314025879)","('NON-ESG', 0.08305557072162628)","('NON-ESG', 0.08194377273321152)"
Line 496,"TRUE strives to change the way materials   flow through society so that all products are eventually  reused and diverted from landfills, incineration and the  environment.2020 RECYCLING AND RECOVERY  79%   7 ,922 metric tons  total non-hazardous waste    recycled 52%  509 metric tons  of hazardous and regulated    waste recovered or recycled 	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Results from Cork:   Taking Recycling to the Next Level After achieving a recycling rate of more than 90 percent,  our Cork, Ireland team extended their success by   recovering reusable materials.
","('Waste_And_Hazardous_Materials_Management', 0.9793884754180908)","('Product_Design_And_Lifecycle_Management', 0.0024650143459439278)","('Employee_Health_And_Safety', 0.0015888980124145746)","(['Operational Eco-Efficiency'], 0.9793884754180908)","('NON-ESG', 0.0024650143459439278)","('NON-ESG', 0.0015888980124145746)"
Line 497,"TRUE strives to change the way materials   flow through society so that all products are eventually  reused and diverted from landfills, incineration and the  environment.2020 RECYCLING AND RECOVERY  79%   7 ,922 metric tons  total non-hazardous waste    recycled 52%  509 metric tons  of hazardous and regulated    waste recovered or recycled 	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Results from Cork:   Taking Recycling to the Next Level After achieving a recycling rate of more than 90 percent,  our Cork, Ireland team extended their success by   recovering reusable materials.
","('Product_Design_And_Lifecycle_Management', 0.9327055215835571)","('Energy_Management', 0.00982504803687334)","('Waste_And_Hazardous_Materials_Management', 0.006669837515801191)","(['Product Stewardship'], 0.9327055215835571)","('NON-ESG', 0.00982504803687334)","('NON-ESG', 0.006669837515801191)"
Line 498,"In 2020, they began   setting aside plastic packaging made from Polyethylene  Terephthalate, a material that can be ground into   flakes and reused if properly isolated in the collection   process.This approach also results in less processing   energy than recycling.
","('Product_Design_And_Lifecycle_Management', 0.5252327919006348)","('Waste_And_Hazardous_Materials_Management', 0.31552883982658386)","('Energy_Management', 0.0158857312053442)","(['Product Stewardship'], 0.5252327919006348)","('NON-ESG', 0.31552883982658386)","('NON-ESG', 0.0158857312053442)"
Line 499,"By taking this extra step, the   team diverted 20 metric tons of plastic for recovery.
","('Waste_And_Hazardous_Materials_Management', 0.8855130076408386)","('Product_Design_And_Lifecycle_Management', 0.03207928314805031)","('Employee_Health_And_Safety', 0.010681086219847202)","(['Operational Eco-Efficiency'], 0.8855130076408386)","('NON-ESG', 0.03207928314805031)","('NON-ESG', 0.010681086219847202)"
Line 500,"Our Cork site made significant progress toward waste  avoidance in 2020 — their recycling initiatives resulted  in 20 metric tons of plastic recovered.
","('Waste_And_Hazardous_Materials_Management', 0.9749985933303833)","('Product_Design_And_Lifecycle_Management', 0.0038458791095763445)","('Water_And_Wastewater_Management', 0.0018537341384217143)","(['Operational Eco-Efficiency'], 0.9749985933303833)","('NON-ESG', 0.0038458791095763445)","('NON-ESG', 0.0018537341384217143)"
Line 501,"Success in Cork:   90% recycling rate achieved   20 metric tons    of plastic recovered       “ Focusing on avoidance and reuse is key  to reducing our environmental impact.
","('Product_Design_And_Lifecycle_Management', 0.7726707458496094)","('Waste_And_Hazardous_Materials_Management', 0.10654769837856293)","('Employee_Health_And_Safety', 0.011897952295839787)","(['Product Stewardship'], 0.7726707458496094)","('NON-ESG', 0.10654769837856293)","('NON-ESG', 0.011897952295839787)"
Line 502,"For the future of our planet, we have a  duty to go beyond standard recycling.”          Seamus Gethins , global director, Global Environment,  Health and SafetyGLOBAL WASTE MANAGEMENT PERSPECTIVE:          SEAMUS GETHINS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Boston Scientific is committed to   conducting business with unwavering  ethics, strong corporate governance   and regulatory compliance.
","('Waste_And_Hazardous_Materials_Management', 0.9802175760269165)","('Water_And_Wastewater_Management', 0.001799562480300665)","('Employee_Health_And_Safety', 0.001613992964848876)","(['Operational Eco-Efficiency'], 0.9802175760269165)","('NON-ESG', 0.001799562480300665)","('NON-ESG', 0.001613992964848876)"
Line 503,"For the future of our planet, we have a  duty to go beyond standard recycling.”          Seamus Gethins , global director, Global Environment,  Health and SafetyGLOBAL WASTE MANAGEMENT PERSPECTIVE:          SEAMUS GETHINS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Boston Scientific is committed to   conducting business with unwavering  ethics, strong corporate governance   and regulatory compliance.
","('Business_Ethics', 0.9714304804801941)","('Management_Of_Legal_And_Regulatory_Framework', 0.0046910797245800495)","('Competitive_Behavior', 0.00271585863083601)","(['Business Ethics'], 0.9714304804801941)","('NON-ESG', 0.0046910797245800495)","('NON-ESG', 0.00271585863083601)"
Line 504,"We insist on integrity in all our working relationships  inside and outside the company.
","('Business_Ethics', 0.9398499131202698)","('Competitive_Behavior', 0.008163953199982643)","('Director_Removal', 0.004116780590265989)","(['Business Ethics'], 0.9398499131202698)","('NON-ESG', 0.008163953199982643)","('NON-ESG', 0.004116780590265989)"
Line 505,"Our practices   protect human rights, promote accountability and  ensure that we act responsibly as a global citizen.
","('Human_Rights_And_Community_Relations', 0.9406564831733704)","('Business_Ethics', 0.006225657183676958)","('Access_And_Affordability', 0.005924413446336985)","(['Community Relations'], 0.9406564831733704)","('NON-ESG', 0.006225657183676958)","('NON-ESG', 0.005924413446336985)"
Line 506,"Creating value   responsiblyPURPOSE Respecting   human rightsHUMANITY Innovating   with integritySCIENCE Creating Value    Responsibly  	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   Jessica Pill leads our efforts to ensure compliance with   regulatory requirements while acting with integrity and   living our core values.
","('Human_Rights_And_Community_Relations', 0.6889935731887817)","('Management_Of_Legal_And_Regulatory_Framework', 0.1422780305147171)","('Access_And_Affordability', 0.018071362748742104)","(['Community Relations'], 0.6889935731887817)","('NON-ESG', 0.1422780305147171)","('NON-ESG', 0.018071362748742104)"
Line 507,"Creating value   responsiblyPURPOSE Respecting   human rightsHUMANITY Innovating   with integritySCIENCE Creating Value    Responsibly  	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly   Jessica Pill leads our efforts to ensure compliance with   regulatory requirements while acting with integrity and   living our core values.
","('Human_Rights_And_Community_Relations', 0.3494757413864136)","('Business_Model_Resilience', 0.08620887994766235)","('Employee_Engagement_Inclusion_And_Diversity', 0.08190423250198364)","('NON-ESG', 0.3494757413864136)","('NON-ESG', 0.08620887994766235)","('NON-ESG', 0.08190423250198364)"
Line 508,"“ Despite how we’ve had to change the way   we work this year, we are doing our part to  keep each other safe and live our values   while continuing to serve patients and   navigate challenges together.”      Jessica Pill , chief compliance officer and vice president,  Compliance Compliance, Ethics   and Integrity  Our work contributes value to the lives of patients,   employees and people in communities around the world.
","('Business_Ethics', 0.8254550099372864)","('Human_Rights_And_Community_Relations', 0.0337660051882267)","('Management_Of_Legal_And_Regulatory_Framework', 0.02096317522227764)","(['Business Ethics'], 0.8254550099372864)","('NON-ESG', 0.0337660051882267)","('NON-ESG', 0.02096317522227764)"
Line 509,"Social responsibility is built into how we deliver innovations,  collaborate and operate.
","('Human_Rights_And_Community_Relations', 0.9339022636413574)","('Access_And_Affordability', 0.005667836870998144)","('Business_Model_Resilience', 0.004978617653250694)","(['Community Relations'], 0.9339022636413574)","('NON-ESG', 0.005667836870998144)","('NON-ESG', 0.004978617653250694)"
Line 510,"Our employees have a shared  commitment to:    Act honestly and ethically in all company matters.
","('Business_Ethics', 0.7727638483047485)","('Human_Rights_And_Community_Relations', 0.0465850904583931)","('Labor_Practices', 0.022023813799023628)","(['Business Ethics'], 0.7727638483047485)","('NON-ESG', 0.0465850904583931)","('NON-ESG', 0.022023813799023628)"
Line 511,"Protect the privacy of patients, customers and employees.
","('Customer_Privacy', 0.8828219771385193)","('Data_Security', 0.03838667646050453)","('Waste_And_Hazardous_Materials_Management', 0.005633020773530006)","(['Privacy Protection'], 0.8828219771385193)","('NON-ESG', 0.03838667646050453)","('NON-ESG', 0.005633020773530006)"
Line 512,"Treat one another with respect and fairness.
","('Business_Ethics', 0.7889524102210999)","('Competitive_Behavior', 0.04717573523521423)","('Labor_Practices', 0.02361837960779667)","(['Business Ethics'], 0.7889524102210999)","('NON-ESG', 0.04717573523521423)","('NON-ESG', 0.02361837960779667)"
Line 513,"Hold one another accountable to ensure quality in   everything we do.The Boston Scientific global compliance team provides  employees with the resources and training they need to  do business with integrity, treat customers and suppliers  fairly, and report ethics concerns when they arise.
","('Business_Ethics', 0.9654805660247803)","('Management_Of_Legal_And_Regulatory_Framework', 0.0033487153705209494)","('Product_Quality_And_Safety', 0.003065922763198614)","(['Business Ethics'], 0.9654805660247803)","('NON-ESG', 0.0033487153705209494)","('NON-ESG', 0.003065922763198614)"
Line 514,"Led by  our chief compliance officer, the team collaborates across  the company to monitor our activities and performance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6779276132583618)","('Business_Ethics', 0.07879979908466339)","('Human_Rights_And_Community_Relations', 0.047301094979047775)","(['Corporate Governance'], 0.6779276132583618)","('NON-ESG', 0.07879979908466339)","('NON-ESG', 0.047301094979047775)"
Line 515,"The chief compliance officer reports quarterly to the risk  committee of our board of directors and more frequently   as needed.
","('Director_Removal', 0.6866133809089661)","('Management_Of_Legal_And_Regulatory_Framework', 0.08836454898118973)","('Business_Model_Resilience', 0.02411424182355404)","(['Anti-Crime Policy & Measures'], 0.6866133809089661)","('NON-ESG', 0.08836454898118973)","('NON-ESG', 0.02411424182355404)"
Line 516,"Code of Conduct   Every employee is required to read and understand the  Boston Scientific Code of Conduct , which is the foundation  for all our business practices and relationships.
","('Business_Ethics', 0.8934057354927063)","('Management_Of_Legal_And_Regulatory_Framework', 0.029758216813206673)","('Director_Removal', 0.008731290698051453)","(['Business Ethics'], 0.8934057354927063)","('NON-ESG', 0.029758216813206673)","('NON-ESG', 0.008731290698051453)"
Line 517,"Employees  complete annual training on the Code of Conduct, as   well as multiple mandatory training courses throughout  SUSTAINABLE DEVELOPMENT GOALS: the year that reinforce company policies, explain   corruption- and compliance-related risks and provide  resources for reporting concerns.
","('Business_Ethics', 0.8190178871154785)","('Management_Of_Legal_And_Regulatory_Framework', 0.08534374088048935)","('Systemic_Risk_Management', 0.011667842976748943)","(['Business Ethics'], 0.8190178871154785)","('NON-ESG', 0.08534374088048935)","('NON-ESG', 0.011667842976748943)"
Line 518,"Many of these trainings  offer scenario-based content that help people respond  ethically to issues they may face in their daily work.
","('Human_Rights_And_Community_Relations', 0.5500187277793884)","('Business_Ethics', 0.13777589797973633)","('Access_And_Affordability', 0.04094348102807999)","(['Community Relations'], 0.5500187277793884)","('NON-ESG', 0.13777589797973633)","('NON-ESG', 0.04094348102807999)"
Line 519,"We continually assess opportunities to adapt our Code of   Conduct in light of developments in the global marketplace,  including emerging technologies and business practices.
","('Business_Model_Resilience', 0.41597938537597656)","('Systemic_Risk_Management', 0.22695517539978027)","('Competitive_Behavior', 0.05895916745066643)","('NON-ESG', 0.41597938537597656)","('NON-ESG', 0.22695517539978027)","('NON-ESG', 0.05895916745066643)"
Line 520,"In January 2020, we released an updated Code of Conduct  with greater specificity about privacy rights, new language  about maintaining a safe and healthy work environment,  additional details about data privacy and expanded   guidance on conflicts of interest.GLOBAL COMPLIANCE:           LEADING WITH INTEGRITY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Non-Retaliation Policy The Boston Scientific Non-Retaliation Policy is an essential  component of our compliance program.
","('Data_Security', 0.8688002824783325)","('Customer_Privacy', 0.06479866802692413)","('Business_Ethics', 0.008660921826958656)","(['Information Security/Cybersecurity & System Availability'], 0.8688002824783325)","('NON-ESG', 0.06479866802692413)","('NON-ESG', 0.008660921826958656)"
Line 521,"In January 2020, we released an updated Code of Conduct  with greater specificity about privacy rights, new language  about maintaining a safe and healthy work environment,  additional details about data privacy and expanded   guidance on conflicts of interest.GLOBAL COMPLIANCE:           LEADING WITH INTEGRITY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Non-Retaliation Policy The Boston Scientific Non-Retaliation Policy is an essential  component of our compliance program.
","('Business_Ethics', 0.9277493953704834)","('Management_Of_Legal_And_Regulatory_Framework', 0.017520802095532417)","('Labor_Practices', 0.007158669177442789)","(['Business Ethics'], 0.9277493953704834)","('NON-ESG', 0.017520802095532417)","('NON-ESG', 0.007158669177442789)"
Line 522,"It prohibits any  form of retaliation, direct or indirect, against an individual  who raises a concern in good faith.
","('Business_Ethics', 0.9111260175704956)","('Management_Of_Legal_And_Regulatory_Framework', 0.017579520121216774)","('Competitive_Behavior', 0.013114790432155132)","(['Business Ethics'], 0.9111260175704956)","('NON-ESG', 0.017579520121216774)","('NON-ESG', 0.013114790432155132)"
Line 523,"This protection   extends to anyone who assists with, or cooperates in,   an investigation or report of misconduct.
","('Business_Ethics', 0.9576123952865601)","('Management_Of_Legal_And_Regulatory_Framework', 0.004035518039017916)","('Employee_Health_And_Safety', 0.0038801205810159445)","(['Business Ethics'], 0.9576123952865601)","('NON-ESG', 0.004035518039017916)","('NON-ESG', 0.0038801205810159445)"
Line 524,"Advice Line  All employees are responsible for immediately reporting  any suspected violation of the Code of Conduct and   related company policies.
","('Business_Ethics', 0.9165552854537964)","('Management_Of_Legal_And_Regulatory_Framework', 0.016845399513840675)","('Product_Quality_And_Safety', 0.008157906122505665)","(['Business Ethics'], 0.9165552854537964)","('NON-ESG', 0.016845399513840675)","('NON-ESG', 0.008157906122505665)"
Line 525,"Ethics concerns may be   confidentially reported through the Boston Scientific   Advice Line.
","('Business_Ethics', 0.9520018100738525)","('Customer_Privacy', 0.005801806692034006)","('Director_Removal', 0.005028434097766876)","(['Business Ethics'], 0.9520018100738525)","('NON-ESG', 0.005801806692034006)","('NON-ESG', 0.005028434097766876)"
Line 526,"The toll-free, 24-hour service is operated by   a third party seven days a week in multiple languages.“INTEGRITY TOGETHER” CAMPAIGN We regularly promote employee awareness of the  Code of Conduct and Non-Retaliation Policy.
","('Business_Ethics', 0.4559796154499054)","('Labor_Practices', 0.14144104719161987)","('Management_Of_Legal_And_Regulatory_Framework', 0.10512495040893555)","('NON-ESG', 0.4559796154499054)","('NON-ESG', 0.14144104719161987)","('NON-ESG', 0.10512495040893555)"
Line 527,"In 2020,  our week-long integrity campaign featured video   messages from senior leaders and interactive virtual  events that emphasized the importance of working  ethically.
","('Business_Ethics', 0.9021759629249573)","('Human_Rights_And_Community_Relations', 0.017213493585586548)","('Management_Of_Legal_And_Regulatory_Framework', 0.007122791837900877)","(['Business Ethics'], 0.9021759629249573)","('NON-ESG', 0.017213493585586548)","('NON-ESG', 0.007122791837900877)"
Line 528,"In addition, regional and country leaders  reinforced the campaign  through local email   messages, videos and   online roundtables.Global Human Rights and Labor Standards  We adhere to human rights and labor laws in every location  where our company operates.
","('Labor_Practices', 0.8152416944503784)","('Human_Rights_And_Community_Relations', 0.09483392536640167)","('Employee_Health_And_Safety', 0.010754551738500595)","(['Labor Practice Indicators'], 0.8152416944503784)","('NON-ESG', 0.09483392536640167)","('NON-ESG', 0.010754551738500595)"
Line 529,"In 2020, we finalized the  Boston Scientific Human Rights Policy , which articulates   our commitment to promoting human rights principles   as recognized and understood by the international   community.
","('Human_Rights_And_Community_Relations', 0.9536619782447815)","('Labor_Practices', 0.00457218661904335)","('Access_And_Affordability', 0.0035742034669965506)","(['Community Relations'], 0.9536619782447815)","('NON-ESG', 0.00457218661904335)","('NON-ESG', 0.0035742034669965506)"
Line 530,"These principles include vigilance against  modern slavery, human trafficking, bribery, discrimination  and harassment.
","('Business_Ethics', 0.9254665970802307)","('Employee_Engagement_Inclusion_And_Diversity', 0.009435037150979042)","('Labor_Practices', 0.008250092156231403)","(['Business Ethics'], 0.9254665970802307)","('NON-ESG', 0.009435037150979042)","('NON-ESG', 0.008250092156231403)"
Line 531,"Our human rights policy supports and is guided by the  principles of the United Nations (UN) International Bill   of Rights as well as:   The Universal Declaration of Human Rights.
","('Human_Rights_And_Community_Relations', 0.9531437754631042)","('Access_And_Affordability', 0.0049736942164599895)","('Labor_Practices', 0.004235432483255863)","(['Community Relations'], 0.9531437754631042)","('NON-ESG', 0.0049736942164599895)","('NON-ESG', 0.004235432483255863)"
Line 532,"The UN Guiding Principles on Business and Human  Rights.
","('Human_Rights_And_Community_Relations', 0.9519397020339966)","('Labor_Practices', 0.005214299075305462)","('Access_And_Affordability', 0.003924710676074028)","(['Community Relations'], 0.9519397020339966)","('NON-ESG', 0.005214299075305462)","('NON-ESG', 0.003924710676074028)"
Line 533,"The International Covenant on Economic, Social and  Cultural Rights.
","('Human_Rights_And_Community_Relations', 0.9550564289093018)","('Management_Of_Legal_And_Regulatory_Framework', 0.004065185785293579)","('Access_And_Affordability', 0.003999351058155298)","(['Community Relations'], 0.9550564289093018)","('NON-ESG', 0.004065185785293579)","('NON-ESG', 0.003999351058155298)"
Line 534,"The International Labor Organization Declaration on  Fundamental Principles and Rights at Work.
","('Labor_Practices', 0.936955451965332)","('Human_Rights_And_Community_Relations', 0.01873529702425003)","('Director_Removal', 0.004478877875953913)","(['Labor Practice Indicators'], 0.936955451965332)","('NON-ESG', 0.01873529702425003)","('NON-ESG', 0.004478877875953913)"
Line 535,"Global Reporting Initiative Sustainability Reporting   Standards.
","('Management_Of_Legal_And_Regulatory_Framework', 0.36073604226112366)","('Systemic_Risk_Management', 0.09657744318246841)","('Product_Quality_And_Safety', 0.08135516196489334)","('NON-ESG', 0.36073604226112366)","('NON-ESG', 0.09657744318246841)","('NON-ESG', 0.08135516196489334)"
Line 536,"We also adhere to disclosure requirements under the   California Transparency in Supply Chains Act and the   U.K. Modern Slavery Act.
","('Supply_Chain_Management', 0.3113447427749634)","('Business_Ethics', 0.19671566784381866)","('Systemic_Risk_Management', 0.16102823615074158)","('NON-ESG', 0.3113447427749634)","('NON-ESG', 0.19671566784381866)","('NON-ESG', 0.16102823615074158)"
Line 537,"As the pandemic  changed how we work,  we continued our Open  Doors initiative using  online resources to   ensure managers could  maintain a virtual open  door with employees,  including those with  compliance concerns.
","('Business_Ethics', 0.8058105111122131)","('Management_Of_Legal_And_Regulatory_Framework', 0.06096475198864937)","('Systemic_Risk_Management', 0.019366087391972542)","(['Business Ethics'], 0.8058105111122131)","('NON-ESG', 0.06096475198864937)","('NON-ESG', 0.019366087391972542)"
Line 538,"EQUIPPING LEADERS TO ADDRESS EMPLOYEE CONCERNS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly BEST-IN-CLASS GLOBAL SECURITY  The Boston Scientific global  security and resiliency team  was ranked in the top 10 of all  U.S. manufacturers’ security  departments in Security magazine’s   2020 Security 500  rankings .
","('Business_Model_Resilience', 0.7279870510101318)","('Data_Security', 0.07291579991579056)","('Systemic_Risk_Management', 0.0366222970187664)","(['Codes of Business Conduct'], 0.7279870510101318)","('NON-ESG', 0.07291579991579056)","('NON-ESG', 0.0366222970187664)"
Line 539,"EQUIPPING LEADERS TO ADDRESS EMPLOYEE CONCERNS	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly BEST-IN-CLASS GLOBAL SECURITY  The Boston Scientific global  security and resiliency team  was ranked in the top 10 of all  U.S. manufacturers’ security  departments in Security magazine’s   2020 Security 500  rankings .
","('Systemic_Risk_Management', 0.20697686076164246)","('Business_Model_Resilience', 0.18401333689689636)","('Customer_Privacy', 0.07188573479652405)","('NON-ESG', 0.20697686076164246)","('NON-ESG', 0.18401333689689636)","('NON-ESG', 0.07188573479652405)"
Line 540,"The team’s  leadership has also been recognized  for   its commitment to diversity, equity and  inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9724066853523254)","('Human_Rights_And_Community_Relations', 0.002352423034608364)","('Employee_Health_And_Safety', 0.0020219222642481327)","(['Human Capital Development'], 0.9724066853523254)","('NON-ESG', 0.002352423034608364)","('NON-ESG', 0.0020219222642481327)"
Line 541,"Risk Management   and Global Security Under the oversight of our board of directors, our   enterprise risk management team supports company   leadership with guidance to achieve performance   objectives.
","('Systemic_Risk_Management', 0.7471210360527039)","('Business_Model_Resilience', 0.1074385717511177)","('Business_Ethics', 0.024662811309099197)","(['Risk & Crisis Management'], 0.7471210360527039)","('NON-ESG', 0.1074385717511177)","('NON-ESG', 0.024662811309099197)"
Line 542,"The team analyzes strategic, operational,   financial, legal and compliance risks to ensure we can  adapt to challenges, pursue opportunities to help patients  and meet commitments to stockholders.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4726759195327759)","('Systemic_Risk_Management', 0.2716485261917114)","('Business_Model_Resilience', 0.04898042604327202)","('NON-ESG', 0.4726759195327759)","('NON-ESG', 0.2716485261917114)","('NON-ESG', 0.04898042604327202)"
Line 543,"Led by our vice  president of global internal audit, our risk management  experts identify enterprise-level developments that   could be barriers to meeting customer and patient   needs or preserving and growing stockholder value.
","('Systemic_Risk_Management', 0.8698822855949402)","('Business_Model_Resilience', 0.03982308506965637)","('Business_Ethics', 0.015088452957570553)","(['Risk & Crisis Management'], 0.8698822855949402)","('NON-ESG', 0.03982308506965637)","('NON-ESG', 0.015088452957570553)"
Line 544,"Any issue that presents a potential risk to the company’s  financial results, operations or reputation is reported   by management to the Board of Directors or one of   its committees.
","('Director_Removal', 0.458062082529068)","('Business_Model_Resilience', 0.09591393172740936)","('Systemic_Risk_Management', 0.09296995401382446)","('NON-ESG', 0.458062082529068)","('NON-ESG', 0.09591393172740936)","('NON-ESG', 0.09296995401382446)"
Line 545,"Matt Sprague leads our team of risk management experts that identify enterprise-   level developments that could be barriers to meeting customer and patient needs.
","('Systemic_Risk_Management', 0.7720138430595398)","('Business_Model_Resilience', 0.0505872517824173)","('Supply_Chain_Management', 0.04512433707714081)","(['Risk & Crisis Management'], 0.7720138430595398)","('NON-ESG', 0.0505872517824173)","('NON-ESG', 0.04512433707714081)"
Line 546,"“ The COVID-19 pandemic has broadened our definition of risk  and expanded the scenarios we plan for in our risk manage - ment approach and processes, resulting in sharper action  plans, escalation paths and lines of communication.”            Matt Sprague,  vice president, Global Internal AuditRISK MANAGEMENT:         PREPARING TO HANDLE ANY SITUATION	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Business Resiliency The Boston Scientific business resiliency strategy ensures  that we can sustain operations and secure our facilities  in the event of a crisis.
","('Systemic_Risk_Management', 0.9188991189002991)","('Business_Model_Resilience', 0.0218017790466547)","('Physical_Impacts_Of_Climate_Change', 0.00938784796744585)","(['Risk & Crisis Management'], 0.9188991189002991)","('NON-ESG', 0.0218017790466547)","('NON-ESG', 0.00938784796744585)"
Line 547,"“ The COVID-19 pandemic has broadened our definition of risk  and expanded the scenarios we plan for in our risk manage - ment approach and processes, resulting in sharper action  plans, escalation paths and lines of communication.”            Matt Sprague,  vice president, Global Internal AuditRISK MANAGEMENT:         PREPARING TO HANDLE ANY SITUATION	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Business Resiliency The Boston Scientific business resiliency strategy ensures  that we can sustain operations and secure our facilities  in the event of a crisis.
","('Business_Model_Resilience', 0.9216256141662598)","('Physical_Impacts_Of_Climate_Change', 0.010169313289225101)","('Product_Design_And_Lifecycle_Management', 0.007038014009594917)","(['Codes of Business Conduct'], 0.9216256141662598)","('NON-ESG', 0.010169313289225101)","('NON-ESG', 0.007038014009594917)"
Line 548,"Our global security and resiliency  team plans and prepares for a range of potential threats,  including wildfires, tornados, earthquakes, hurricanes and  the effects of climate change.
","('Physical_Impacts_Of_Climate_Change', 0.8073478937149048)","('Business_Model_Resilience', 0.09588339179754257)","('Critical_Incident_Risk_Management', 0.009870554320514202)","(['Climate Change'], 0.8073478937149048)","('NON-ESG', 0.09588339179754257)","('NON-ESG', 0.009870554320514202)"
Line 549,"They use risk and impact  assessments to plan for disasters or events that could   interfere with our ability to deliver products for patients   or jeopardize the safety of our people, suppliers or   communities.
","('Product_Quality_And_Safety', 0.516139805316925)","('Product_Design_And_Lifecycle_Management', 0.32846325635910034)","('Selling_Practices_And_Product_Labeling', 0.028109155595302582)","(['Product Quality & Recall Management'], 0.516139805316925)","('NON-ESG', 0.32846325635910034)","('NON-ESG', 0.028109155595302582)"
Line 550,"The team also works closely with our   IT disaster recovery experts to identify technology   vulnerabilities so we can make the right investments   to keep company operations secure.
","('Critical_Incident_Risk_Management', 0.9607835412025452)","('Employee_Health_And_Safety', 0.00517719890922308)","('Physical_Impacts_Of_Climate_Change', 0.004645640030503273)","(['Risk & Crisis Management'], 0.9607835412025452)","('NON-ESG', 0.00517719890922308)","('NON-ESG', 0.004645640030503273)"
Line 551,"When COVID-19 cases first emerged, our   security, resiliency and medical teams acted  quickly to protect our people and business  operations while taking steps to ensure that our devices and therapies would continue to reach patients.
","('Business_Model_Resilience', 0.8966156840324402)","('Product_Design_And_Lifecycle_Management', 0.009748796932399273)","('Physical_Impacts_Of_Climate_Change', 0.009702973067760468)","(['Codes of Business Conduct'], 0.8966156840324402)","('NON-ESG', 0.009748796932399273)","('NON-ESG', 0.009702973067760468)"
Line 552,"Our employees provided on-site support to customers   in accordance with guidance from local health authorities,  as well as hospital protocols.
","('Access_And_Affordability', 0.6679373383522034)","('Employee_Health_And_Safety', 0.07689924538135529)","('Critical_Incident_Risk_Management', 0.04754532128572464)","(['Health Outcome Contribution'], 0.6679373383522034)","('NON-ESG', 0.07689924538135529)","('NON-ESG', 0.04754532128572464)"
Line 553,"To prevent on-site outbreaks  and ensure extra safety, employees who could perform  their job functions from home worked remotely with   flexible work arrangements.
","('Employee_Health_And_Safety', 0.9635854959487915)","('Critical_Incident_Risk_Management', 0.013730018399655819)","('Labor_Practices', 0.00234333542175591)","(['Operational Eco-Efficiency'], 0.9635854959487915)","('NON-ESG', 0.013730018399655819)","('NON-ESG', 0.00234333542175591)"
Line 554,"We also shipped personal   protective equipment (PPE) to company locations for   employees’ use, provided COVID-19 testing for employees  and issued pandemic guidance for teams globally.
","('Employee_Health_And_Safety', 0.9479484558105469)","('Critical_Incident_Risk_Management', 0.00931671541184187)","('Product_Design_And_Lifecycle_Management', 0.0049352096393704414)","(['Operational Eco-Efficiency'], 0.9479484558105469)","('NON-ESG', 0.00931671541184187)","('NON-ESG', 0.0049352096393704414)"
Line 555,"Based on virus-tracking data, we implemented new   safety protocols, adapted facilities for social distancing   and rolled out plans for the tiered resumption of   manufacturing operations in locations where case   counts subsided.
","('Product_Quality_And_Safety', 0.8636470437049866)","('Employee_Health_And_Safety', 0.04883064702153206)","('Product_Design_And_Lifecycle_Management', 0.009675893001258373)","(['Product Quality & Recall Management'], 0.8636470437049866)","('NON-ESG', 0.04883064702153206)","('NON-ESG', 0.009675893001258373)"
Line 556,"Ty Harris leads the company’s business resiliency efforts to help  ensure continuity in operations and safety for our employees.
","('Employee_Health_And_Safety', 0.8746713995933533)","('Employee_Engagement_Inclusion_And_Diversity', 0.02802105061709881)","('Product_Quality_And_Safety', 0.012537909671664238)","(['Operational Eco-Efficiency'], 0.8746713995933533)","('NON-ESG', 0.02802105061709881)","('NON-ESG', 0.012537909671664238)"
Line 557,"“ We have a strong global resiliency model to   protect the enterprise in the event of a crisis.
","('Business_Model_Resilience', 0.9131110906600952)","('Physical_Impacts_Of_Climate_Change', 0.01171908900141716)","('Supply_Chain_Management', 0.008044796995818615)","(['Codes of Business Conduct'], 0.9131110906600952)","('NON-ESG', 0.01171908900141716)","('NON-ESG', 0.008044796995818615)"
Line 558,"In  early January, when our global intelligence team  alerted us to the COVID-19 outbreak in Wuhan, we  were able to act immediately to anticipate the   extent of the threat and keep employees safe.
","('Critical_Incident_Risk_Management', 0.48851269483566284)","('Data_Security', 0.16011059284210205)","('Physical_Impacts_Of_Climate_Change', 0.06805805116891861)","('NON-ESG', 0.48851269483566284)","('NON-ESG', 0.16011059284210205)","('NON-ESG', 0.06805805116891861)"
Line 559,"With  new protocols and work streams, we kept critical  operations intact and created work environments  without community-spread at our sites.”  Ty Harris,  director, Global Security and Resiliency   Protecting Global Assets Our global security and resiliency team ensures the   safety of our people as well as enterprise assets and   operations.
","('Business_Model_Resilience', 0.6157169938087463)","('Data_Security', 0.11947085708379745)","('Systemic_Risk_Management', 0.047426704317331314)","(['Codes of Business Conduct'], 0.6157169938087463)","('NON-ESG', 0.11947085708379745)","('NON-ESG', 0.047426704317331314)"
Line 560,"The team uses industry-standard protocols   and global situational awareness tactics to manage   our security posture and to maintain a global security   operations center 24 hours a day, seven days a week.
","('Data_Security', 0.943003237247467)","('Systemic_Risk_Management', 0.007829906418919563)","('Customer_Privacy', 0.005144776776432991)","(['Information Security/Cybersecurity & System Availability'], 0.943003237247467)","('NON-ESG', 0.007829906418919563)","('NON-ESG', 0.005144776776432991)"
Line 561,"Their work to maintain and enhance physical security   and cybersecurity is supported by a network of partners  specializing in cybersecurity, environment, health and   safety, supply chain, global regulation and data privacy.BUSINESS CONTINUITY:           RESILIENCY AND THE GLOBAL PANDEMIC	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyGovernance  The Boston Scientific Board of Directors has well-estab - lished corporate governance guidelines  and adopted   written charters for each of its standing committees   (audit, executive compensation and human resources,   risk, nominating and governance).
","('Data_Security', 0.9415701031684875)","('Systemic_Risk_Management', 0.009763720445334911)","('Business_Model_Resilience', 0.00474234763532877)","(['Information Security/Cybersecurity & System Availability'], 0.9415701031684875)","('NON-ESG', 0.009763720445334911)","('NON-ESG', 0.00474234763532877)"
Line 562,"Their work to maintain and enhance physical security   and cybersecurity is supported by a network of partners  specializing in cybersecurity, environment, health and   safety, supply chain, global regulation and data privacy.BUSINESS CONTINUITY:           RESILIENCY AND THE GLOBAL PANDEMIC	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyGovernance  The Boston Scientific Board of Directors has well-estab - lished corporate governance guidelines  and adopted   written charters for each of its standing committees   (audit, executive compensation and human resources,   risk, nominating and governance).
","('Director_Removal', 0.40937376022338867)","('Management_Of_Legal_And_Regulatory_Framework', 0.2849167585372925)","('Business_Ethics', 0.08744503557682037)","('NON-ESG', 0.40937376022338867)","('NON-ESG', 0.2849167585372925)","('NON-ESG', 0.08744503557682037)"
Line 563,"Our Code of Conduct  reflects the company’s commitment to good corporate  governance and compliance with the rules and listing   standards of the New York Stock Exchange and other   legal requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7563034892082214)","('Business_Ethics', 0.1358785778284073)","('Director_Removal', 0.016881076619029045)","(['Corporate Governance'], 0.7563034892082214)","('NON-ESG', 0.1358785778284073)","('NON-ESG', 0.016881076619029045)"
Line 564,"Global Tax Strategy and Compliance Our business makes a positive economic and  social impact around the world, strengthening  the communities where our people live and  work.
","('Human_Rights_And_Community_Relations', 0.9574819803237915)","('Access_And_Affordability', 0.006268394645303488)","('Ecological_Impacts', 0.003313566790893674)","(['Community Relations'], 0.9574819803237915)","('NON-ESG', 0.006268394645303488)","('NON-ESG', 0.003313566790893674)"
Line 565,"In keeping with our commitment to  social responsibility, we prioritize our role as a responsible  taxpayer.
","('Human_Rights_And_Community_Relations', 0.9552009105682373)","('Ecological_Impacts', 0.004205869045108557)","('Access_And_Affordability', 0.004096874501556158)","(['Community Relations'], 0.9552009105682373)","('NON-ESG', 0.004205869045108557)","('NON-ESG', 0.004096874501556158)"
Line 566,"We comply with all applicable tax laws, regulations  and related disclosure requirements in every jurisdiction  where we operate.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9735352993011475)","('Energy_Management', 0.0028482333291321993)","('Director_Removal', 0.002275938168168068)","(['Corporate Governance'], 0.9735352993011475)","('NON-ESG', 0.0028482333291321993)","('NON-ESG', 0.002275938168168068)"
Line 567,"Our tax professionals are committed   to the highest compliance standards and use processes  based on standardization and automation to minimize   our tax risk.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6436112523078918)","('Business_Ethics', 0.22645023465156555)","('Product_Quality_And_Safety', 0.030098382383584976)","(['Corporate Governance'], 0.6436112523078918)","('NON-ESG', 0.22645023465156555)","('NON-ESG', 0.030098382383584976)"
Line 568,"Political Involvement and Contributions Boston Scientific supports public policies that  promote diversity, equity and inclusion and   improve patient health, our employees’ lives  and the communities we serve.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9704364538192749)","('Human_Rights_And_Community_Relations', 0.003628611797466874)","('Employee_Health_And_Safety', 0.0026587191969156265)","(['Human Capital Development'], 0.9704364538192749)","('NON-ESG', 0.003628611797466874)","('NON-ESG', 0.0026587191969156265)"
Line 569,"We advocate for policies that focus on increasing patient access to  life-changing and life-saving technologies.
","('Access_And_Affordability', 0.8826410174369812)","('Product_Quality_And_Safety', 0.011371411383152008)","('Employee_Health_And_Safety', 0.009149719960987568)","(['Health Outcome Contribution'], 0.8826410174369812)","('NON-ESG', 0.011371411383152008)","('NON-ESG', 0.009149719960987568)"
Line 570,"The company  posts annual updates  on contributions to political action  committees, corporate contributions to state officials   and memberships in associations that engage in public  policy advocacy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9360610842704773)","('Human_Rights_And_Community_Relations', 0.008561951108276844)","('Director_Removal', 0.006789879407733679)","(['Corporate Governance'], 0.9360610842704773)","('NON-ESG', 0.008561951108276844)","('NON-ESG', 0.006789879407733679)"
Line 571,"To advance sound public policy, the Boston Scientific   Corporation Political Action Committee (PAC) facilitates   voluntary political contributions by eligible employees   and our board of directors in accordance with federal   law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7269399762153625)","('Director_Removal', 0.1056494265794754)","('Labor_Practices', 0.038329098373651505)","(['Corporate Governance'], 0.7269399762153625)","('NON-ESG', 0.1056494265794754)","('NON-ESG', 0.038329098373651505)"
Line 572,"While the PAC supports our company values, it   does not accept any contributions made on behalf of   any corporations, including Boston Scientific, nor does it  contribute to presidential campaigns.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7053861021995544)","('Competitive_Behavior', 0.069978728890419)","('Director_Removal', 0.034339189529418945)","(['Corporate Governance'], 0.7053861021995544)","('NON-ESG', 0.069978728890419)","('NON-ESG', 0.034339189529418945)"
Line 573,"The PAC is run by   a governing board of senior employees who represent   our primary businesses.
","('Director_Removal', 0.6485804915428162)","('Labor_Practices', 0.062218077480793)","('Management_Of_Legal_And_Regulatory_Framework', 0.04731178656220436)","(['Anti-Crime Policy & Measures'], 0.6485804915428162)","('NON-ESG', 0.062218077480793)","('NON-ESG', 0.04731178656220436)"
Line 574,"The nominating and governance  committee of our board of directors annually reviews   political contributions made by our company and the   PAC.
","('Director_Removal', 0.5839182734489441)","('Management_Of_Legal_And_Regulatory_Framework', 0.17168310284614563)","('Business_Ethics', 0.03196011111140251)","(['Anti-Crime Policy & Measures'], 0.5839182734489441)","('NON-ESG', 0.17168310284614563)","('NON-ESG', 0.03196011111140251)"
Line 575,"Contributions to political candidates are bipartisan,   and to be eligible for funding, candidates must meet   one or more of the following criteria:   Policy alignment: The candidate is aligned with   the company’s top public policy priorities; or,    Leadership and jurisdiction: The candidate serves   in elected leadership within the Congress and/or sits   on a congressional committee with jurisdiction over  issues impacting our business; or,     Constituency: The candidate represents a district or   state in which a company facility exists and/or serves   a significant population of our employees; or,    Values and reputation: The candidate’s character   and integrity align with BSC’s corporate reputation   and values.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6125043630599976)","('Director_Removal', 0.07680203765630722)","('Employee_Engagement_Inclusion_And_Diversity', 0.06993459910154343)","(['Corporate Governance'], 0.6125043630599976)","('NON-ESG', 0.07680203765630722)","('NON-ESG', 0.06993459910154343)"
Line 576,"Contributions to political candidates are bipartisan,   and to be eligible for funding, candidates must meet   one or more of the following criteria:   Policy alignment: The candidate is aligned with   the company’s top public policy priorities; or,    Leadership and jurisdiction: The candidate serves   in elected leadership within the Congress and/or sits   on a congressional committee with jurisdiction over  issues impacting our business; or,     Constituency: The candidate represents a district or   state in which a company facility exists and/or serves   a significant population of our employees; or,    Values and reputation: The candidate’s character   and integrity align with BSC’s corporate reputation   and values.
","('Business_Ethics', 0.7721966505050659)","('Director_Removal', 0.030662357807159424)","('Customer_Privacy', 0.02889866568148136)","(['Business Ethics'], 0.7721966505050659)","('NON-ESG', 0.030662357807159424)","('NON-ESG', 0.02889866568148136)"
Line 577,"Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblySetting Industry Standards Boston Scientific collaborates with trade associations   and regulatory bodies around the world to set new   standards in quality and stay informed about regulatory   developments so we can be agile in our response.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8162086606025696)","('Product_Quality_And_Safety', 0.05120331048965454)","('Business_Ethics', 0.026421261951327324)","(['Corporate Governance'], 0.8162086606025696)","('NON-ESG', 0.05120331048965454)","('NON-ESG', 0.026421261951327324)"
Line 578,"We  make it a priority to help shape industry and regulatory  approaches to quality by sharing the best practices   behind our patient-centric systems.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9615388512611389)","('Competitive_Behavior', 0.004789099097251892)","('Business_Ethics', 0.004008076153695583)","(['Corporate Governance'], 0.9615388512611389)","('NON-ESG', 0.004789099097251892)","('NON-ESG', 0.004008076153695583)"
Line 579,"FDA Digital Health: We are working closely with the FDA  through the Digital Health Software Precertification Pilot  Program to expedite patient access to safe and effective  software-based medical innovations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.739590048789978)","('Product_Quality_And_Safety', 0.04792625829577446)","('Access_And_Affordability', 0.04088587686419487)","(['Corporate Governance'], 0.739590048789978)","('NON-ESG', 0.04792625829577446)","('NON-ESG', 0.04088587686419487)"
Line 580,"Medical Device Innovation Consortium: We are part of  this public-private partnership with the FDA to advance  solutions that promote patient access to innovative   medical technologies.
","('Access_And_Affordability', 0.2716970145702362)","('Customer_Welfare', 0.1643250584602356)","('Product_Design_And_Lifecycle_Management', 0.11579412966966629)","('NON-ESG', 0.2716970145702362)","('NON-ESG', 0.1643250584602356)","('NON-ESG', 0.11579412966966629)"
Line 581,"Responsible Marketing Boston Scientific is committed to ethical and responsible  marketing and promotion.
","('Selling_Practices_And_Product_Labeling', 0.2330268770456314)","('Competitive_Behavior', 0.1817265748977661)","('Customer_Welfare', 0.1637435108423233)","('NON-ESG', 0.2330268770456314)","('NON-ESG', 0.1817265748977661)","('NON-ESG', 0.1637435108423233)"
Line 582,"Our Code of Conduct and   other employee policies emphasize the importance of   fair and honest communications with patients, customers  and the public.
","('Business_Ethics', 0.915419340133667)","('Customer_Privacy', 0.009509468451142311)","('Human_Rights_And_Community_Relations', 0.00936479214578867)","(['Business Ethics'], 0.915419340133667)","('NON-ESG', 0.009509468451142311)","('NON-ESG', 0.00936479214578867)"
Line 583,"The company’s sales and marketing training  for all customer-facing employees covers fair and honest   marketing practices, respect for intellectual property,   interactions with physicians and public officials, and   conflicts of interest.
","('Business_Ethics', 0.6853474974632263)","('Competitive_Behavior', 0.15940149128437042)","('Management_Of_Legal_And_Regulatory_Framework', 0.018223052844405174)","(['Business Ethics'], 0.6853474974632263)","('NON-ESG', 0.15940149128437042)","('NON-ESG', 0.018223052844405174)"
Line 584,"2020 Responsible Sales and     Marketing Training:   $1.9 million  invested    in sales and marketing training     programs   +12,000 hours of training    for customer-facing employees	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Supporting Supplier Diversity Our approach to supplier selection involves building   diversity, equity and inclusion throughout the Boston   Scientific supplier network.
","('Supply_Chain_Management', 0.5313441753387451)","('Employee_Engagement_Inclusion_And_Diversity', 0.1465834528207779)","('Labor_Practices', 0.052351441234350204)","(['Supply Chain Management'], 0.5313441753387451)","('NON-ESG', 0.1465834528207779)","('NON-ESG', 0.052351441234350204)"
Line 585,"2020 Responsible Sales and     Marketing Training:   $1.9 million  invested    in sales and marketing training     programs   +12,000 hours of training    for customer-facing employees	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly Supporting Supplier Diversity Our approach to supplier selection involves building   diversity, equity and inclusion throughout the Boston   Scientific supplier network.
","('Employee_Engagement_Inclusion_And_Diversity', 0.965881884098053)","('Human_Rights_And_Community_Relations', 0.0034040180034935474)","('Employee_Health_And_Safety', 0.002692664973437786)","(['Human Capital Development'], 0.965881884098053)","('NON-ESG', 0.0034040180034935474)","('NON-ESG', 0.002692664973437786)"
Line 586,"In 2020, as part of our   combating racism strategy, we took steps to further   expand the number of Black-owned enterprises that   provide supply chain services for our business in the   United States.
","('Supply_Chain_Management', 0.9502712488174438)","('Product_Design_And_Lifecycle_Management', 0.004638828337192535)","('Labor_Practices', 0.004167071543633938)","(['Supply Chain Management'], 0.9502712488174438)","('NON-ESG', 0.004638828337192535)","('NON-ESG', 0.004167071543633938)"
Line 587,"We also supported small and diverse   vendors during the pandemic by shortening payment  terms for those whose business with us is under $250,000.
","('Systemic_Risk_Management', 0.2559719383716583)","('Management_Of_Legal_And_Regulatory_Framework', 0.22996126115322113)","('Business_Ethics', 0.12627451121807098)","('NON-ESG', 0.2559719383716583)","('NON-ESG', 0.22996126115322113)","('NON-ESG', 0.12627451121807098)"
Line 588,"We prioritize partnerships with certified companies that  share our dedication to improving the quality of patient  care, including businesses that are:    Minority-owned   Women-owned   Small or disadvantaged   Service-disabled  Veteran-owned    LGBTQ-owned   Disability-owned “ I’ve never been more impressed by our   diverse network of suppliers than I was   in 2020.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9552790522575378)","('Access_And_Affordability', 0.005796997807919979)","('Human_Rights_And_Community_Relations', 0.004076284356415272)","(['Human Capital Development'], 0.9552790522575378)","('NON-ESG', 0.005796997807919979)","('NON-ESG', 0.004076284356415272)"
Line 589,"Each came through to ensure   our products were available wherever they  were needed in the world.
","('Product_Design_And_Lifecycle_Management', 0.9514276385307312)","('Product_Quality_And_Safety', 0.006957975681871176)","('Selling_Practices_And_Product_Labeling', 0.004778196569532156)","(['Product Stewardship'], 0.9514276385307312)","('NON-ESG', 0.006957975681871176)","('NON-ESG', 0.004778196569532156)"
Line 590,"We are proud   to partner with businesses with so much   diversity of talent and perspective.”            Saken Khokhar,  manager, Supplier DiversityPROTECTING SUPPLY CHAIN STABILITY IN In early 2020, the Boston Scientific global  sourcing team shifted resources to keep  our supply chain stable; as a result,   we did not experience manufacturing outages amid the pandemic.
","('Supply_Chain_Management', 0.9519493579864502)","('Labor_Practices', 0.004975514952093363)","('Systemic_Risk_Management', 0.004043419845402241)","(['Supply Chain Management'], 0.9519493579864502)","('NON-ESG', 0.004975514952093363)","('NON-ESG', 0.004043419845402241)"
Line 591,"The interventions we  took included:    Tracking supplier status and inventory in risk  areas and taking action to prevent shortages.
","('Supply_Chain_Management', 0.942947268486023)","('Labor_Practices', 0.008107651025056839)","('Systemic_Risk_Management', 0.004272054880857468)","(['Supply Chain Management'], 0.942947268486023)","('NON-ESG', 0.008107651025056839)","('NON-ESG', 0.004272054880857468)"
Line 592,"Monitoring safety stock levels and building up  product supplies as warranted.
","('Product_Quality_And_Safety', 0.9196871519088745)","('Selling_Practices_And_Product_Labeling', 0.010341882705688477)","('Employee_Health_And_Safety', 0.010265478864312172)","(['Product Quality & Recall Management'], 0.9196871519088745)","('NON-ESG', 0.010341882705688477)","('NON-ESG', 0.010265478864312172)"
Line 593,"Mitigating risk for technology and material   shortages by identifying new vendors.
","('Supply_Chain_Management', 0.6354089379310608)","('Systemic_Risk_Management', 0.06580932438373566)","('Employee_Health_And_Safety', 0.03348411247134209)","(['Supply Chain Management'], 0.6354089379310608)","('NON-ESG', 0.06580932438373566)","('NON-ESG', 0.03348411247134209)"
Line 594,"Analyzing continuity risks by product family.Sustainable Supply Chain The company’s manufacturing and supply chain teams  lead our efforts to plan, source, manufacture and distribute   more than 17,000 products to customers and patients  worldwide.
","('Supply_Chain_Management', 0.7387160062789917)","('Product_Design_And_Lifecycle_Management', 0.13475915789604187)","('Waste_And_Hazardous_Materials_Management', 0.013149973005056381)","(['Supply Chain Management'], 0.7387160062789917)","('NON-ESG', 0.13475915789604187)","('NON-ESG', 0.013149973005056381)"
Line 595,"More than 22,000 indirect and direct suppliers   meet the highest quality standards for materials and  service, ethical conduct, and compliance with all applicable  laws and regulations.
","('Business_Ethics', 0.6860088109970093)","('Product_Quality_And_Safety', 0.09179207682609558)","('Management_Of_Legal_And_Regulatory_Framework', 0.03478140011429787)","(['Business Ethics'], 0.6860088109970093)","('NON-ESG', 0.09179207682609558)","('NON-ESG', 0.03478140011429787)"
Line 596,"To identify supply chain partners   supporting product development and ongoing supply for  manufacturing, we use a standardized supplier performance  tool that assesses each organization’s business practices  and corporate citizenship.
","('Supply_Chain_Management', 0.9227324724197388)","('Product_Design_And_Lifecycle_Management', 0.018004080280661583)","('Waste_And_Hazardous_Materials_Management', 0.004998897202312946)","(['Supply Chain Management'], 0.9227324724197388)","('NON-ESG', 0.018004080280661583)","('NON-ESG', 0.004998897202312946)"
Line 597,"This protocol enables us to build  relationships with responsible, high-performing suppliers  who make significant contributions to our work.
","('Supply_Chain_Management', 0.9127954244613647)","('Product_Design_And_Lifecycle_Management', 0.010185585357248783)","('Water_And_Wastewater_Management', 0.007047766353935003)","(['Supply Chain Management'], 0.9127954244613647)","('NON-ESG', 0.010185585357248783)","('NON-ESG', 0.007047766353935003)"
Line 598,"2020 Supplier Diversity:   Worked with 3,200     diverse suppliers  Spent $599 million on    the services of diverse suppliers PERSPECTIVE ON SUPPORTING SUPPLIER DIVERSITY:           SAKEN KHOKHAR	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly The new SYNERGY™ XD Bioabsorbable Polymer   Stent single-barrier packaging system reduced total  shipping weight by 26.9 metric tons globally.
","('Supply_Chain_Management', 0.7450035810470581)","('Employee_Engagement_Inclusion_And_Diversity', 0.05316585302352905)","('Labor_Practices', 0.04369545355439186)","(['Supply Chain Management'], 0.7450035810470581)","('NON-ESG', 0.05316585302352905)","('NON-ESG', 0.04369545355439186)"
Line 599,"2020 Supplier Diversity:   Worked with 3,200     diverse suppliers  Spent $599 million on    the services of diverse suppliers PERSPECTIVE ON SUPPORTING SUPPLIER DIVERSITY:           SAKEN KHOKHAR	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment Responsibly The new SYNERGY™ XD Bioabsorbable Polymer   Stent single-barrier packaging system reduced total  shipping weight by 26.9 metric tons globally.
","('Product_Design_And_Lifecycle_Management', 0.7579588294029236)","('Energy_Management', 0.06837933510541916)","('Waste_And_Hazardous_Materials_Management', 0.039843782782554626)","(['Product Stewardship'], 0.7579588294029236)","('NON-ESG', 0.06837933510541916)","('NON-ESG', 0.039843782782554626)"
Line 600,"Packaging and Labeling  Packaging practices at Boston Scientific reflect the critical  need to ensure the highest quality sterilization, distribution,  storage and use of our medical devices.
","('Product_Design_And_Lifecycle_Management', 0.5384645462036133)","('Selling_Practices_And_Product_Labeling', 0.1985933780670166)","('Customer_Welfare', 0.050006043165922165)","(['Product Stewardship'], 0.5384645462036133)","('NON-ESG', 0.1985933780670166)","('NON-ESG', 0.050006043165922165)"
Line 601,"We collaborate  with customers and conduct usability assessments to   ensure we are meeting their needs and requirements.
","('Product_Design_And_Lifecycle_Management', 0.3162945806980133)","('Business_Model_Resilience', 0.23942294716835022)","('Competitive_Behavior', 0.05725010111927986)","('NON-ESG', 0.3162945806980133)","('NON-ESG', 0.23942294716835022)","('NON-ESG', 0.05725010111927986)"
Line 602,"The company has controls in place to verify that our   product labeling meets global labeling regulations and   all internal quality standards.Sustainability in Packaging and Labeling We develop packaging sustainability goals under the  guidance of a global sustainability packaging and labeling  steering committee.
","('Selling_Practices_And_Product_Labeling', 0.704923689365387)","('Product_Quality_And_Safety', 0.08869187533855438)","('Product_Design_And_Lifecycle_Management', 0.07160643488168716)","(['Marketing Practices'], 0.704923689365387)","('NON-ESG', 0.08869187533855438)","('NON-ESG', 0.07160643488168716)"
Line 603,"Our packaging and labeling practices  include optimizing design, reducing waste and limiting  emissions from shipping.
","('Product_Design_And_Lifecycle_Management', 0.4126233458518982)","('Waste_And_Hazardous_Materials_Management', 0.29837456345558167)","('Selling_Practices_And_Product_Labeling', 0.09054137766361237)","('NON-ESG', 0.4126233458518982)","('NON-ESG', 0.29837456345558167)","('NON-ESG', 0.09054137766361237)"
Line 604,"In 2020, we conducted a   global survey with customers to learn more about their  sustainability practices and how we can work together   to reduce waste and emissions.
","('Product_Design_And_Lifecycle_Management', 0.3470306992530823)","('Waste_And_Hazardous_Materials_Management', 0.25339630246162415)","('Energy_Management', 0.08911691606044769)","('NON-ESG', 0.3470306992530823)","('NON-ESG', 0.25339630246162415)","('NON-ESG', 0.08911691606044769)"
Line 605,"As a member of the  Healthcare Plastics Recycling Council, we participated   in its work to increase the recycling of plastics in clinical  settings.
","('Waste_And_Hazardous_Materials_Management', 0.6637648344039917)","('Product_Design_And_Lifecycle_Management', 0.18148401379585266)","('Supply_Chain_Management', 0.019028963521122932)","(['Operational Eco-Efficiency'], 0.6637648344039917)","('NON-ESG', 0.18148401379585266)","('NON-ESG', 0.019028963521122932)"
Line 606,"This work has improved our ability to trace raw  materials and learn how our customers dispose of the  plastics used to safely deliver our products.
","('Product_Design_And_Lifecycle_Management', 0.9472680687904358)","('Selling_Practices_And_Product_Labeling', 0.007206853944808245)","('Product_Quality_And_Safety', 0.005810951814055443)","(['Product Stewardship'], 0.9472680687904358)","('NON-ESG', 0.007206853944808245)","('NON-ESG', 0.005810951814055443)"
Line 607,"Boston Scientific packaging teams routinely share case  studies to communicate the company’s support for   sustainability and to share successful practices with   our global teams.
","('Product_Design_And_Lifecycle_Management', 0.8689568638801575)","('Customer_Welfare', 0.01811910606920719)","('Supply_Chain_Management', 0.016892971470952034)","(['Product Stewardship'], 0.8689568638801575)","('NON-ESG', 0.01811910606920719)","('NON-ESG', 0.016892971470952034)"
Line 608,"In 2020, we shared the following   accomplishments:     Packaging consolidation: By consolidating sterile barrier  systems and sourcing more packaging materials locally  in Clonmel, Ireland, the Neuromodulation team avoided   using 755 kg of plastic and 1.03 metric tons of carbon  emissions.
","('Product_Design_And_Lifecycle_Management', 0.7031440138816833)","('Waste_And_Hazardous_Materials_Management', 0.09392447024583817)","('Energy_Management', 0.04780683293938637)","(['Product Stewardship'], 0.7031440138816833)","('NON-ESG', 0.09392447024583817)","('NON-ESG', 0.04780683293938637)"
Line 609,"Cold chain packaging redesign: By developing new   packaging for SpaceOAR™ Hydrogel and SpaceOAR   Vue™ Hydrogel that uses cold chain technology, we  shipped more product per pallet and extended the   time products can spend in transport.
","('Product_Design_And_Lifecycle_Management', 0.9523406624794006)","('Waste_And_Hazardous_Materials_Management', 0.005602594465017319)","('Energy_Management', 0.004590610042214394)","(['Product Stewardship'], 0.9523406624794006)","('NON-ESG', 0.005602594465017319)","('NON-ESG', 0.004590610042214394)"
Line 610,"Packaging material efficiency: By shifting from two-pouch  packaging to a single-pouch and thinner carton for the  SYNERGY™ XD Bioabsorbable Polymer Stent, we reduced  total shipping weight by 26.9 metric tons worldwide.
","('Product_Design_And_Lifecycle_Management', 0.8916305303573608)","('Energy_Management', 0.02423454448580742)","('Selling_Practices_And_Product_Labeling', 0.011528117582201958)","(['Product Stewardship'], 0.8916305303573608)","('NON-ESG', 0.02423454448580742)","('NON-ESG', 0.011528117582201958)"
Line 611,"REDUCING WASTE WITH ELECTRONIC INSTRUCTIONS To reduce paper waste, we host an eLabeling website   where customers can download Instructions for Use  (IFU) for an increasing number of Boston Scientific   products.
","('Waste_And_Hazardous_Materials_Management', 0.9841635823249817)","('Water_And_Wastewater_Management', 0.0012898881686851382)","('Data_Security', 0.001145937480032444)","(['Operational Eco-Efficiency'], 0.9841635823249817)","('NON-ESG', 0.0012898881686851382)","('NON-ESG', 0.001145937480032444)"
Line 612,"Many IFU booklets that were previously   printed and shipped with devices are now available  online in multiple languages.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2280162125825882)","('Product_Design_And_Lifecycle_Management', 0.08938712626695633)","('Access_And_Affordability', 0.08368062227964401)","('NON-ESG', 0.2280162125825882)","('NON-ESG', 0.08938712626695633)","('NON-ESG', 0.08368062227964401)"
Line 613,"By converting to   electronic-only instructions for customers in Korea   and Russia, we cut paper waste in the region by   35 metric tons in 2020.
","('Waste_And_Hazardous_Materials_Management', 0.9835283756256104)","('Water_And_Wastewater_Management', 0.0017816786421462893)","('Air_Quality', 0.0013193705817684531)","(['Operational Eco-Efficiency'], 0.9835283756256104)","('NON-ESG', 0.0017816786421462893)","('NON-ESG', 0.0013193705817684531)"
Line 614,"2020 Packaging Sustainability  Snapshot:   164 metric tons of     packaging removed from waste     stream  1,100 acres of forest saved  5,300 products diverted    from landfills during development  697 pallet shipments avoidedPACKAGING MATERIAL EFFICIENCY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyBoston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-bostonscientific.com©	2021	Boston	Scientific	Corporation	or	its	affiliates.
","('Waste_And_Hazardous_Materials_Management', 0.5157631039619446)","('Product_Design_And_Lifecycle_Management', 0.3449120819568634)","('Product_Quality_And_Safety', 0.018309734761714935)","(['Operational Eco-Efficiency'], 0.5157631039619446)","('NON-ESG', 0.3449120819568634)","('NON-ESG', 0.018309734761714935)"
Line 615,"2020 Packaging Sustainability  Snapshot:   164 metric tons of     packaging removed from waste     stream  1,100 acres of forest saved  5,300 products diverted    from landfills during development  697 pallet shipments avoidedPACKAGING MATERIAL EFFICIENCY	 Boston	Scientific	2020	Performance	Report		 Our Mission  Patient Spotlight Table of Contents A Message to Company Profile Transforming Care Investing in  Advancing Protecting the Creating Value      Stakeholders    Our People Possibilities Environment ResponsiblyBoston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-bostonscientific.com©	2021	Boston	Scientific	Corporation	or	its	affiliates.
","('Competitive_Behavior', 0.18480326235294342)","('Management_Of_Legal_And_Regulatory_Framework', 0.15451651811599731)","('Customer_Welfare', 0.0720934197306633)","('NON-ESG', 0.18480326235294342)","('NON-ESG', 0.15451651811599731)","('NON-ESG', 0.0720934197306633)"
Line 616,"All	rights	reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 617,PR2020,"('Physical_Impacts_Of_Climate_Change', 0.25799205899238586)","('Management_Of_Legal_And_Regulatory_Framework', 0.1700216680765152)","('Business_Model_Resilience', 0.09902501851320267)","('NON-ESG', 0.25799205899238586)","('NON-ESG', 0.1700216680765152)","('NON-ESG', 0.09902501851320267)"
